Imidazo[4,5-d]pyridazine derivatives, their preparation and therapeutic application

Abstract

The present invention relates to a compound of formula (I) where R1 represents H, (C1-C6)alkyl-; hydroxy-(C1-C6)alkyl-; NH2-(C1-C6)alkyl-; NH-(C1-C6)alkyl-(C1-C6)alkyl-; N((C1-C6)alkyl)2-(C1-C6)alkyl-; (C2-C6)alkenyl-; (C2-C6)alkynyl-; phenyl(C1-C6)alkyl-; (C3-C10)cycloalkyl(C1-C6)alkyl-; heterocycloalkyl(C1-C6) of (C3-C10 members); heteroaryl(C1-C6) of (C5-C10 members); heterocycloalkyl-NH-(C1-C16) of (C3-C10 members); and (C3-C10) member heterocycloalkyl-N(C(O)-(C1-C6)alkyl)-(C1-C16)alkyl-; R2 represents a halogen atom, a (C1-C6)alkyl- group, or other well-defined groups; and R3 represents a deuterium atom; H, (C1-C6)alkyl-; (C2-C6)alkenyl-; (C2-C6)alkynyl-; (C1-C6)alkylthio-; -OR6; -NR7R8; (C3-C10) member heterocycloalkyl-; (C5-C10) member heteroaryl-; -(C6-C10) member aryl; and (C3-C10)cycloalkyl-.The present invention also relates to intermediates of these compounds, processes for their preparation, a medicament and a pharmaceutical composition containing them, and their therapeutic uses, in particular as TLR7 and / or TLR8 agonists, as well as their use in a vaccine.

Description

Imidazo[4,5-d]pyridazine derivatives, their preparation and therapeutic application This disclosure relates to novel imidazo[4,5-d]pyridazine compounds, processes for their preparation, novel intermediate products, and therapeutic uses thereof, for example, as Toll-like receptor 7 agonists and / or Toll-like receptor 8 agonists. Background of the invention The innate immune system contains several families of terminally encoded pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). These receptors recognize microbial components called pathogen-associated molecular patterns (PAMPs), which are highly conserved molecular structures across a wide range of pathogens, including viruses, fungi, bacteria, and parasites. It is well known that TLRs are promising targets for the development of new and effective therapeutic agents. More specifically, TLR7 and TLR8 are located within endolysosomes and play an important role in the immune response during viral infection due to their ability to recognize single-stranded RNA pAMPs, as well as synthetic small molecules. Their stimulation leads to intracellular signaling and the subsequent activation of genes encoding, among others, costimulatory molecules, proinflammatory cytokines, and type I interferons. Several small molecule TLR7 agonists (commonly referred to as TLR7 agonists) and / or TLR8 agonists (commonly referred to as TLR8 agonists) have already been described, for example, Imiquimod (R-837), Resiquimod (R-848) and Gardiquimod. For example, resiquimod can act simultaneously as a TLR7 and TLR8 agonist. Some other synthetic small molecules, such as imiquimod, preferentially activate TLR7. Activation of TLRs such as TLR7 and / or TLR8 by an agonist can induce the secretion of type I interferons such as IFN and IFNβ, tumor necrosis factor (TNF), and interleukins such as IL6 and IL12, which are important players in initiating innate and adaptive immunity. The secretion of these cytokines, associated with the expression of costimulatory molecules, is known to induce the maturation of dendritic cells, monocytes, and macrophages, facilitating antigen presentation and stimulating the adaptive immune response. TLR7 and / or TLR8 agonists have already been published as adjuvants for vaccines and for the treatment of infections and diseases, for example, to treat skin and bladder cancer, renal cell carcinoma, autoimmune diseases, inflammatory diseases, and allergic diseases. Suzuki Toshinobu et al., (J. of Heterocyclic Chemistry, vol.15, No. 8, pages 1451-1453, 1978) describes some diaminoimidazo[4, 5-d]pyridazine compounds and intermediate compounds. Hevener Kirk et al. (J. of Medicinal Chemistry, vol. 53, No. 1, pages 166-177, 2010) disclose structural studies of pterin-based inhibitors of dihydropteroate synthase, which is a key enzyme in bacterial folate synthesis and the target of the sulfonamide class of antibacterials. Waleed Hussein et al. (Expert opinion on therapeutic patents, vol. 24, No. 4, pages 453-470, 2014) describes Toll-like receptor agonists. Kieffer Madeleine et al. (Expert opinion on therapeutic patents, vol.30, No. 11, pages 825-845, 2020) describes a small molecule agonist of Toll-like receptors 7 and 8. Document WO91 / 19715 discloses non-peptide imidazo[4,5-d]pyridazine 1H-substituted compounds for use in the treatment of circulatory and cardiovascular disorders. However, there is still a need to provide novel compounds that are useful as TLR7 agonists and / or TLR8 agonists. The objective of this disclosure, therefore, is to provide novel compounds that act as TLR7 and / or TLR8 agonists. Summary of the invention This disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: where: R1 represents: a hydrogen atom, or a selected group of: to) an alkyl group (C1-C6) -; a hydroxy-alkyl (C1-C6) group -; an NH2-alkyl (C1-C6) group -; an NH-alkyl (C1-C6) -alkyl (C1-C6) - group; an N (alkyl (C1-C6) ) 2-alkyl (C1-C6) - group; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; b) a phenyl-alkyl (C1-C6) group - which is either unsubstituted or substituted with at least one substituent selected from: b1.- an alkoxy group (C1-C6) -; b2.- a hydroxyl group; b3) a -C (O) -H group; and b4.- an alkyl (C1-C6) group - which is unsubstituted or substituted with at least one substituent selected from: b4.1.- a hydroxyl group; and b4.2.- a group -NR4R5 where R4 and R5 are selected independently of each other from: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl group (C1-C16) -; b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, an alkoxy (C1-C6)-alkyl (C1-C6) group or an alkoxy (C1-C6)-alkoxy (C1-C6)-alkyl (C1-C6) group; b4.2.4.- an alkyl group (C1-C6) -S (O2) -; b4.2.5.- an alkyl group (C1-C6) -NH-C (O) -; b4.2.6.- an alkyl group (C1-C16) -C (O) -; b4.2.7.- an alkyl group (C1-C16) -OC (O) -; b4.2.8.- a group CH3-[O- (CH2) 2]nC (O) - where n is an integer from 1 to 30; b4.2.9.- a cycloalkyl (C3-C10) group - which is unsubstituted or substituted with at least one substituent selected from: a hydroxyl group; and an alkyl (C1-C6) group -; or b4.2.10.- a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(O)- and -SO2-; b4.2.11.- a phenyl-C (O) - group; b4.2.12.- an alkoxy group (C1-C6) -phenyl-alkyl (C1-C6) -OC (O) -; b4.2.13.- a group alkyl (C1-C16) -C (O) -NH-phenyl-alkyl (C1-C6) -OC (O) -; b4.2.14.- an alkyl (C1-C16) -OC (O) -alkyl (C1-C6) - group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group and a CH3-[O-(CH2)2]n group, where n is an integer from 1 to 30; c) - a cycloalkyl (C3-C10) -alkyl (C1-C6) group - that is unsubstituted or substituted with at least one substituent selected from -NH2 and an NH2-alkyl (C1-C6) group -; d) - a (C3-C10) alkyl-membered (C1-C6) heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group - and a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; and e) - a (C1-C6) membered heteroaryl-(C5-C10) alkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said heteroaryl being unsubstituted or substituted with at least one substituent selected from: an alkyl group (C1-C6) -; an NH2-alkyl (C1-C6) group - and a cyano group; f) - a (C3-C10) member-NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S (O) , SO2 and sulfur; g) - a (C3-C10) N-membered heterocycloalkyl group (C(O)-alkyl(C1-C6))-alkyl(C1-C16) -, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S(O), SO2 and sulfur; R2 represents a halogen atom, or a selected group of: an alkyl group (C1-C6) -; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; an alkylthio (C1-C6) group -; an alkylthio (C1-C6) -alkyl (C1-C6) - group; an alkyl (C1-C6) -S (O) - group; an alkyl group (C1-C6) -S (O2) -; an alkyl (C1-C6) group -S (O) -alkyl (C1-C6) -; an alkyl (C1-C6) group -S (O2) -alkyl (C1-C6) -; an alkoxy group (C1-C6) -; an alkoxy (C1-C6) -alkyl (C1-C6) group; a haloalkoxy (C1-C6) -alkyl (C1-C6) - group; a cycloalkyl (C3-C5) -O-alkyl (C1-C6) - group; an alkyl (C1-C6) -NH-alkyl (C1-C6) group; a (C1-C6 alkyl) 2-N-alkyl (C1-C6) group; an alkyl (C1-C6) -NH- group; and a (alkyl (C1-C6) ) 2N- group; R3 represents: a deuterium atom; a hydrogen atom or a selected group of: to) an alkyl group (C1-C6) -; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; and an alkylthio (C1-C6) group -; b) an -OR6 group where R6 is selected from: a hydrogen atom; an alkyl group (C1-C6) -; a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; a cycloalkyl (C3-C10) group -; a phenyl group; a phenyl-alkyl (C1-C6) group -; and a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(=O)- and -S(=O)2-; c) a group -NR7R8 where R7 and R8 are selected independently of each other from: a hydrogen atom; a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; an alkyl group (C1-C6) - unsubstituted or substituted with a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur; or a phenyl group that is either unsubstituted or substituted with at least one substituent selected from: a cyan group and an NR9R10-alkyl (C1-C6) group - where: R9 and R10 are selected, independently of each other, from: a hydrogen atom; an alkyl group (C1-C6) -; a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group - and a CH3-[O-(CH2)2]n- group where n is an integer from 1 to 30; or R7 and R8 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from: a phenyl group and a hydroxy-(C1-C6)alkyl-phenyl- group; d) a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur; and) a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heteroaryl group of (C5-C10) members being unsubstituted or substituted with at least one (C1-C6) alkyl group; F) an aryl group of (C6-C10) members; and g) a cycloalkyl (C3-C10) group -, provided that at least one of R1 and R3 is different from a hydrogen atom. The disclosure also relates to processes for the preparation of compounds of formula (I) in accordance with this disclosure. Therefore, according to a specific embodiment, the disclosure relates to a first process for the preparation of the compounds of formula (I) or a pharmaceutically acceptable salt thereof according to the present disclosure, as illustrated in Scheme 1 below (also referred to as Synthesis Method 1 in the present disclosure) and as detailed below. According to another specific embodiment, the disclosure relates to a second process for the preparation of the compounds of formula (I) or a pharmaceutically acceptable salt thereof according to this disclosure, as illustrated in Scheme 2 below (also referred to as Synthesis Method 2, Synthesis Method 2a and Synthesis Method 2b in this disclosure) and as detailed below. According to another specific embodiment, the disclosure relates to a third process for the preparation of the compounds of formula (I) or a pharmaceutically acceptable salt thereof according to the present disclosure, as illustrated in Scheme 3 below (also referred to as Synthesis Method 3 in the present disclosure) and as detailed below. According to another specific embodiment, the disclosure relates to a fourth process for the preparation of the compounds of formula (I) or a pharmaceutically acceptable salt thereof according to this disclosure, as illustrated in Scheme 4 below (also referred to as Synthesis Method 4, Synthesis Method 4a and Synthesis Method 4b in this disclosure) and as detailed below. The disclosure also refers to intermediate compounds or a pharmaceutically acceptable salt thereof from the formulas: where R1, R1a, R2, R3a, HAL and G1 are as defined in this disclosure. This disclosure also relates to specific intermediate compounds or a pharmaceutically acceptable salt thereof selected from: in which: Compounds (H) and (J) or a pharmaceutically acceptable salt thereof belong to formula (VIIa) as defined herein; Compounds (Ia) and (K) or a pharmaceutically acceptable salt thereof belong to formula (VIIIa) as defined herein; Compounds (L) and (N) or a pharmaceutically acceptable salt thereof belong to formula (VIII) as defined herein and Compounds (M) and (R) or a pharmaceutically acceptable salt thereof belong to formula (IX) as defined in this disclosure. Compounds of formula (I) may comprise one or more asymmetric carbon atoms. Therefore, they may exist as enantiomers, preferably pure enantiomers, or as diastereomers and a mixture thereof. Compounds of formula (I) may also exist in tautomeric forms. In fact, this disclosure should be understood to cover all isomers of formulas (I), (Ia), (VIIa), (VIII), (VIIIa), (IX), and (X) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric, and optical forms, and mixtures thereof (e.g., racemic or non-racemic mixtures). It should be understood that in this disclosure, isomers may be restricted to geometric, optical, and tautomeric isomers having the same molecular formula. The compounds in formulas (I), (Ia), (VIIa), (VIII), (VIIIa), (IX), and (X) may exist as bases, acids, zwitterions, or addition salts with acids or bases, particularly pharmaceutically acceptable salts. These addition salts, bases, acids, and zwitterions are part of the disclosure. Therefore, the disclosure relates, among other things, to the compounds in formulas (I), (Ia), (VIIa), (VIII), (VIIIa), (IX), and (X), or pharmaceutically acceptable salts thereof. These salts can be prepared with pharmaceutically acceptable acids or bases, although salts of other useful acids or bases, for example, for purifying or isolating the compounds of formulas (I), (Ia), (VIIa), (VIII), (VIIIa), (IX) and (X), are also part of the disclosure. Among the suitable salts that are part of the disclosure, the following can be cited: hydrochloride and trifluoroacetate. Another subject matter of this disclosure is a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for use as a medicament. Another subject matter of this disclosure is a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for use in therapy, especially as a TLR7 agonist and / or as a TLR8 agonist. Another subject matter of this disclosure is a compound of formula (I) in accordance with the disclosure selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of a disease or disorder associated with TLR7 and / or TLR8 activity such as a proliferative cell disease, cancer, chronic myelogenous disease, hairy cell leukemia, a dermatological disease such as a skin lesion or skin cancer (e.g., external genital and perianal warts / condyloma acuminata, genital herpes, actinic keratosis, basal cell carcinoma, cutaneous T-cell lymphoma), an autoimmune disease, an inflammatory disease, a respiratory disease, septicemia, an allergy (e.g., allergic rhinitis or respiratory allergy), asthma, graft rejection, graft-versus-host disease, or immunodeficiency. Another subject matter of this disclosure is a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of cancer. Another subject matter of this disclosure is a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for use in a vaccine. For example, a compound of formula (I) may be used as a vaccine adjuvant, or the vaccine may be a self-adjuvanted vaccine. References to treatment methods in the subsequent paragraphs of this description are to be interpreted as references to the compounds, pharmaceutical compositions, and medicaments of the present invention for use in a method for treating the human (or animal) body therapeutically (or for diagnosis). Another subject matter of this disclosure is a method of treating a disease or disorder associated with TLR7 and / or TLR7 / 8 activity, such as a proliferative cell disease, cancer, chronic myelogenous disease, hairy cell leukemia, a dermatological disease such as a skin lesion or skin cancer (e.g., warts / external genital and perianal condyloma acuminata, genital herpes, actinic keratosis, basal cell carcinoma, cutaneous T-cell lymphoma), an autoimmune disease, an inflammatory disease, a respiratory disease, septicemia, or an allergy (e.g.,an allergic rhinitis or respiratory allergy), asthma, graft rejection, graft-versus-host disease, immunodeficiency, comprising administering to a subject in need, for example, a human being, a therapeutically effective amount of a compound of formula (I) in accordance with the selected disclosure from the lists above and below, or a pharmaceutically acceptable salt thereof. This disclosure also relates, in another aspect, to a method of preventing and / or treating a disease or disorder associated with TLR7 and / or TLR7 / 8 activity, such as a proliferative cell disease, cancer, chronic myelogenous disease, hairy cell leukemia, a dermatological disease such as a skin lesion or skin cancer (e.g., warts / external genital and perianal condyloma acuminata, genital herpes, actinic keratosis, basal cell carcinoma, cutaneous T-cell lymphoma), an autoimmune disease, an inflammatory disease, a respiratory disease, sepsis, an allergy (e.g., allergic rhinitis or respiratory allergy), asthma, graft rejection, graft-versus-host disease, immunodeficiency, in a patient in need, e.g., a human being.comprising immunizing said patient with a vaccine comprising a compound of formula (I) according to the disclosure selected from the lists above and below, or a pharmaceutically acceptable salt thereof. This disclosure also relates, in another aspect, to a vaccine adjuvant. This disclosure further relates to the use of a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, for the manufacture of a vaccine and / or a drug to prevent and / or treat a disease or disorder associated with TLR7 and / or TLR7 / 8 activity, such as a proliferative cell disease, cancer, chronic myelogenous disease, hairy cell leukemia, a dermatological disease such as a skin lesion or skin cancer (e.g., external genital and perianal warts / condyloma acuminata, genital herpes, actinic keratosis, basal cell carcinoma, cutaneous T-cell lymphoma), an autoimmune disease, an inflammatory disease, a respiratory disease, sepsis, an allergy (e.g., allergic rhinitis or respiratory allergy), asthma, graft rejection, graft-versus-host disease,an immunodeficiency. Another subject matter of this disclosure is a medicinal product comprising as an active ingredient an effective dose of a compound of formula (I) according to the disclosure selected from the lists above and below, or a pharmaceutically acceptable salt thereof. Another subject matter of this disclosure is a pharmaceutical composition comprising as an active ingredient an effective dose of a compound of formula (I) selected from the lists above and below, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. Definitions In the context of this disclosure, the terms below have the following definitions unless otherwise stated throughout this descriptive report: a "halogen atom": an atom of fluorine, chlorine, bromine or iodine and, for example, an atom of fluorine and chlorine; a "hydroxyl group": a "-OH" group; an "oxo group": a "=O" group; a "cyano group": a "-CN" group; an "alkyl (Cx-Cy)" group: an aliphatic group based on a linear or branched saturated hydrocarbon comprising x and y carbon atoms, for example, from 1 to 6 carbon atoms, or from 1 to 16 carbon atoms. By way of example, but not limitation, mention may be made of: methyl, ethyl, propyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, octyl, nonyl, decyl and the like; An "alkenyl (Cx-Cy)" group: an aliphatic group based on a linear or branched hydrocarbon comprising at least one unsaturation (double bond) and comprising from x to ay carbon atoms (x being an integer of at least 2), for example, from 2 to 6 carbon atoms. By way of example, but not limitation, mention may be made of: ethenyl, propenyl, butenyl, pentenyl, hexenyl groups and the like; An "(Cx-Cy)alkynyl" group: an aliphatic group based on a linear or branched hydrocarbon comprising at least one triple bond and comprising from x to ay carbon atoms (x being an integer of at least 2), for example, from 2 to 6 carbon atoms. By way of example, but not limitation, mention may be made of: ethynyl, propynyl, butynyl, pentynyl, hexynyl groups and the like; an "alkoxy (Cx-Cy)" group: an -O-alkyl group where the alkyl group is as defined above. For example, an alkoxy (C1-C6) group. By way of example, but not limitation, mention may be made of: methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, isobutoxy, pentoxy, hexyloxy, heptyloxy, octyloxy, noniloxy, decyloxy and the like; a "haloalkoxy (Cx-Cy)" group: an -O-alkyl group where the alkyl group is as defined above and is further substituted with at least one halogen atom as defined above. For example, a haloalkoxy (C1-C6) group. By way of example, but not limitation, mention may be made of: chloromethoxy, fluoromethoxy, dichloromethoxy, 2-fluoropropoxy groups and the like; an "alkylthio (Cx-Cy)" group: an -S-alkyl group where the alkyl group is as defined above. For example, an alkylthio (C1-C6) group. By way of example, but not limitation, mention may be made of: methylthio, ethylthio, propylthio, isopropylthio, linear, secondary or tertiary butylthio, isobutylthio, pentylthio, hexylthio, heptylthio, octylthio, nonylthio, decylthio, and the like; a "cycloalkyl (C3-C10)" group or a "cycloalkyl (C3-C5)" group: a cyclic alkyl group comprising, unless otherwise stated, from 3 to 10 carbon atoms (referred to as "cycloalkyl (C3-C10)") or from 3 to 5 carbon atoms ("cycloalkyl C3-C5)"), saturated or partially unsaturated, and unsubstituted or substituted. By way of example, but not limitation, mention may be made of: cyclopropyl, cyclobutyl, cyclopentyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and the like; a "(C3-C10) heterocycloalkyl group": a monocyclic alkyl group comprising, unless otherwise stated, from 3 to 10 carbon atoms (referred to as "a (C3-C10) member heterocycloalkyl group") and comprising from 1 to 4 heteroatoms selected from oxygen, nitrogen, sulfur, -S(O)- and -SO2- (in other words, one heteroatom replaces one carbon atom). Said heterocycloalkyl group may be saturated or partially saturated and unsubstituted or substituted.Examples of heterocycloalkyl groups may include, but are not limited to, the following: piperazine, morpholino, pyrrolidine, tetrahydropyran, thietano dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran, tetrahydrofuran, azetidine, oxetano, thietano, 2H-pyrrole, 1H-, 2H- or 3H-pyrroline, tetrahydrothiophene, oxadiazole and, for example, 1,3,4-oxadiazole or 1,3,5-oxadioazole, thiadiazole and, for example, 1,3,4-thiadiazole, isoxazoline, 2- or 3-pyrazoline, pyrroline, pyrazolidine, imidazoline, imidazolidine, thiazolidine, isooxazoline, isoxazolidine, dioxalane, oxathiazole, oxathiadiazole, dioxazole and similar; A "(C5-C10) heteroaryl group" means: a cyclic aromatic group comprising 5 to 10 carbon atoms and comprising 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur (referred to as "a (C5-C10) member heteroaryl group") (in other words, one heteroatom replaces one carbon atom). Such a heteroaryl group may be unsubstituted or substituted. By way of example of 5- to 10-membered heteroaryl groups, mention may be made of, but is not limited to, the following groups: pyridine, furan, pyrrole, thiophene, pyrazole, oxazole, isoxazole, triazole, tetrazole, oxadiazole, furazan, thiazole, isothiazole, thiadiazole, imidazole, pyrimidine, pyridazine, triazine, and the like; An "aryl (C6-C10)" group: a cyclic aromatic group comprising 6 to 10 carbon atoms (referred to as "an aryl (C6-C10) member"). Such an aryl group may be unsubstituted or substituted. Examples of 6- to 10-membered aryl groups include, but are not limited to, phenyl, naphthyl, and similar groups; A "deuterium atom" (D or 2H) is a stable, non-radioactive isotope of hydrogen and has an atomic weight of 2.0144; a "hydroxyl protecting group" means: Ethers, Silyl Ethers, Esters, carbonates, carbamates etc, such as Acetyl (Ac) , Benzoyl (Bz) , Benzyl (Bn) , ß-methoxyethoxymethyl ether (MEM) , dimethoxytrityl, [bis-(4-methoxyphenyl)phenylmethyl] (DMT) , methoxymethyl ether (MOM) , methoxytrityl [(4-methoxyphenyl)diphenylmethyl] (MMT) , pmethoxybenzyl ether (PMB) , p-methoxyphenyl ether (PMP) , methylthiomethyl ether, pivaloyl (Piv) , tetrahydropyranyl (THP) , tetrahydrofuran (THF) , trityl (triphenylmethyl, Tr) , silyl ether (for example, trimethylsilyl (TMS) , tert-butyldimethylsilyl (TBDMS) , tri-iso-propylsilyloxymethyl (TOM) and triisopropylsilyl (TIPS) ethers), methyl ethers, ethoxyethyl ethers (EE), for example, acetyl (Ac), benzyl (Bn), ß-methoxyethoxymethyl ether (MEM), dimethoxytrityl, [bis-(4-methoxyphenyl)phenylmethyl] (DMT), p-methoxybenzyl ether (PMB), tetrahydropyranyl (THP), trityl (triphenylmethyl, Tr), trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBDMS).(See the manual "Greene's protective groups in organic synthesis", PGM WUTS and TW GREENE, fourth edition, 1807 Wiley 207, Wiley Interscience) ;. An "amino protecting group" means: carbamates, amides, alkyls, enamines, imides, imines, etc., such as the carbobenzyloxy group (Cbz), p-methoxybenzyl carbonyl group (Moz or MeOZ), tert-butyloxycarbonyl group (BOC), 9-fluorenylmethyloxycarbonyl group (Fmoc), acetyl group (Ac), benzoyl group (Bz), benzyl group (Bn), carbamate group, p-methoxyphenyl group (PMP), tosyl group (Ts), p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), Troc group (trichloroethyl chloroformate), other sulfonamides, for example, the carbobenzyloxy group (Cbz), tert-butyloxycarbonyl group (BOC) , 9-fluorenylmethyloxycarbonyl group (Fmoc) , acetyl group (Ac) , benzoyl group (Bz) , p-methoxybenzyl group (PMB) , 3, 4-dimethoxybenzyl (DMPM) , Troc group (trichloroethyl chloroformate) . (See the manual "Greene's Protective Groups in organic Synthesis", PGM WUTS and TW GREENE, fourth edition, 1807 Wiley 207, Wiley Interscience. A "carboxylic acid protecting group" means: Esters, silicic esters, amides, hydrazides, etc., such as methyl esters, benzyl esters, tert-butyl esters, esters of 2,6-disubstituted phenols (e.g., 2,6-dimethylphenol, 2,6-diisopropylphenol, 2,6-di-tert-butylphenol), silicic esters, orthoesters, oxazoline, e.g., methyl esters and benzyl esters. (See the manual "Greene's Protective Groups in Organic Synthesis", PGM WUTS and TW GREENE, fourth edition, 1807 Wiley 207, Wiley Interscience); A "protecting aldehyde group" or a protecting ketone group (also called carbonyl protecting groups) means: acetals and ketals, dithioacetals and ketals, substituted hydrazones, oximes, etc., such as acetals and ketals, acytals and dithianes. (See the manual "Greene's Protective Groups in Organic Synthesis", PGM WUTS and TW GREENE, fourth edition, 1807 Wiley 207, Wiley Interscience); A "zwitterion" means: a globally neutral molecule with a positive and negative electrical charge and that has an acid group and a basic group. "ambient temperature" (also referred to as ta) in this disclosure means a temperature ranging from 18 °C to 30 °C, for example, from 18 °C to 25 °C; "TLR": The expressions "Toll-like receptor" and "TLR" refer to any member of a family of highly conserved mammalian proteins that recognize pathogen-associated molecular patterns and act as key signaling elements in innate immunity. TLR polypeptides share a characteristic structure that includes an extracellular domain with leucine-rich repeats, a transmembrane domain, and an intracellular domain that is involved in TLR signaling; "TLR7": The terms "Toll-like receptor 7" and "TLR7" refer to nucleic acids or polypeptides that share at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more sequence identity with a publicly available TLR7 sequence, e.g., GenBank accession number AAZ99026 for human TLR7 polypeptide, or GenBank accession number AAK62676 for murine TLR7 polypeptide; "TLR8": The terms "Toll-like receptor 8" and "TLR8" refer to nucleic acids or polypeptides that share at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more sequence identity with a publicly available TLR7 sequence, e.g., GenBank accession number AAZ95441 for human TLR8 polypeptide, or GenBank accession number AAK62677 for murine TLR8 polypeptide; "TLR agonist": is a substance that binds, directly or indirectly, to a TLR (e.g., TLR7 and / or TLR8) to induce TLR signaling. Any detectable difference in TLR signaling may indicate that an agonist stimulates or activates a TLR. Signaling differences may manifest, for example, as changes in the expression of target genes, in the phosphorylation of signal transduction components, in the intracellular localization of downstream elements such as NF-κB, in the association of certain components (such as IRAK) with other intracellular proteins or structures, or in the biochemical activity of components such as kinases (such as MAPK); "immune response": An "immunological response" or "immune response" to an antigen or composition, as used herein, refers to the development in a subject of a humoral and / or cellular immune response to the antigen or composition; Immune responses include innate and adaptive immune responses. Innate immune responses are rapid-acting responses that provide a first line of defense for the immune system. In contrast, adaptive immunity uses the selection and clonal expansion of immune cells that have somatically rearranged receptor genes (e.g., T and B cell receptors) that recognize antigens from a given pathogen or disorder (e.g., a tumor), thereby providing specificity and immune memory. Innate immune responses, among their many effects, lead to a rapid burst of inflammatory cytokines and the activation of antigen-presenting cells (APCs) such as macrophages and dendritic cells.To distinguish pathogens from self-components, the innate immune system uses a variety of relatively invariant receptors that detect pathogen-specific features known as pathogen-associated molecular patterns, or PAMPs. The mechanism behind this potentiation of immune responses has been reported to involve pattern recognition receptors (PRRs), which are differentially expressed on a variety of immune cells, including neutrophils, monocytes, macrophages, dendritic cells, natural killer cells, B lymphocytes, and some non-immune cells such as epithelial and endothelial cells. The engagement of PRRs leads to the activation of some of these cells and their secretion of cytokines and chemokines, as well as the maturation and migration of other cells. This, in turn, creates an inflammatory environment that leads to the establishment of the adaptive immune response.PRRS include non-phagocytic receptors, such as Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) proteins, and receptors that induce phagocytosis, such as sequestering receptors, mannose receptors, and β-glucan receptors. Dendritic cells are recognized as some of the most important cell types for initiating the priming of CD4+ helper T cells without prior activation and for inducing the differentiation of CD8+ T cells into cytotoxic T lymphocytes. TLR signaling has been reported to play an important role in determining the quality of these helper T cell responses, for example, by determining the nature of the TLR signal and the specific type of TH response observed (e.g., TH1 versus TH2 response).A combination of antibody (humoral) and cellular immunity occurs as part of a TH1 type response, whereas a TH2 type response is predominantly an antibody response. A "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" refers to an immune response mediated by T lymphocytes and / or other white blood cells. An important aspect of cellular immunity involves an antigen-specific response by cytotoxic T lymphocytes (CTLs). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on cell surfaces. CTLs help induce and promote the destruction of intracellular microbes, or the lysis of cells infected with such microbes. Another aspect of cellular immunity involves an antigen-specific response by helper T lymphocytes.Helper T cells act to help stimulate the function and focus the activity of nonspecific effector cells against cells that present peptide antigens in association with MHC molecules on their surface. A "cellular immune response" also refers to the production of cytokines, chemokines, and other such molecules produced by activated T cells and / or other white blood cells, including those derived from CD4+ and CD8+ T cells. A TLR7 and / or TLR8-associated "immune response" is an immune response that involves the activation of TLR7 and / or TLR8 receptors. Activation of TLR7 and / or TLR8 receptors can be determined in vitro using methods such as those described in the Examples. "Induce": "Induce" and variations thereof refer to any measurable increase in cellular activity. For example, the induction of an immune response may include, for instance, an increase in the production of a cytokine, the activation, proliferation, or maturation of a population of immune cells, and / or another indicator of enhanced immune function. Detailed description of this disclosure The disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: where: R1 represents: a hydrogen atom, or a selected group of: to) an alkyl group (C1-C6) -; a hydroxy-alkyl (C1-C6) group -; an NH2-alkyl (C1-C6) group -; an NH-alkyl (C1-C6) -alkyl (C1-C6) - group; an N (alkyl (C1-C6) ) 2-alkyl (C1-C6) - group; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; b) a phenyl-alkyl (C1-C6) group - which is either unsubstituted or substituted with at least one substituent selected from: b1.- an alkoxy group (C1-C6) -; b2.- a hydroxyl group; b3) a -C (O) -H group; and b4.- an alkyl (C1-C6) group - which is unsubstituted or substituted with at least one substituent selected from: b4.1.- a hydroxyl group; and b4.2.- a group -NR4R5 where R4 and R5 are selected independently of each other from: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl group (C1-C16) -; b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, an alkoxy (C1-C6)-alkyl (C1-C6) group or an alkoxy (C1-C6)-alkoxy (C1-C6)-alkyl (C1-C6) group; b4.2.4.- an alkyl group (C1-C6) -S (O2) -; b4.2.5.- an alkyl group (C1-C6) -NH-C (O) -; b4.2.6.- an alkyl group (C1-C16) -C (O) -; b4.2.7.- an alkyl group (C1-C16) -OC (O) -; b4.2.8.- a group CH3-[O- (CH2) 2]nC (O) - where n is an integer from 1 to 30; b4.2.9.- a cycloalkyl (C3-C10) group - which is unsubstituted or substituted with at least one substituent selected from: a hydroxyl group; and an alkyl (C1-C6) group -; or b4.2.10.- a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(O)- and -SO2-; b4.2.11.- a phenyl-C (O) - group; b4.2.12.- an alkoxy group (C1-C6) -phenyl-alkyl (C1-C6) -OC (O) -; b4.2.13.- a group alkyl (C1-C16) -C (O) -NH-phenyl-alkyl (C1-C6) -OC (O) -; b4.2.14.- an alkyl (C1-C16) -OC (O) -alkyl (C1-C6) - group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group and a CH3-[O-(CH2)2]n group, where n is an integer from 1 to 30; c) - a cycloalkyl (C3-C10) -alkyl (C1-C6) group - that is unsubstituted or substituted with at least one substituent selected from -NH2 and an NH2-alkyl (C1-C6) group -; d) - a (C3-C10) alkyl-membered heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, wherein said heterocycloalkyl group is unsubstituted or substituted with at least one substituent selected from an alkyl (C1-C6) group - and a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; and e) - a (C1-C6) membered heteroaryl-(C5-C10) alkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said heteroaryl being unsubstituted or substituted with at least one substituent selected from: an alkyl group (C1-C6) -; an NH2-alkyl (C1-C6) group - and a cyano group; f) - a (C3-C10) member-NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S (O) , SO2 and sulfur; g) - a (C3-C10) N-membered heterocycloalkyl group (C(O)-alkyl(C1-C6))-alkyl(C1-C16) -, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S(O), SO2 and sulfur; R2 represents a halogen atom, or a selected group of: an alkyl group (C1-C6) -; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; an alkylthio (C1-C6) group -; an alkylthio (C1-C6) -alkyl (C1-C6) - group; an alkyl (C1-C6) -S (O) - group; an alkyl group (C1-C6) -S (O2) -; an alkyl (C1-C6) group -S (O) -alkyl (C1-C6) -; an alkyl (C1-C6) group -S (O2) -alkyl (C1-C6) -; an alkoxy group (C1-C6) -; an alkoxy (C1-C6) -alkyl (C1-C6) group; a haloalkoxy (C1-C6) -alkyl (C1-C6) - group; a cycloalkyl (C3-C5) -O-alkyl (C1-C6) - group; an alkyl (C1-C6) -NH-alkyl (C1-C6) group; a (C1-C6 alkyl) 2-N-alkyl (C1-C6) group; an alkyl (C1-C6) -NH- group; and a (alkyl (C1-C6) ) 2N- group; R3 represents: a deuterium atom; a hydrogen atom or a selected group of: to) an alkyl group (C1-C6) -; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; and an alkylthio (C1-C6) group -; b) an -OR6 group where R6 is selected from: a hydrogen atom; an alkyl group (C1-C6) -; a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; an alkenyl group (C2-C6) -; an alkynyl group (C2-C6) -; a cycloalkyl (C3-C10) group -; a phenyl group; a phenyl-alkyl (C1-C6) group -; and a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(=O)- and -S(=O)2-; c) a group -NR7R8 where R7 and R8 are selected independently of each other from: a hydrogen atom; a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; an alkyl group (C1-C6) - unsubstituted or substituted with a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur; or a phenyl group that is either unsubstituted or substituted with at least one substituent selected from: a cyan group and an NR9R10-alkyl (C1-C6) group - where: R9 and R10 are selected, independently of each other, from: a hydrogen atom; an alkyl group (C1-C6) -; a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group - and a CH3-[O-(CH2)2]n- group where n is an integer from 1 to 30; R7 and R8 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from: a phenyl group and a hydroxy-(C1-C6)alkyl-phenyl- group; d) a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur; and) a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heteroaryl group of (C5-C10) members being unsubstituted or substituted with at least one (C1-C6) alkyl group; F) an aryl group of (C6-C10) members; and g) a cycloalkyl group (C3-C10) -. provided that at least one of R1 and R3 is different from a hydrogen atom Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds comprises the compounds for which R1 represents a hydrogen atom or a selected group of: to) an alkyl group (C1-C6) -; a hydroxy-alkyl group (C1-C6) - or an NH2-alkyl (C1-C6) group -; b) a phenyl-alkyl (C1-C6) group - which is either unsubstituted or substituted with a substituent, selected from: b1.- an alkoxy group (C1-C6) -; b3.- a group -C (O) -H and b4.- an alkyl (C1-C6) group - substituted with at least one substituent selected from: b4.1.- a hydroxyl group; b4.2.- a group -NR4R5 where R4 and R5 are selected independently of each other, from: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl group (C1-C16) -; b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, an alkoxy (C1-C6)-alkyl (C1-C6) group or an alkoxy (C1-C6)-alkoxy (C1-C6)-alkyl (C1-C6) group; b4.2.4.- an alkyl group (C1-C6) -S (O2) -; b4.2.5.- an alkyl group (C1-C6) -NH-C (O) -; b4.2.6.- an alkyl group (C1-C16) -C (O) -; b4.2.7.- an alkyl group (C1-C16) -OC (O) -; b4.2.8.- a group CH3-[O- (CH2) 2]nC (O) - where n is an integer from 1 to 30; b4.2.9.- a cycloalkyl (C3-C10) group - which is unsubstituted or substituted with at least one alkyl (C1-C6) group or a hydroxyl group; b4.2.10.- a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and -SO2-; b4.2.11.- a phenyl-C (O) - group; b4.2.12.- an alkoxy group (C1-C6) -phenyl-alkyl (C1-C6) -OC (O) -; b4.2.13.- a group alkyl (C1-C16) -C (O) -NH-phenyl-alkyl (C1-C6) -OC (O) -; b4.2.14.- an alkyl (C1-C16) -OC (O) -alkyl (C1-C6) - group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to two heteroatoms selected from oxygen and nitrogen; c) - a cycloalkyl (C3-C10) -alkyl (C1-C6) group - that is unsubstituted or substituted with a substituent selected from -NH2 and an NH2-alkyl (C1-C6) group -; d) - an unsubstituted (C1-C6)-alkyl-membered heterocycloalkyl group comprising one to two nitrogen heteroatoms; e) - a (C1-C6) alkyl-membered heteroaryl group - comprising a nitrogen heteroatom, said heteroaryl being unsubstituted or substituted with at least one substituent selected from: an NH2-alkyl (C1-C6) group - and a cyano group; f) - a (C3-C10) member-NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising a heteroatom selected from oxygen, nitrogen, S (O) , SO2 and sulfur; g) - a (C3-C10) member-N (C (O) -alkyl (C1-C6) ) -alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising a heteroatom selected from oxygen, nitrogen, S (O) , SO2 and sulfur. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds comprises the compounds for which R1 represents: a hydrogen atom or a selected group of: to) a methyl group; a C (OH) (CH3) 2-CH2- group, a C (CH3) (CH2OH) 2-CH2- group, a CH (CH2OH) 2-CH2- group; an NH2- (CH2) 4- group, an NH2- (CH2) 5- group or an NH2- (CH2) 6- group; b) - a phenylmethyl group (i.e., a benzyl group), the phenyl group being unsubstituted or substituted with at least one substituent selected from: b1.- a methoxy group, such as a methoxy group in the para position of the phenyl group; b3.- a -C (O) -H group, such as -C (O) -H in the para position of the phenyl group; b4.- a methyl group substituted with at least one substituent selected from: b4.1.- a hydroxyl group; b4.2.- a group -NR4R5 where R4 and R5 are selected, independently of each other, from: b4.2.1.- a hydrogen atom; b4.2.2.- a methyl group, an isopropyl group, a pentyl group, a hexyl group, a nonyl group, a decyl group; b4.2.3.- a CH3-O-(CH2)2- group, a CH3-O-((CH2)2-O)n-(CH2)2- group, a CH3-O-((CH2)2-O)7-(CH2)2- group, a CH3-O-((CH2)2-O)5-(CH2)2- group, a CH3-O-((CH2)2-O)3-(CH2)2- group, a CH3-O-((CH2)2-O)2-(CH2)2- group or a CH3-O-(CH2)2-O-(CH2)2- group; b4.2.4.- a group CH3-S (O2) -; b4.2.5.- a group CH3-CH2-NH-C (O) -; b4.2.6.- a group CH3-C (O) -, a group CH3-CH2-C (O) -, a group CH3- (CH2) 5-C (O) -, a group CH3- (CH2) 9-C (O) - or a group CH3- (CH2) 3-C (O) -; b4.2.7.- a group CH3-CH2-OC (O) -; b4.2.8.- a group CH3-[O- (CH2) 2]2-C (O) - or a group CH3-O- (CH2) 2-C (O) -; b4.2.9.- a cyclopropyl group or a cyclobutyl group, the cyclopropyl or cyclobutyl group being without substituting the substituted with at least one substituent selected from a hydroxyl group or a methyl group; b4.2.10.- a tetrahydropyranyl group or a thiethane dioxide group; b4.2.11.- a phenyl-C (O) - group; b4.2.12.- a group CH3-O-phenyl-CH2-OC (O) -; b4.2.13.- a group CH3-C (O) -NH-phenyl-CH2-OC (O) -; b4.2.14.- a group C (CH3) 3-OC (O) -CH2- or a group C (CH3) 3-OC (O) - (CH2) 2-; the R4 and R5 together with the nitrogen atom form a piperazinyl group, a morpholino group or a pyrrolidinyl group; c) - a cyclohexyl-CH2- group that is unsubstituted or substituted with at least one substituent selected from an -NH2 group and an NH2-CH2- group; d) - a piperazinyl-(CH2)2- group, a piperidinyl-CH2- group or a piperidinyl-(CH2)2- group; and e) - a pyridyl-CH2- group that is unsubstituted or substituted with at least one substituent selected from an NH2-CH2- group and a cyano group; f) - a tetrahydropyranyl-NH- (CH2) 4- group, a tetrahydropyranyl-NH- (CH2) 6- group, a dioxothietanyl-NH- (CH2) 4- group or a dioxothietanyl-NH- (CH2) 6- group; (g) - a tetrahydropyranyl-N(C(O)-CH3)-(CH2)4- group, a tetrahydropyranyl-N(C(O)-CH3)-(CH3)6- group, a dioxothiethanyl-N(C(O)-CH2)-(CH2)4- group, or a dioxothiethanyl-N(C(O)-CH3)-(CH2)6- group. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject matter of disclosure, a group of compounds comprises the compounds for which R2 represents a group selected from: an alkyl group (C1-C6) -; an alkylthio (C1-C6) group -; an alkyl (C1-C6) -S (O) - group; an alkyl (C1-C6) -NH-alkyl (C1-C6) group; an alkyl (C1-C6) -NH- group; and an alkoxy (C1-C6) -alkyl (C1-C6) group. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds comprises the compounds for which R2 represents a selected group of: a methyl group, an ethyl group, an n-propyl group, an n-butyl group; a CH3- (CH2) 2-S- group; a CH3- (CH2) 2-S (O) - group; a CH3-S- (CH2) 2- group; a CH3-CH2-O-CH2- group; a CH3-O- (CH2) 2- group; a CH3-CH2-NH-CH2- group; and a CH3- (CH2) 2-NH- group. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds consists of compounds for which R2 represents an alkyl group (C1-C6), for example, a butyl group such as an n-butyl group, a methyl group, or a propyl group such as an n-propyl group. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds comprises the compounds for which R3 represents: a hydrogen atom or a selected group of: a) - an alkyl group (C1-C6) -; an alkenyl group (C2-C6) -; an alkylthio (C1-C6) group -; b) an -OR6 group where R6 is selected from: a hydrogen atom; an alkyl group (C1-C6) -; a CH3-[O-(CH2)2]n- group where n is an integer from 1 to 30; an alkenyl group (C2-C6); a cycloalkyl group (C3-C10); a phenyl group; a phenyl (C1-C6 alkyl) group -; and a (C3-C10) member heterocycloalkyl group comprising a heteroatom selected from oxygen, sulfur, -S(O)- and -SO2-; c) a group -NR7R8 where R7 and R8 are selected independently of each other, from: a hydrogen atom; a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; an alkyl group (C1-C6) - unsubstituted or substituted with: a (C5-C10) membered heteroaryl group comprising an oxygen atom; or a phenyl group that is either unsubstituted or substituted with at least one substituent selected from: a cyan group and an NR9R10-alkyl (C1-C6) group - wherein R9 and R10 are selected independently of each other from: a hydrogen atom; an -alkyl group (C1-C6) or a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to two heteroatoms selected from oxygen and nitrogen, said heterocycloalkyl group of (C3-C10) members being substituted with at least one (C1-C6) alkyl group -, for example, one to three (C1-C6) alkyl groups -, such as a (C1-C6) alkyl group -; or R7 and R8 together with the nitrogen atom to which they are attached form a (C3C10) member heterocycloalkyl group comprising a nitrogen heteroatom, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent, for example, one to three substituents, such as a substituent selected from: a phenyl group and a hydroxy-(C1-C6)alkyl-phenyl- group; d) a (C3-C10) member heterocycloalkyl group comprising a heteroatom selected from oxygen and nitrogen; and) a (C5-C10) member heteroaryl group comprising one to two heteroatoms selected from oxygen, nitrogen, and sulfur, said heteroaryl group of (C5-C10) members - being unsubstituted or substituted with at least one (C1-C6) alkyl group -, for example, one to three (C1-C6) alkyl groups -, such as one (C1-C6) alkyl group -; F) an aryl group of (C6-C10) members- and g) a cycloalkyl group (C3-C10) -. Among the compounds of formula (I) or a pharmaceutically acceptable salt thereof that are the subject of disclosure, a group of compounds comprises the compounds for which R3 represents: a hydrogen atom or a selected group of: to) an isopropyl group, an isobutyl group, an isopentyl group; a C- (CH3) (=CH2) - group, a (CH3) 2C=CH- group, a (CH3) 2CH-CH=CH- group; an isopropylthio- group; b) an -OR6 group where R6 represents: a hydrogen atom; a methyl group, an ethyl group, an isopropyl group, an n-propyl group, an n-butyl group, a sec-butyl group; a CH3-O- (CH2) 2- group; a propenyl group; a cyclopentyl group; an unsubstituted phenyl group, a phenyl-CH2- group; a tetrahydropyranyl group, a thiolane group, a thiolane oxide group, a thiolane dioxide group, or a tetrahydrofuranyl group; c) a group -NR7R8 where R7 and R8 are selected independently of each other, from: a hydrogen atom; a CH3-O- (CH2) 2- group; a methyl group, an isopropyl group; a furanyl- (CH2) 3- group; a phenyl- (CH2)- group, said phenyl group being unsubstituted or substituted with at least one substituent, for example, from one to five substituents, such as a substituent selected from: a cyan group and an NR9R10-CH2- group where R9 and R10 are selected independently of each other, from: a hydrogen atom; a methyl group or a CH3-O- (CH2) 2- group; or R9 and R10 together form with the nitrogen atom to which they are attached a morpholino group or a piperazinyl group, said morpholino group or piperazinyl group being unsubstituted or substituted with at least one methyl group, or R7 and R8 together form with the nitrogen atom to which they are attached a pyrrolidinyl group, wherein said pyrrolidinyl group is unsubstituted or substituted with at least one substituent, for example, one to three substituents, such as a substituent selected from: a phenyl group or an OH-CH2-phenyl- group, for example, an OH-CH2- group is in the para position of the phenyl group; d) a tetrahydrofuranyl group, a dihydropyrrolyl group or a dihydrofuranyl group; and) a thienyl group, a furanyl group, a pyrrolyl group, a pyrazolyl group, said thienyl group, furanyl group, pyrrolyl group or pyrazolyl group being unsubstituted or substituted with at least one methyl group, for example, one to three methyl groups, such as a methyl group; F) a phenyl group; g) a cyclopentenyl group, a cyclopentyl group, a cyclohexenyl group, and a cyclohexyl group. All these subgroups, taken alone or in combination, are part of this disclosure. The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, provided that at least one of R1 and R3 is different from a hydrogen atom. According to another particular embodiment, the disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, provided that R1 and R3 are simultaneously distinct from a hydrogen atom. According to another embodiment, the disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: where: R1 represents a selected group of: to) an alkyl group (C1-C6), for example, a methyl group; an NH2-alkyl (C1-C6) group -, for example, an NH2- (CH2) 4- group, an NH2- (CH2) 5- group, an NH2- (CH2) 6- group; b) - a phenyl-alkyl (C1-C6) group -, for example, a benzyl group, the phenyl group being unsubstituted or substituted with at least one substituent, for example, from one to five substituents, such as a substituent, selected from: b1.- an alkoxy group (C1-C6), for example a methoxy group, such as a methoxy group in the para position of the phenyl group; b3.- -C (O) -H, such as -C (O) -H in the para position of the phenyl group and b4.- an alkyl group (C1-C6), for example a methyl group, such as a methyl group in the para and / or meta positions of the phenyl group, said alkyl group being in turn unsubstituted or substituted with at least one substituent, for example, a substituent, selected from: b4.1.- a hydroxyl group; b4.2.- a group -NR4R5, where R4 and R5 are independent of each other: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl (C1-C16) group -, for example, an isopropyl group; b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, for example, n being 6 or 8; b4.2.5.- an alkyl (C1-C6)-NH-C(O)- group, for example, a CH3-CH2-NH-C(O)- group; b4.2.6.- an alkyl group (C1-C16) -C (O) -, for example, CH3-C (O) -; b4.2.7.- an alkyl (C1-C16) -OC (O) - group, for example, a CH3-CH2-OC (O) - group; b4.2.8.- a CH3-[O-(CH2)2]nC(O)- group, where n is an integer from 1 to 30, for example, n ≥ 1; b4.2.9.- a cycloalkyl (C3-C10)- group, for example, a cyclobutyl group, said cycloalkyl group being unsubstituted or substituted with at least one substituent, for example, from one to five substituents, such as an alkyl (C1-C6) group, for example, a methyl group; b4.2.10.- a (C3-C10) member heterocycloalkyl group comprising a heteroatom that is -SO2-, for example, a thiethane dioxide group; b4.2.12.- an alkoxy (C1-C6)-phenyl-alkyl (C1-C6)-OC(O)- group, for example, a CH3-O-para-phenyl-CH2-OC(O)- group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6)-alkyl group and a CH3-[O-(CH2)2]n- group, n being an integer from 1 to 30; for example, R4 and R5 together with the nitrogen atom to which they are attached form a piperazinyl group; c) - a cycloalkyl (C3-C10) alkyl (C1-C6) group -, for example, a cyclohexyl-CH2- group, said cycloalkyl being unsubstituted or substituted with at least one substituent, for example, one to five substituents, such as a substituent selected from NH2, and an NH2-alkyl (C1-C6) group -, for example, an NH2-CH2- group; d) - a (C3-C10) alkyl-membered (C1-C6) heterocycloalkyl group -, for example, a piperazinyl-(CH2)2- group or a piperidinyl-(CH2)2- group, said heterocycloalkyl group comprising 1 to 2 nitrogen heteroatoms, for example, a piperazinyl group or a piperidinyl group; e) - a (C5-C10) alkyl-membered (C1-C6) heteroaryl group -, for example, a pyridyl-CH2- group, said heteroaryl comprising a nitrogen heteroatom, for example, a pyridyl group, said heteroaryl being unsubstituted or substituted with at least one substituent, for example, one to three substituents, such as a substituent, which is a cyano group; f) - a (C3-C10) member -NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising one to four heteroatoms, for example, a heteroatom, selected from oxygen, nitrogen, S(O), SO2 and sulfur, for example, a dioxothiethanyl-NH-(CH2)4- group and (g) - a (C3-C10) member-N(C(O)-alkyl(C1-C6))-alkyl(C1-C16)- heterocycloalkyl group, said heterocycloalkyl group comprising one to four heteroatoms, for example, a heteroatom, selected from oxygen, nitrogen, S(O), SO2 and sulfur, for example, a tetrahydropyranyl-N(C(O)-(CH3))-(CH2)4- group, a tetrahydropyranyl-N(C(O)-(CH3))-(CH3)6- group, a dioxothietanyl-N(C(O)-(CH3))-(CH2)4- group or a dioxothietanyl-N(C(O)-(CH3))-(CH2)6- group; R2 represents a selected group of: an alkyl group (C1-C6), for example, an n-butyl group or an n-propyl group; an alkoxy (C1-C6) alkyl (C1-C6) group -, for example, a CH3CH2-O-CH2- group and an alkyl (C1-C6) S (O) - group, for example, a CH3CH2CH2-S (O) - group; R3 represents a selected group of: a) - a (C1-C6) alkyl group -, for example, an isopropyl group, an isobutyl group or an isopentyl group; an alkenyl group (C2-C6) -, for example a propenyl group such as C (CH3) (=CH2) -, a butenyl group such as (CH3) 2C=CH- or a pentenyl group such as (CH3) 2CH-CH=CH-; an alkylthio (C1-C6) group -, for example, an isopropylthio group; b) - an -OR6 group, being R6: an alkyl (C1-C6) group -, for example, a methyl group, an isopropyl group, an n-propyl group, an n-butyl group or a sec-butyl group; a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, for example, CH3-O-(CH2)2-; an alkenyl (C2-C6)- group, for example, a propenyl group such as -CH2-CH=CH2; a cycloalkyl group (C3-C10), for example, a cyclopentyl group; a phenyl group; a phenyl-alkyl (C1-C6) group - for example, a benzyl group; or a (C3-C10) member heterocycloalkyl group comprising a heteroatom selected from oxygen, sulfur, -S(O)- and -SO2-, for example, a tetrahydropyranyl group, a thiolane dioxide group, a thiolane group, a thiolane oxide group and a tetrahydrofuranyl group; c) - a group -NR7R8, R7 and R8 are selected independently of each other from: a hydrogen atom; a group CH3-[O-(CH2)2]n- where n is an integer from 1 to 30, for example, CH3-O-(CH2)2-; an alkyl (C1-C6) group, for example a methyl group or an isopropyl group, said alkyl (C1-C6) group being either unsubstituted or substituted with a phenyl group (to form, for example, a benzyl group), said phenyl group being either unsubstituted or substituted with at least one NH2-alkyl (C1-C6)-, for example, one to five NH2-alkyl (C2-C6)-, such as an NH2-alkyl (C1-C6) 2-, such as NH1-: or R7 and R8 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising a nitrogen heteroatom, for example a pyrrolidinyl group; d) - a (C3-C10) member heterocycloalkyl group comprising an oxygen heteroatom, for example a tetrahydrofuranyl group or a dihydrofuranyl group; E) - a (C5-C10) member heteroaryl group - comprising one to two heteroatoms selected from oxygen, nitrogen and sulfur, for example a thienyl group, a furanyl group or a pyrrolyl group, said (C5-C10) member heteroaryl group being - unsubstituted or substituted with at least one (C1-C6) alkyl group - for example, one to three (C1-C6) alkyl groups - such as a (C1-C6) alkyl group - for example, a methyl group and g) - a (C3-C10) cycloalkyl group - for example, a cyclopentenyl group, a cyclopentyl group, a cyclohexenyl group or a cyclohexyl group. According to another embodiment, the disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: where: R1 represents a hydrogen atom or a group selected from: to) an alkyl (C1-C6) group - for example, a methyl group; a hydroxy-alkyl (C1-C6) group -, for example, a C (OH) (CH3) 2-CH2- group, a C (CH3) (CH2OH) 2-CH2- group or a CH (CH2OH) 2-CH2- group; b) a phenyl-alkyl (C1-C6) group -, for example, a benzyl group, the phenyl group being unsubstituted or substituted with at least one alkyl (C1-C6) group -, for example, from one to five alkyl (C1-C6) groups -, such as a methyl group, such as a methyl group in the para and / or meta position of the phenyl group, said alkyl group, which may substitute for said phenyl group, being in turn unsubstituted or substituted with at least one -NR4R5 group, for example, an -NR4R5 group, R4 and R5 being independently of each other: b4.2.1) a hydrogen atom; b4.2.2) an alkyl (C1-C16) group -, for example, a methyl group, a hexyl group or a decyl group; b4.2.3) a CH3-[O-(CH2)2]n- group where n is an integer from 1 to 30, for example, n being 1, 2, 3, 4 or 12; b4.2.4) an alkyl (C1-C6) -S (O2) - group, for example, a CH3-S (O2) - group; b4.2.6) an alkyl (C1-C16) -C (O) - group, for example, a CH3-CH2C (O) - group; b4.2.9) a (C3-C10) cycloalkyl group -, for example, a cyclopropyl group or a cyclobutyl group, said cycloalkyl group being unsubstituted or substituted with at least one (C1-C6) alkyl group -, for example, one to five (C1-C6) alkyl groups -, such as a (C1-C6) alkyl group -, for example, a methyl group or with at least one hydroxyl group; b4.2.10) a (C3-C10) membered heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(O)- and -SO2, for example, a thiethane dioxide group; b4.2.11.- a phenyl-C (O) - group; b4.2.13) a (C1-C16)-alkyl-C(O)-NH-phenyl-(C1-C6)-alkyl-OC(O)- group, for example, a CH3-C(O)-NH-phenyl-CH2-OC(O)- group; b4.2.14) an alkyl (C1-C16) -OC (O) -alkyl (C1-C6) - group, for example, a C (CH3) 3-OC (O) -CH2- group or a C (CH3) 3-OC (O) - (CH2) 2- group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, for example, one to two heteroatoms selected from nitrogen and oxygen, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group and a CH3-[O-(CH2)2]n group, where n is an integer from 1 to 30, for example, R4 and R5 together with the nitrogen atom to which they are attached form a pyrrolidinyl group or a morpholine group; c) a cycloalkyl (C3-C10) -alkyl (C1-C6) - group, for example a cyclohexyl-CH2- group, said cycloalkyl being unsubstituted or substituted with at least one NH2 group, for example, one to five NH2 groups, such as an NH2 group; and) a (C5-C10) alkyl-membered heteroaryl group (C1-C6) -, for example, a pyridyl-CH2- group, said heteroaryl comprising a nitrogen heteroatom, for example, a pyridyl group, said heteroaryl being unsubstituted or substituted with at least one (C1-C6) alkyl-NH2 group -, for example, NH2-CH2-, for example, one to three (C1-C6) alkyl-NH2 groups -, for example, one to three NH2-CH2- groups, such as a (C1-C6) alkyl-NH2 group -, for example, an NH2-CH2- and F) a (C3-C10) member heterocycloalkyl group -NH-alkyl (C1-C16) -, said heterocycloalkyl group comprising one to four heteroatoms, for example, a heteroatom, selected from oxygen, nitrogen, S (O) , SO2 and sulfur, for example, a tetrahydropyranyl-NH- (CH2) 4- group, a tetrahydropyranyl-NH- (CH2) 6- group or a dioxothiethanyl-NH- (CH2) 6- group; R2 represents a selected group of: an alkyl (C1-C6) group -, for example, a methyl group, an n-butyl group; an alkylthio (C1-C6) group -, for example, a CH3CH2CH2S- group; an alkyl (C1-C6) -NH-alkyl (C1-C6) group -, for example, a CH3CH2-NH-CH2 group; an alkyl (C1-C6) -NH- group, for example, a CH3CH2CH2-NH- group; R3 represents a selected group of: to) an alkyl (C1-C6) group -, for example, an isopentyl group; an alkenyl group (C2-C6) -, for example, a (CH3) 2-CH-CH=CH- group; an alkylthio (C1-C6) group - for example, an isopropylthio group b) an -OR6 group, where R6 is an alkyl (C1-C6) group -, for example, an isopropyl group and c) a group -NR7R8, R7 and R8 being selected independently of each other by one hydrogen atom; an alkyl (C1-C6) group, for example, a methyl group or an isopropyl group; an alkyl (C1-C6) group substituted with a phenyl group, for example, a benzyl group, said phenyl group being unsubstituted or substituted with at least one NR9R10-alkyl (C1-C6) group, for example, one to five NR9R10-alkyl (C1-C6) groups, such as an NR9R10-alkyl (C1-C6) group, for example, an NR9R10-CH2- group, R9 and R10 being independently of each other an alkyl (C1-C6)- group, for example, a methyl group, or a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, for example, a CH3-O-(CH2)2- group, or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to two heteroatoms selected from oxygen and nitrogen, for example, a morpholino group or R7 and R8 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising a nitrogen heteroatom, for example a pyrrolidinyl group, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent, for example, one to three substituents, such as a substituent selected from a phenyl group and a (C1-C6) hydroxyalkyl group, for example, an OH-CH2-phenyl group such as an OH-CH2-phenyl group; d) a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, for example, a dihydropyrrolyl group or a pyrrolidinyl group or and) a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C5-C10) member heteroaryl group being either unsubstituted or substituted with at least one (C1-C6) alkyl group, for example, a pyrrolyl group. According to another embodiment, the disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt: where: R1 represents a selected group of: to) an alkyl (C1-C6) group - for example, a methyl group; a hydroxy-alkyl (C1-C6) group -, for example, a C (OH) (CH3) 2-CH2- group, a CH (CH2OH) 2-CH2- group or a C (CH2OH) 2 (CH3) -CH2- group; b) a phenyl-alkyl (C1-C6) group - for example, a benzyl group, the phenyl group being unsubstituted or substituted with at least one alkyl (C1-C6) group - for example, from one to five alkyl (C1-C6) groups - such as a methyl group, such as a methyl group in the para and / or meta position(s) of the phenyl group, said alkyl group being in turn unsubstituted or substituted with at least one substituent, for example, a substituent, selected from: b4.1.- a hydroxyl group; b4.2.- a group -NR4R5, R4 and R5 being independent of each other: b4.2.1.- a hydrogen atom; b4.2.6.- an alkyl (C1-C16) -C (O) - group, for example, a CH3-C (O) - group; b4.2.9.- a cycloalkyl (C3-C10) group, for example a cyclopropyl group or a cyclobutyl group, said cycloalkyl group being unsubstituted or substituted with at least one alkyl (C1-C6) group -, for example, one to five alkyl (C1-C6) groups -, such as an alkyl (C1-C6) group -, for example, a methyl group; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, e.g., a nitrogen atom; c) a cycloalkyl (C3-C10) alkyl (C1-C6) group -, for example, a cyclohexyl-CH2- group, said cycloalkyl being unsubstituted or substituted with at least one substituent, for example, from one to five substituents, such as a substituent selected from NH2, and an NH2-alkyl (C1-C6) group -, for example, an NH2-CH2- group; and and) a (C5-C10) alkyl (C1-C6)-membered heteroaryl group, for example, a pyridyl-CH2- group, said heteroaryl comprising a nitrogen heteroatom, for example, a pyridyl group, said heteroaryl being unsubstituted or substituted with at least one (C1-C6)-alkyl NH2 group, for example, one to three (C1-C6)-alkyl NH2 groups, such as a (C1-C6)-alkyl NH2 group, for example, an NH2-CH2- group; R2 represents a selected group of: an alkyl (C1-C6) group -, for example, an n-butyl group; an alkoxy (C1-C6) alkyl (C1-C6) group -, for example, a CH3CH2-O-CH2- group; an alkylthio (C1-C6) group -, for example, a CH3CH2CH2-S- group; an alkyl (C1-C6) -NH-alkyl (C1-C6) group -, for example, a CH3CH2-NH-CH2 group; an alkyl (C1-C6) -NH- group, for example, a CH3CH2CH2-NH- group; R3 represents a selected group of: b) an -OR6 group, R6 being an alkyl (C1-C6) group -, for example, an isopropyl group and c) a group -NR7R8, R7 and R8 being independently selected from each other from an alkyl (C1-C6) group, for example, a methyl group; and an alkyl (C1-C6) group substituted with a phenyl group, for example, a benzyl group, said phenyl group being either unsubstituted or substituted with at least one NR9R10-alkyl (C1-C6) group, for example, one to five NR9R10-alkyl (C1-C6) groups, such as an NR9R10-alkyl (C1-C6) group, for example, an NR9R10-CH2- group, R9 and R10 being independently selected from each other from an alkyl (C1-C6) group, for example, a methyl group or a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, for example, a -(CH2)2-OCH3 group or d) a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, e.g. a dihydropyrrolyl group. According to another embodiment, the disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt: where: R1 represents: a hydrogen atom, or a selected group of: to) an alkyl (C1-C6) group - for example, a methyl group; b) a phenyl-alkyl (C1-C6) group - for example a phenylmethyl group - (i.e. a benzyl group) that is either unsubstituted or substituted with at least one substituent selected from: b1.- an alkoxy group (C1-C6) - for example, a methoxy group; and b4.- an alkyl (C1-C6) group -, for example, a methyl group, which is unsubstituted or substituted with at least one: b4.2.- group -NR4R5 wherein R4 and R5 are selected independently of each other from: b4.2.1.- a hydrogen atom; and b4.2.3.- a group CH3-[O- (CH2) 2]n- where n is an integer from 1 to 30, for example, n is 12; and c) - a cycloalkyl (C3-C10) -alkyl (C1-C6) group -, for example a cyclohexylmethyl- group, which is unsubstituted or substituted with at least one -NH2 group; R2 represents a selected group of: an alkyl (C1-C6) group - for example, a methyl group or an n-butyl group; an alkyl (C1-C6) group -NH-alkyl (C1-C6) -, for example, a CH3CH2-NH-CH2 group; and an alkyl (C1-C6) -NH- group, for example, a CH3CH2CH2-NH- group; R3 represents: a hydrogen atom or a selected group of: b) an -OR6 group where R6 is selected from: a hydrogen atom; and an alkyl (C1-C6) group -, for example, an isopropyl group; c) a group -NR7R8 where R7 and R8 are selected independently of each other from: a hydrogen atom; an alkyl (C1-C6) group - for example a methyl group or an isopropyl group, unsubstituted or substituted with a phenyl group that is either unsubstituted or substituted with at least one: an NR9R10-alkyl (C1-C6) group - where: R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, for example, a piperazinyl group, said heterocycloalkyl group of (C3-C10) members being unsubstituted or substituted with at least one substituent selected from an (C1-C6) alkyl group -, for example, a methyl group; d) a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, for example, a dihydropyrrolyl group or a pyrrolidinyl group; and and) a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, for example a pyrazolyl group or a pyrrolyl group, said (C5-C10) member heteroaryl group being either unsubstituted or substituted with at least one (C1-C6) alkyl group, for example a methyl group. provided that at least one of R1 and R3 is different from a hydrogen atom In this disclosure, the symbol in the link denotes a covalent bonding site. When R1 represents an alkyl (C1-C6) group -, examples of suitable R1 groups that may be mentioned include a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group or a hexyl group, for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group. When R1 represents a (C1-C6)-hydroxyalkyl group, examples of suitable R1 groups include a hydroxymethyl group, a dihydroxyethyl group, a hydroxypropyl group, a hydroxybutyl group, a dihydroxybutyl group, a trihydroxybutyl group, a hydroxypentyl group, a dihydroxypentyl group, a hydroxyhexyl group, for example, a hydroxybutyl group such as C(OH)(CH3)2-CH2-, a dihydroxybutyl group such as CH(CH2OH)2-CH2-, or a dihydroxypentyl group such as C(CH3)(CH2OH)2-CH2-. In other words, at least one hydroxyl group replaces a hydrogen atom belonging to the alkyl moiety. When R1 represents an NH2-alkyl (C1-C6)- group, examples of suitable R1 groups that may be mentioned include an NH2-methyl- group, an NH2-ethyl- group, an NH2-propyl- group, an NH2-butyl- group, an NH2-pentyl- group, or an NH2-hexyl- group, for example, an NH2-butyl- group such as NH2-(CH2)4-, an NH2-pentyl- group such as NH2-(CH2)5-, or an NH2-hexyl- group such as NH2-(CH2)6-. When R1 represents an NH-alkyl (C1-C6) -alkyl (C1-C6) - group, examples of suitable R1 groups that can be mentioned include an NH (CH3) -CH2- group, an NH (C2H5) -CH2- group, an NH (CH3) - (CH2) 3- group, or an NH (C3H7) - (CH2) 6- group. When R1 represents an N (C1-C6) alkyl 2-alkyl (C1-C6) - group, examples of suitable R1 groups that may be mentioned include an N (CH3) 2-CH2- group, an N (CH3) (C2H5) -CH2- group, an N (C3H7) (CH3) - (CH2) 3- group, or an NH (C4H9) - (CH2) 6- group. When R1 represents an alkenyl (C2-C6) group -, examples of suitable R1 groups that may be mentioned include an ethenyl (or vinyl) group, a propenyl group, a butenyl group, a pentenyl group or a hexenyl group, for example, a vinyl group or a propenyl group. When R1 represents an alkynyl (C2-C6) group -, examples of suitable R1 groups that may be mentioned include an ethynyl group, a propynyl group, a butynyl group, a pentinyl group or a hexynyl group, e.g., an ethynyl group or a propynyl group. When R1 represents a phenyl-alkyl (C1-C6) group -, examples of suitable R1 groups that may be mentioned include a benzyl group, a phenylpropyl group, a phenylbutyl group, a phenylpentyl group, or a phenylhexyl group, e.g., a benzyl group. When R1 represents a (C1-C6) phenyl-alkyl group, wherein the phenyl group is substituted with a (C1-C6) alkyl group, for example, a methyl group, such as a methyl group in one or more para and / or meta positions of the phenyl group, and wherein said (C1-C6) alkyl group is in turn substituted with an -NR4R5 group, examples of (C3-C10) member heterocycloalkyl groups suitable for groups R4 and R5 that may be mentioned include: piperazine, morpholino, pyrrolidine, tetrahydropyran, thiethane dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran, tetrahydrofuran, azetidine, oxetano, thietano, 2H-pyrrole, 1H-, 2H- or 3H-pyrroline, tetrahydrothiophene, oxadiazole, 1, 3, 4-oxadiazole, 1, 3, 5-oxadioazole, thiadiazole, 1, 3, 4-thiadiazole, isoxazoline, 2- or 3-pyrazoline, pyrroline, pyrazolidine, imidazoline, imidazolidine, thiazolidine, isooxazoline, isoxazolidine, dioxalane, oxathiazole, oxathiadiazole and dioxazole, for example,tetrahydropyran or thiethane dioxide such as, When R1 represents a phenyl-alkyl (C1-C6) group, wherein the phenyl group is substituted with an alkyl (C1-C6) group, for example, a methyl group, such as a methyl group in one or more para and / or meta positions of the phenyl group, and wherein said alkyl (C1-C6) group is in turn substituted with an -NR4R5 group, examples of suitable unsubstituted or substituted cycloalkyl (C3-C10) groups for groups R4 and R5 that may be mentioned include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, or a cyclohexenyl group, for example, a cyclopropyl group or a cyclobutyl group, such as When R1 represents a (C1-C6) phenyl-alkyl group, wherein the phenyl group is substituted with a (C1-C6) alkyl group, for example, a methyl group, such as a methyl group in one or more para and / or meta positions of the phenyl group, and wherein said (C1-C6) alkyl group is in turn substituted with an -NR4R5 group, wherein R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group, examples of suitable -NR4R5 groups that may be mentioned include an unsubstituted or substituted (C3-C10) member heterocycloalkyl group, for example, an unsubstituted or substituted piperazinyl group, an unsubstituted or substituted morpholino group, or an unsubstituted or substituted pyrrolidinyl group, such as When R1 represents a heteroaryl group of (C5-C10) members-alkyl (C1-C6) - unsubstituted or substituted, examples of suitable R1 groups that may be mentioned include a pyridyl-CH2- group, a pyridyl-(CH2)2- group, a pyridyl-(CH2)3- group, a pyridyl-(CH2)4- group, a pyridyl-(CH2)5- group, a pyridyl-(CH2)6- group, a pyridyl-(C(CH3)2) group, for example, a pyridyl-CH2- group in which the pyridyl group is unsubstituted or substituted and is, for example, the following: When R1 represents a (C3-C10) member-C1-C6 alkyl heterocycloalkyl group, examples of suitable R1 groups that may be mentioned include a (C1-C6) piperazinyl alkyl group, a (C1-C6) piperidinyl alkyl group, a (C1-C6) morpholino alkyl group, a (C1-C6) tetrahydrofuran alkyl group, or a (C1-C6) tetrahydropyran alkyl group, for example, a piperazinyl-(CH2)2- group, a piperazinyl-CH2- group, a piperazinyl-(CH2)3- group, a piperazinyl-(CH2)4- group, a piperidinyl-(CH2)- group, or a piperidinyl-(CH2)2- group, such as When R1 represents an unsubstituted or substituted cycloalkyl (C3-C10) -alkyl (C1-C6) group, examples of suitable R1 groups that may be mentioned include a cyclopropyl-alkyl (C1-C6) group, a cyclopropenyl-alkyl (C1-C6) group, a cyclobutyl-alkyl (C1-C6) group, a cyclobutenyl-alkyl (C1-C6) group, a cyclopentyl-alkyl (C1-C6) group, a cyclopentenyl-alkyl (C1-C6) group, a cyclohexyl-alkyl (C1-C6) group, a cyclooctyl-alkyl (C1-C6) group, a cyclonononyl-alkyl (C1-C6) group, or a cyclodecyl-alkyl (C1-C6) group, for example, a cyclohexyl-CH2- group in which the cyclohexyl group is unsubstituted or substituted, such as: When R1 represents a (C3-C10) member heterocycloalkyl-NH-alkyl (C1-C16)-group, examples of suitable R1 groups that may be mentioned include a dioxothiethanyl-NH-alkyl (C1-C16)-group, a piperazinyl-NH-alkyl (C1-C16)-group, a piperidinyl-NH-alkyl (C1-C16)-group, a morpholino-NH-alkyl (C1-C16)-group, a tetrahydrofuranyl-NH-alkyl (C1-C16)-group, or a tetrahydropyranyl-NH-alkyl (C1-C16)-group, for example, a tetrahydropyranyl-NH-(CH2)4-group, a tetrahydropyranyl-NH-(CH2)6-group, a dioxothiethanyl-NH-(CH2)4-group, or a dioxothiethanyl-NH-(CH2)6-group, such as When R1 represents a (C3-C10) member heterocycloalkyl-N(C(O)-C1-C6)-alkyl-C1-C16)-group, examples of suitable R1 groups that may be mentioned include a dioxothiethanyl-N(C(O)-C1-C6)-alkyl-C1-C16)-group, a piperazinyl-N(C(O)-C1-C6)-alkyl-C1-C16)-group, a piperidinyl-N(C(O)-C1-C6)-alkyl-C1-C16)-group, a morpholino-N(C(O)-C1-C6)-alkyl-C1-C16)-group, a tetrahydrofuranyl-N(C(O)-C1-C6)-alkyl-C1-C16)-group, or a group tetrahydropyranyl-N(C(O)-alkyl(C1-C6))-alkyl(C1-C16)-, for example, a tetrahydropyranyl-N(C(O)CH3)-(CH2)4- group, a tetrahydropyranyl-N(C(O)CH3)-(CH2)6- group, a dioxothiethanyl-N(C(O)CH3)-(CH2) group 4-, a dioxothiethanyl-N(C(O)CH3)-(CH2)6- group such as When R2 represents an alkyl (C1-C6) group -, examples of suitable R2 groups that may be mentioned include: a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group or a hexyl group, for example, a methyl group, an ethyl group, a propyl group such as an n-propyl group, a butyl group such as an n-butyl group. When R2 represents an alkenyl group (C2-C6) -, examples of suitable R2 groups that may be mentioned include an ethenyl (or vinyl) group, a propenyl group, a butenyl group, a pentenyl group, or a hexenyl group, for example, a vinyl group or a propenyl group. When R2 represents an alkynyl group (C2-C6) -, examples of suitable R2 groups that may be mentioned include an ethynyl group, a propynyl group, a butynyl group, a pentinyl group or a hexynyl group, e.g., an ethynyl group or a propynyl group. When R2 represents an alkylthio (C1-C6)- group, examples of suitable R2 groups that may be mentioned include a methylthio group, an ethylthio group, a propylthio group, a butylthio group, a pentylthio group, or a hexylthio group, for example, a propylthio group such as CH3-(CH2)2-S-. When R2 represents an alkylthio (C1-C6) -alkyl (C1-C6) - group, examples of suitable R2 groups that can be mentioned include a methylthiomethyl group, a methylthioethyl group, an ethylthiopropyl group, a butylthioethyl group, a pentylthiohexyl group, for example, CH3-S- (CH2) 2-. When R2 represents an alkyl (C1-C6) -S (O) - group, examples of suitable R2 groups that may be mentioned include a methyl-S (O) - group, an ethyl-S (O) - group, a propyl-S (O) - group, a butyl-S (O) - group, a pentyl-S (O) - group, a hexyl-S (O) - group, for example, a methyl-S (O) - group, an ethyl-S (O) - group, or a propyl-S (O) - group. When R2 represents an alkyl (C1-C6) -SO2- group, examples of suitable R2 groups that can be mentioned include a methyl-SO2- group, an ethyl-SO2- group, a propyl-SO2- group, a butyl-SO2- group, a pentyl-SO2- group, a hexyl-SO2- group, for example, a methyl-SO2- group or an ethyl-SO2- group. When R2 represents a (C1-C6) S(O)-alkyl (C1-C6)- group, examples of suitable R2 groups that may be mentioned include a methyl-S(O)-methyl group, an ethyl-S(O)-propyl group, or a pentyl-S(O)-hexyl group. When R2 represents a (C1-C6)-SO2-alkyl (C1-C6)- group, examples of suitable R2 groups that may be mentioned include a methyl-SO2-methyl- group, an ethyl-SO2-propyl- group, and a hexyl-SO2-butyl- group. When R2 represents an alkoxy (C1-C6) group -, examples of suitable R2 groups that may be mentioned include a methoxy group, an ethoxy group, a propoxy group such as an n-propoxy group or an isopropoxy group, a butoxy group such as an n-butoxy group, a sec-butoxy group, a tert-butoxy group or an isobutoxy group, a pentyloxy group such as an n-pentyloxy group, an isopentyloxy group, a tert-pentyloxy group or a hexyloxy group such as an n-hexyloxy group, an isohexyloxy group or a tert-hexyloxy group. When R2 represents an alkoxy (C1-C6) -alkyl (C1-C6) group, examples of suitable R2 groups that may be mentioned include a methoxymethyl group, a methoxyethyl group, an ethoxypropyl group, a butoxyethyl group, such as CH3-CH2-O-CH2- or CH3-O-(CH2)2-. When R2 represents a (C1-C6)-halokoxy-alkyl (C1-C6)-group, examples of suitable R2 groups that may be mentioned include a trifluoromethoxymethyl group or a difluoromethoxyethyl group, When R2 represents a cycloalkyl (C3-C5) -O-alkyl (C1-C6) - group, examples of suitable R2 groups that may be mentioned include a cyclopropyl-O-methyl group, a cyclopropyl-O-ethyl group, a cyclopropyl-O-hexyl group, a cyclopropenyl-O-ethyl group, a cyclobutyl-O-methyl group, a cyclobutyl-O-propyl group, a cyclobutenyl-O-butyl group, a cyclopentyl-O-methyl group, a cyclopentyl-O-ethyl group, or a cyclopentenyl-O-ethyl group, such as a cyclobutyl-O-methyl group or a cyclopentyl-O-ethyl group. When R2 represents an alkyl (C1-C6) -NH- group, examples of suitable R2 groups that may be mentioned include a methyl-NH- group, an ethyl-NH- group, a propyl-NH- group, a butyl-NH- group, a pentyl-NH- group, or a hexyl-NH- group such as CH3NH-, CH3CH2NH-, or CH3CH2CH2NH-. When R2 represents a (C1-C6) alkyl 2-N- group, examples of suitable R2 groups that may be mentioned include a (CH3) 2-N- group, a (C2H5) 2-N- group, a (CH3)(C2H5)N group, or a (C3H7) 2-N- group. When R2 represents a (C1-C6)NH-alkyl (C2-C6)- group, examples of suitable R2 groups that may be mentioned include a CH3-NH-CH2- group, a CH3-CH2-NH-CH2- group, a CH3-NH-C1H5- group, or a C3H7-NH-CH2- group. When R2 represents a (C1-C6) alkyl 2-N-alkyl (C1-C6) - group, examples of suitable R5 groups that may be mentioned include a (CH3) 2-N-CH2- group, a (CH3) (C2H2) N-CH2- group, or a (CH3) (C2H5) N-C3H7- group. When R3 represents an alkyl (C1-C6) group -, examples of suitable R3 groups that may be mentioned include: a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group or a hexyl group, for example, a propyl group, a butyl group and a pentyl group, such as an isopropyl group, an isobutyl group or an isopentyl group. When R3 represents an alkenyl group (C2-C6) -, examples of suitable R3 groups that may be mentioned include: an ethenyl (or vinyl) group, a propenyl group, a butenyl group, a pentenyl group, or a hexenyl group, for example, a propenyl group such as C (CH3) (=CH2) -, a butenyl group such as (CH3) 2C=CH-, or a pentenyl group such as (CH3) CH-. When R3 represents an alkynyl group (C2-C6) -, examples of suitable R3 groups that may be mentioned include: an ethynyl group, a propynyl group, a butynyl group, a pentinyl group or a hexynyl group, e.g., an ethynyl group or a propynyl group. When R3 represents an alkylthio (C1-C6) group -, examples of suitable R3 groups that may be mentioned include: a methylthio- group, an ethylthio- group, a propylthio- group, a butylthio- group, a pentylthio- group, or a hexylthio- group, for example, a propylthio- group such as an isopropylthio- group. When R3 represents a -OR6 group and in which R6 is an alkyl (C1-C6) group -, examples of suitable R6 groups that may be mentioned include: a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group or a hexyl group, for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group, an ethyl group, an isopropyl group, an n-propyl group, an n-butyl group or a sec-butyl group. When R3 represents a -OR6 group and R6 is a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, examples of suitable R6 groups that can be mentioned include: CH3-O-(CH2)2-, CH3-[O-(CH2)2]2-, CH3-[O-(CH2)2]3-, CH3-[O-(CH2)2]4-, CH3-[O-(CH2)2]5-, CH3-[O-(CH2)2]6-, CH3-[O-(CH2)2]7-, CH3-[O-(CH2)2]8-, CH3-[O-(CH2)2]9-, CH3-[O-(CH2)2]10-, CH3-[O-(CH2)2]11-, CH3-[O-(CH2)2]10-, CH3-[O-(CH2)2]11-, CH3-[O-(CH2)2]12-, CH3-[O-(CH2)2]13-, CH3-[O-(CH2)2]14-, CH3-[O-(CH2)2]15-, CH3-[O-(CH2)2]16-, CH3-[O-(CH2)2]17-, CH3-[O-(CH2)2]18-, CH3-[O-(CH2)2]19-, CH3-[O-(CH2)2]10-, CH3-[O-(CH2)2]11-, CH3-[O-(CH2)2]12-, CH3-[O-(CH2)2]13-, CH3-[O-(CH2)2]14-, CH3-[O-(CH2)2]15-, CH3-[O-(CH2)2]16-, CH3-[O-(CH2)2]17-, CH3- 2]12-, CH3-[O- (CH2) 2]13-, CH3-[O- (CH2) 2]14-, CH3-[O- (CH2) 2]15-, CH3-[O- (CH2) 2]16-, CH3-[O- (CH2) 2]17-, CH3-[O- (CH2) 2]18-, CH3-[O- (CH2) 2]19-, CH3-[O- (CH2) 2]20-, CH3-[O- (CH2) 2]21-, CH3-[O- (CH2) 2]22-, CH3-[O- (CH2) 2]23-, CH3-[O- (CH2) 2]24-, CH3-[O- (CH2) 2]25-, CH3-[O- (CH2)2]26-, CH3-[O- (CH2) 2]27-, CH3-[O- (CH2) 2]28-, CH3-[O- (CH2) 2]29-, CH3-[O- (CH2) 2]30-, such as CH3-[O- (CH2) 2]24- and CH3-O- (CH2) 2-.When R3 represents a -OR6 group and R6 is an alkenyl group (C2-C6) -, examples of suitable R6 groups that may be mentioned include an ethenyl group, a propenyl group, a butenyl group, a pentenyl group or a hexenyl group, for example, a propenyl group such as CH=CH-CH2-. When R3 represents an -OR6 group and R6 is an alkynyl (C2-C6) group, examples of suitable R6 groups that may be mentioned include: an ethynyl group, a propynyl group, a butynyl group, a pentynyl group, or a hexynyl group, for example, an ethynyl group or a propynyl group. When R3 represents an -OR6 group and R6 is a cycloalkyl (C3-C10) group, examples of suitable R6 groups that may be mentioned include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, or a cyclohexenyl group, for example, a cyclopentyl group. When R3 represents a -OR6 group and R6 is a phenyl (alkyl (C1-C6)) group, examples of suitable R6 groups that can be mentioned include a benzyl group (i.e., a phenylmethyl group), a phenylpropyl group, a phenylbutyl group, a phenylpentyl group, or a phenylhexyl group, e.g., a benzyl group. When R3 represents an -OR6 group and R6 is a (C3-C10) member heterocycloalkyl group, examples of suitable R6 groups that may be mentioned include piperazine, morpholino, pyrrolidine, tetrahydropyran, thietano dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran, tetrahydrofuran, azetidine, oxetano, thietano, 2H-pyrrole, 1H-, 2H- or 3H-pyrroline, tetrahydrothiophene, oxadiazole, 1,3,4-oxadiazole, 1,3,5-oxadioazole, thiadiazole, 1,3,4-thiadiazole, isoxazoline, 2- or 3-pyrazoline, pyrroline, pyrazolidine, imidazoline, imidazolidine, thiazolidine, isooxazoline, isoxazolidine, dioxalane, oxatiazole, oxatiadiazole and dioxazole, for example, piperazine, morpholino, pyrrolidine, tetrahydropyran, thiethane dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran and tetrahydrofuran groups, such as a tetrahydropyran group, a thiolane dioxide group, a thiolane group,a thiolane oxide group and a tetrahydrofuranyl group, for example, When R3 represents a -NR7R8 group and R7 and R8 together with the nitrogen to which they are attached form an unsubstituted or substituted 3-10 member heterocycloalkyl group, examples of suitable -NR7R8 groups that may be mentioned include an unsubstituted or substituted piperazine, morpholino, or pyrrolidine, for example, an unsubstituted or substituted pyrrolidine group, such as When R3 represents a -NR7R8 group and R7 and / or R8 represent a 5-10 member heteroaryl-alkyl (C1-C6) group, examples of suitable R7 and / or R8 groups that may be mentioned include a pyridinealkyl (C1-C6) group, furanoalkyl (C1-C6) group, pyrrolealkyl (C1-C6) group, thiophenalkyl (C1-C6) group, pyrazolalkyl (C1-C6) group, oxazolalkyl (C1-C6) group, isoxazolalkyl (C1-C6) group, triazolalkyl (C1-C6) group, tetrazolalkyl (C1-C6) group, oxadiazolalkyl (C1-C6) group, furazanalkyl (C1-C6) group, thiazolalkyl (C1-C6) group, and isothiazolalkyl group. (C1-C6)-, (C1-C6)-thiadiazol-alkyl group, (C1-C6)-imidazol-alkyl group, (C1-C6)-pyrimidin-alkyl group, (C1-C6)-pyridazin-alkyl group, and (C1-C6)-triazin-alkyl group, for example, a furanyl-CH2- group, a furanyl-(CH2)2- group, a furanyl-(CH2)3- group, a furanyl-(CH2)4- group, a furanyl-(CH2)5- group, a furanyl-(CH2)6- group such as When R3 represents an -NR7R8 group, that R7 and / or R8 represents a phenyl-alkyl (C1-C6) group -, for example, a benzyl group, and that phenyl group is substituted with at least one substituent, such as an NR9R10-alkyl (C1-C6) group -, examples of suitable NR9R10-alkyl (C1-C6) groups that may be mentioned include: For R3, when R9 and R10 together form with the nitrogen atom to which they are attached an unsubstituted or substituted (C3-C10) member heterocycloalkyl group, examples of suitable NR9R10 groups that may be mentioned include: piperazine, morpholino, pyrrolidine, tetrahydropyran, thiethane dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran, tetrahydrofuran, azetidine, oxetano, thietano, 2H-pyrrole, 1H-, 2H- or 3H-pyrroline, tetrahydrothiophene, oxadiazole, 1,3,4-oxadiazole, 1,3,5-oxadioazole, thiadiazole, 1,3,4-thiadiazole, isoxazoline, 2- or 3-pyrazoline, pyrroline, pyrazolidine, imidazoline, imidazolidine, thiazolidine, isooxazoline, soxazolidine, dioxalane, oxatiazole, oxatiadiazole and dioxazole, for example, a morpholino group or a piperazinyl group, such as and When R3 represents a (C3-C10) member heterocycloalkyl group, examples of suitable 3-10 member heterocycloalkyl groups that may be mentioned include piperazine, morpholino, pyrrolidine, tetrahydropyran, dihydropyrrole, thietano dioxide, piperidine, thiolane, thiolane oxide, thiolane dioxide, dihydrofuran, tetrahydrofuran, azetidine, oxetano, thietano, 2H-pyrrole, 1H-, 2H- or 3H-pyrroline, tetrahydrothiophene, oxadiazole, 1,3,4-oxadiazole, 1,3,5-oxadioazole, thiadiazole, 1,3,4-thiadiazole, isoxazoline, 2- or 3-pyrazoline, pyrroline, pyrazolidine, imidazoline, imidazolidine, thiazolidine, isooxazoline, isoxazolidine, dioxalane, oxatiazole, oxatiadiazole and dioxazole, for example, a tetrahydrofuranyl group, a dihydropyrrolyl group or a dihydrofuranyl group, such as When R3 represents a cycloalkyl (C3-C10) group, suitable examples of cycloalkyl (C3-C10) groups that may be mentioned include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, or a cyclohexenyl group, for example, a cyclopentenyl group, a cyclopentyl group, a cyclohexenyl group, or a cyclohexyl group, such as When R3 represents a heteroaryl group of (C5-C10) members—unsubstituted or substituted—examples of suitable groups that may be mentioned include pyridine, furan, pyrrole, thiophene, pyrazole, oxazole, isoxazole, triazole, tetrazole, oxadiazole, furazane, thiazole, isothiazole, thiadiazole, imidazole, pyrimidine, pyridazine, and triazine groups, for example, a thienyl group, a furanyl group, a pyrrolyl group, or a pyrazolyl group, such as When R3 represents an aryl (C6-C10)- group, examples of suitable aryl (C6-C10)- groups that can be mentioned include the naphthyl group and the phenyl group. According to another realization, R3 represents: For the purposes of this disclosure, examples of suitable CH3-[O-(CH2)2]n groups, where n is an integer from 1 to 30, that may be mentioned include: CH3-O-(CH2)2-, CH3-[O-(CH2)2]2-, CH3-[O-(CH2)2]3-, CH3-[O-(CH2)2]4-, CH3-[O-(CH2)2]5-, CH3-[O-(CH2)2]6-, CH3-[O-(CH2)2]7-, CH3-[O-(CH2)2]3-, CH3-[O-(CH2)2]9-, CH3-[O-(CH2)2]10-, CH3-[O-(CH2)2]11-, CH3-[O-(CH2)2]12-, CH3-[O- (CH2) 2]13-, CH3-[O- (CH2) 2]14-, CH3-[O- (CH2) 2]15-, CH3-[O- (CH2) 2]16-, CH3-[O- (CH2) 2]17-, CH3-[O- (CH2) 2]18-, CH3-[O- (CH2) 2]19-, CH3-[O- (CH2) 2]20-, CH3-[O- (CH2) 2]21-, CH3-[O- (CH2) 2]22-, CH3-[O- (CH2) 2]23-, CH3-[O- (CH2) 2]24-, CH3-[O- (CH2) 2]25-, CH3-[O- (CH2) 2]26-, CH3-[O- (CH2) 2]27-, CH3-[O- (CH2) 2]28-, CH3-[O- (CH2) 2]29-, CH3-[O- (CH2) 2]30-, such as CH3-[O- (CH2) 2]24- and CH3-O- (CH2) 2. Among the compounds of formula (I) that are the subject of this disclosure, the following compounds may be mentioned, for example: (1) 2-butyl-7-isopropoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (2) 2-butyl-N7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (3) 2-butyl-7-(isopropylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (4) 2-butyl-1-(4-methoxybenzyl)-7-(2-methoxyethoxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (5) 2-butyl-1-(4-methoxybenzyl)-7-propoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (6) 7-(allyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (7) 7-(sec-butoxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (8) 7-butoxy-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (9) 2-butyl-7-(cyclopentyloxy)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (10) 2-butyl-1-(4-methoxybenzyl)-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (11) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-3-yl)-1H-imidazo[4,5d]pyridazin-4-amine; (12) (E) -2-butyl-1-(4-methoxybenzyl)-7-(3-methylbut-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (13) 2-butyl-7-isopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (14) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (15) clorhidrato de 2-butil-7-(ciclopent-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amina; (16) 2-butyl-7-cyclopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (17) 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (18) 2-butyl-7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (19) 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine dihydrochloride; (20) 2,2,2-trifluoroacetate of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (21) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (22) 2, 2, 2-trifluoroacetate de 1-(4-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (23) 1- (((1S, 3R)-3-aminocyclohexyl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine (y enantiómero) ; (24) 1-(4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)-2-methylpropan-2-ol; (25) Trans 1-(4-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (26) 1-((5-(aminomethyl)pyridin-2-yl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (27) 6- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) nicotinonitrile; (28) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl)methyl)bencyl)acetamide; (29) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) undecanamide; (30) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) pentanamida; (31) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl)bencyl)-3-(2-methoxyethoxy)propanamida; (32) 1- (((1S, 3S)-3-aminocyclohexyl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-]pyridazin-4-amine (y enantiómero) ; (33) 2, 2, 2-trifluoroacetate de 1-(3-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (34) 4- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzaldehído; (35) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) phenyl) methanol; (36) 2-butyl-1-(4-((cyclopropylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (37) 1, 1-dióxido de 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazinyl) metil) bencil) amino) thiethane; (38) N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-1-yl) metil) bencil) -N- (1, 1-dioxidotietan-3-yl) acetamida; (39) 2-butyl-7-isopropoxy-1-(4-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (40) 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (41) 2-butyl-N7, N7, 1-trimethyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamine; (42) 2-butyl-1-methyl-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (43) 2-butyl-N7-(4-((dimethylamino)methyl)bencyl)-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamine; (44) 2-butyl-N7, 1-dimethyl-N7-(4-(morpholinomethyl)bencyl)-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (45) 4- ( ( (4-amino-2-butil-1-metil-1H-imidazo[4, 5-d]pyridazin-7-yl) (metil) amino) metil) benzonitrilo; (46) N7-(4-(aminomethyl)benzyl)-2-butyl-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (47) 2-butyl-N7- (4- ( ( (2-methoxyethyl) (methyl) amino) methyl) benzyl) -N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamina; (48) 2-butyl-7-ethoxy-1-(4-methoxybenzyl) -1H-imidazo[4, 5-d]pyridazin-4-amina; (49) 2-butyl-1-(4-methoxybenzyl)-N7-(2-methoxyethyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (50) 2-butyl-7-methoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (51) 2-butyl-7-cyclohexyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (52) 7-(benzyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (53) 2-butyl-1-(4-methoxybenzyl)-N7-methyl-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (54) (S)-2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (55) 2-butyl-7-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (56) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (57) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydro-2H-pyran-4-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (58) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrothiophen-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (59) 2-butyl-1-(4-methoxybenzyl)-7-(tetrahydrofuran-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (60) 2-butyl-1-(4-methoxybenzyl)-7-(2-methylprop-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (61) 2-butyl-7-isobutyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (62) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (63) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (64) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (65) isomer A of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (66) 2-butyl-7-(cyclohex-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (67) 2-butyl-7-(furan-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (68) 1,1-dioxide of 3-((4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (69) isomer B of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (70) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (71) 2-Butyl-1-(4-methoxybenzyl)-N7,N7-dimethyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (72) 2-butyl-1-(4-methoxybenzyl)-7-phenoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (73) 2-Butyl-7-(2,5-dihydrofuran-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (74) 2-butyl-7-isopropoxy-1-(pyridin-3-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (75) 2-butyl-7-isopropoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (76) 2, 2, 2-trifluoroacetate de 2-butyl-7-isopropoxy-1-(pyridin-4-ylmethyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (77) 1-(5-aminopentyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (78) 2-butyl-7-isopropoxy-1-(2-(piperidin-4-yl)ethyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (79) 2-butyl-7-isopropoxy-1-(2-(piperazin-1-yl)ethyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (80) 1-bencyl-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (81) 2-butyl-1-(cyclohexylmethyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (82) 2-butyl-7-isopropoxy-1-(4-(((tetrahidro-2H-pyran-4-yl) amino) methyl) bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (83) dichlorhydrate of 2-butyl-7-isopropoxy-1-(4-((isopropylamino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (84) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl)bencyl) heptanamide; (85) hydrochloride of (4-(1-(4-amino-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazin-7-yl) pyrrolidin-3-yl) phenyl) methanol; (86) 2-butyl-7-isopropoxy-1-methyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (87) N7-(4-(aminomethyl)bencyl)-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (88) 2-butyl-N7-isopropyl-1-methyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (89) 2-butyl-1-methyl-7-(3-phenylpyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (90) N7-bencyl-2-butyl-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (91) 2-butyl-1-methyl-N7-(4-((4-metilpiperazin-1-yl)methyl)benzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (92) 2-butyl-1-(4-methoxybenzyl)-7-phenyl-1H-imidazo[4,5-d]pyridazin-4-amine; (93) 4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-ol; (94) 2-butyl-N7-(3-(furan-2-yl)propyl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (95) 2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (96) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrazol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (97) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (98) 2-butyl-N7-isopropyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (99) 2-butyl-7-(isopropylthio)-1H-imidazo[4,5-d]pyridazin-4-amine; (100) dichlorhydrate sal of (1R, 3R)-3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) amino) cyclobutan-1-ol; (101) 2-butyl-7-isopropoxy-1-(4-(pyrrolidin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (102) 2-butyl-7-isopropoxy-1-(4-(morpholinomethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (103) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) propionamida; (104) 2-butyl-7-isopropoxy-1-(4-(((2-methoxyethyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (105) 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2- (2-methoxietoxi) etoxi]etoxi]etoxi]etoxi]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (106) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) benzamida; (107) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl)bencyl)-3-methoxypropanamida; (108) 2-butyl-7-isopropoxy-1-(4- (((2-(2-(2-methoxyethoxy)ethyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (109) 2-butyl-1-(4-((hexilamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (110) 2-butyl-1-(4-((decylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (111) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) ethyl carbamate; (112) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) carbamate de 4-methoxybencyl; (113) 1-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl)-3-ethylurea; (114) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) 4-acetamidobencyl carbamate; (115) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) methanesulfonamida; (116) 2-butyl-1-(4-((dimethylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (117) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) tert-butyl glycinate; (118) 2-butyl-7-isopropoxy-1-(4-((methylamino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (119) 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) amino) tert-butyl propanoate; (120) 1- (4- (5, 8, 11-trioxa-2-azadodecyl) bencyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (121) 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (122) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2- [2- [2- [2- (2-methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (123) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2- [ (124) 2-butyl-7-isopropoxy-1-(3-((methylamino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (125) 2-butyl-1-(3-((dimethylamino)methyl)benzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (126) salt dichlorhidrato de 2-butyl-1-(3-((cyclobutylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amina; (127) salt dichlorhidrato de 2-butyl-1-(3-((cyclopropylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amina; (128) salt dichlorhidrato de 2-butyl-7-isopropoxy-1-(3-((isopropylamino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amina; (129) 1, 1-dioxide de 3-((3-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl) phenyl) amino) tietano; (130) salt dichlorhidrato de 2-butyl-7-isopropoxy-1-(3-((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amina; (131) 2-Butyl-7-isopropoxy-1-(3-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4,5-d]piridazin-4-amina; (132) (E) -1-(4-(aminomethyl)bencyl)-2-butyl-7-(3-metilbut-1-en-1-il)-1H-imidazo[4, 5-d]pyridazin-4-amina; (133) 1-(4-(aminomethyl)bencyl)-2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (134) 1-(4-(aminomethyl)bencyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (135) 2, 2, 2-trifluoroacetate de 1-(4-(aminomethyl)bencyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (137) 1-(((1R, 4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-((E)-3-methylbut-1-en-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine (138) 1- (((1R, 4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (139) 1- ( ( (1R, 4R) -4-aminocyclohexyl) methyl) -2-butyl-7- ( (E) -3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (140) 1- ( ( (1R, 4R) -4-aminocyclohexyl) methyl) -2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (141) 1-( ( (1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (142) 1-( ( (1R,4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (143) 3-[(4-aminocyclohexyl)methyl]-2-butyl-4-pyrrolidin-1-yl-imidazo[4,5-d]pyridazin-7-amine; (144) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-(2,5-dihydro-1H-pyrrol-3-yl)imidazo[4,5-d]pyridazin-4-amine; (145) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-pyrrolidine-3-yl-imidazo[4,5-d]pyridazin-4-amine; (146) dihydrochloride salt of 3-(6-aminohexyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (147) dihydrochloride salt of 2-butyl-4-isopropoxy-3-[6-(tetrahydropyran-4-ylamino)hexyl]imidazo[4,5-d]pyridazin-7-amine; (148) N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)hexyl]-N-tetrahydropyran-4-yl-acetamide; (149) dihydrochloride salt of 3-(4-aminobutyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (150) hydrochloride salt of 2-butyl-4-isopropoxy-3-[4-(tetrahydropyran-4-ylamino)butyl]imidazo[4,5-d]pyridazin-7-amine; (151) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)butyl]-N-tetrahydropyran-4-yl-acetamide; (152) 2-Butyl-3-[4-[(1,1-dioxothiethan-3-yl)amino]butyl]-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (153) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)butyl]-N-(1,1-dioxothiethan-3-yl)acetamide; (154) 2-butyl-3-[6-[(1, 1-dioxotietan-3-yl)amino]hexyl]-4-isopropoxy-imidazo[4, 5-d]pyridazin-7-amine; (155) N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) hexyl]-N-(1, 1-dioxotietan-3-yl) acetamida hydrochloride salt; (156) sal chloride hydrate of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) methyl]-2-methyl-propane-1, 3-diol; (157) sal chloride hydrate of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) methyl]propane-1, 3-diol; (158) 1-(4-(aminomethyl)bencyl)-7-isopropoxy-2-propyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (159) 1-(4-(aminomethyl)bencyl)-2-(ethoxymethyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (160) 1-(4-(aminomethyl)bencyl)-7-isopropoxy-2-methyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (161) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfanyl-imidazo[4,5-d]pyridazin-7-amine; (162) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfinyl-imidazo[4, 5-d]pyridazin-7-amine; (163) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-N2-propyl-imidazo[4,5-d]pyridazine-2,7-diamine; (164) 3-[[4-(aminomethyl)phenyl]methyl]-2-(ethylaminomethyl)-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (165) 2-butyl-7-isopropoxy-1-(piperidin-4-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; either a pharmaceutically acceptable salt of the same. Among the compounds listed above, the following compounds of interest can be cited, for example: (1) 2-butyl-7-isopropoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (2) 2-butyl-N7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (3) 2-butyl-7-(isopropylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (4) 2-butyl-1-(4-methoxybenzyl)-7-(2-methoxyethoxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (5) 2-butyl-1-(4-methoxybenzyl)-7-propoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (6) 7-(allyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (7) 7-(sec-butoxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (8) 7-butoxy-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (9) 2-butyl-7-(cyclopentyloxy)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (10) 2-butyl-1-(4-methoxybenzyl)-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (11) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-3-yl)-1H-imidazo[4,5d]pyridazin-4-amine; (12) (E) -2-Butyl-1-(4-methoxybenzyl)-7-(3-methylbut-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (13) 2-butyl-7-isopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (14) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (15) 2-butyl-7-(cyclopent-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (16) 2-butyl-7-cyclopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (17) 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (18) 2-butyl-7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (19) dichlorhydrate of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (20) 2, 2, 2-trifluoroacetate of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (25) Trans 1-(4-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (26) 1-((5-(aminomethyl)pyridin-2-yl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (27) 6- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) nicotinonitrile; (28) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl)methyl)bencyl)acetamide; (29) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) undecanamide; (30) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)pentanamide; (31) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)-3-(2-methoxyethoxy)propanamide; (34) 4-( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzaldehyde; (35) (4-( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) fenil) methanol; (37) 1, 1-dióxido de 3- ( (4- ( (4-amino-2-butil-7-isopropoxy-1H-imidazo[4, 5-d]pyridazinil) metil) benzyl) amino) tietano; (48) 2-butyl-7-ethoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (49) 2-butyl-1-(4-methoxybenzyl)-N7-(2-methoxyethyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (50) 2-butyl-7-methoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (51) 2-butyl-7-cyclohexyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (52) 7-(benzyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (53) 2-butyl-1-(4-methoxybenzyl)-N7-methyl-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (54) (S)-2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (55) 2-butyl-7-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (56) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (57) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydro-2H-pyran-4-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (58) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrothiophen-3-yl)oxy)-1H-imidazo[4,5-d]pyridazin-4-amine; (59) 2-Butyl-1-(4-methoxybenzyl)-7-(tetrahydrofuran-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (60) 2-butyl-1-(4-methoxybenzyl)-7-(2-methylprop-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (61) 2-butyl-7-isobutyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (62) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (63) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (64) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (65) isomer A of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (66) 2-butyl-7-(cyclohex-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (67) 2-butyl-7-(furan-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (68) 1,1-dioxide of 3-((4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (69) isomer B of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (70) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (71) 2-Butyl-1-(4-methoxybenzyl)-N7,N7-dimethyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (72) 2-butyl-1-(4-methoxybenzyl)-7-phenoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (73) 2-Butyl-7-(2,5-dihydrofuran-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (75) 2-butyl-7-isopropoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (76) 2,2,2-trifluoroacetate of 2-butyl-7-isopropoxy-1-(pyridin-4-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (77) 1-(5-aminopentyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (78) 2-butyl-7-isopropoxy-1-(2-(piperidin-4-yl)ethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (79) 2-butyl-7-isopropoxy-1-(2-(piperazin-1-yl)ethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (80) 1-benzyl-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (81) 2-butyl-1-(cyclohexylmethyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (87) N7-(4-(aminomethyl)benzyl)-2-butyl-1-methyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (92) 2-butyl-1-(4-methoxybenzyl)-7-phenyl-1H-imidazo[4,5-d]pyridazin-4-amine; (94) 2-butyl-N7-(3-(furan-2-yl)propyl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (97) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (105) 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2- [2- (2-methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (107) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)-3-methoxypropanamide; (111) (4-( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) carbamato de ethylo; (112) (4-( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) carbamato de 4-methoxybencilo; (113) 1-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)-3-ethylurea; (122) di2, 2, 2-trifluoroacetate de 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2- (2-methoxietoxi) etoxi]etoxi]etoxi]etoxi]etoxi]etoxi]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (128) dichlorhydrate sal of 2-butyl-7-isopropoxy-1-(3-((isopropylamino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (131) 2-butyl-7-isopropoxy-1-(3-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (134) 1-(4-(aminomethyl)bencyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (137) 1- ( ( (1R, 4R) -4- (aminomethyl) cyclohexyl) methyl) -2-butyl-7- ( (E) -3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (138) 1- (((1R, 4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (139) 1- ( ( (1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7- ( (E)-3-methylbut-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (140) 1- ( ( (1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7-isopentyl-1H-imidazo[4,5-d]pyridazin-4-amine; (142) 1-( ( (1R,4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (143) 3-[(4-aminocyclohexyl)methyl]-2-butyl-4-pyrrolidin-1-yl-imidazo[4,5-d]pyridazin-7-amine; (146) dihydrochloride salt of 3-(6-aminohexyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (148) N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)hexyl]-N-tetrahydropyran-4-yl-acetamide; (149) dihydrochloride salt of 3-(4-aminobutyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (151) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl)butyl]-N-tetrahidropyran-4-yl-acetamida; (152) 2-butyl-3-[4-[ (1, 1-dioxotietan-3-yl) amino]butyl]-4-isopropoxy-imidazo[4, 5-d]pyridazin-7-amine; (153) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) butyl]-N-(1, 1-dioxotietan-3-yl) acetamida; (155) N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) hexyl]-N-(1, 1-dioxotietan-3-yl) acetamida hydrochloride salt; (158) 1-(4-(aminomethyl)bencyl)-7-isopropoxy-2-propyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (159) 1-(4-(aminomethyl)bencyl)-2-(ethoxymethyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (162) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfinyl-imidazo[4, 5-d]pyridazin-7-amine; (165) 2-butyl-7-isopropoxy-1-(piperidin-4-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; either a pharmaceutically acceptable salt of the same. Among the compounds listed above, the following compounds of interest can be cited, for example: (21) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (22) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazine-4-amine 2,2,2-trifluoroacetate; (23) 1-(((1S,3R)-3-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (and enantiomer); (24) 1-(4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)-2-methylpropan-2-ol; (32) 1- ( ( (1S, 3S) -3-aminocyclohexyl) metil) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-]piridazin-4-amine (y enantiómero) ; (33) 2, 2, 2-trifluoroacetato de 1- (3- (aminometil) bencil) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (36) 2-butyl-1- (4- ( (ciclopropilamino) metil) bencil) -7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (38) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl)-N-(1, 1-dioxidothiethan-3-yl) acetamida; (39) 2-butyl-7-isopropoxy-1-(4-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (40) 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (41) 2-butyl-N7, N7, 1-trimethyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamine; (42) 2-butyl-1-methyl-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (43) 2-Butyl-N7-(4-((dimethylamino)methyl)bencyl)-N7,1-dimethyl-1H-imidazo[4,5-d]piridazin-4,7-diamina; (44) 2-Butyl-N7,1-Dimethyl-N7-(4-(morphinomethyl)bencyl)-1H-imidazo[4,5-d]piridazina-4,7-diamina; (45) 4-((4-amino-2-butyl-1-methyl-1H-imidazo[4,5-d]pyridazin-7-il)(methyl)amino)methyl)benzonitrilo; (46) N7-(4-(aminomethyl)bencyl)-2-butyl-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazina-4,7-diamina; (47) 2-butyl-N7-(4-((2-metoxyetil) (methyl) amino) methyl) phenyl) -N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazina-4, 7-diamina; (74) 2-Butyl-7-isopropoxy-1-(pyridin-3-ylmethyl)-1H-imidazo[4,5-d]piridazin-4-amina; (82) sal clorhidrato de 2-butyl-7-isopropoxy-1- (4- ( ( (tetrahidro-2H-piran-4-il) amino) metil) bencil) -1H-imidazo[4, 5-d]piridazin-4-amina; (83) sal dichlorhidrato de 2-butyl-7-isopropoxy-1-(4-((isopropylamino) metil) bencil)-1H-imidazo[4, 5-d]piridazin-4-amine; (84) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-1-yl) metil) bencil) heptanamide; (85) sal hydrochloride de (4-(1-(4-amino-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazin-7-yl) pyrrolidin-3-yl) phenyl) methanol; (86) 2-butyl-7-isopropoxy-1-methyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (88) 2-butyl-N7-isopropyl-1-methyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (89) 2-butyl-1-methyl-7-(3-phenylpyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (90) N7-bencyl-2-butyl-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (91) 2-butyl-1-methyl-N7-(4-((4-methylpiperazin-1-yl)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (95) 2-Butyl-1-(4-metoxibencil)-1H-imidazo[4,5-d]pyridazin-4-amina; (98) 2-Butyl-N7-isopropyl-1H-imidazo[4, 5-d]piridazina-4, 7-diamina; y (99) 2-Butyl-7-(isopropyltio)-1H-imidazo[4, 5-d]pyridazin-4-amina; (100) salt dichlorhidrato de (1R,3R) -3-( (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl) phenyl) amino) cyclobutan-1-ol; (101) 2-Butyl-7-isopropoxy-1-(4-(pyrrolidin-1-ylmethyl)bencyl)-1H-imidazo[4,5-d]piridazin-4-amina; (102) 2-Butyl-7-isopropoxy-1-(4-(morphinomethyl)bencyl)-1H-imidazo[4,5-d]pyridazin-4-amina; (103) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)bencyl)propionamide; (104) 2-butyl-7-isopropoxy-1-(4-((2-metoxyethyl)amino)methyl)bencyl)-1H-imidazo[4,5-d]pyridazin-4-amina; (106) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) benzamida; (108) 2-butyl-7-isopropoxy-1-(4- (((2-(2-(2-methoxyethoxy)ethyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (109) 2-butyl-1-(4-((hexilamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (110) 2-butyl-1-(4-((decylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (114) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) 4-acetamidobencyl carbamate; (115) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) methanesulfonamida; (116) 2-butyl-1-(4-((dimethylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (117) (4-( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) glycinato de tert-butilo; (118) 2-butyl-7-isopropoxy-1-(4-((methylamino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (119) 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) amino) propanoato de tercbutilo; (120) 1-(4-(5,8,11-trioxa-2-azadodecyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (121) 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (123) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2- [ (124) 2-butyl-7-isopropoxy-1-(3-((methylamino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (125) 2-butyl-1-(3-((dimethylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (126) sal dichlorhidrato de 2-butyl-1-(3-((cyclobutylamino) metil) bencil)-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (127) sal dichlorhidrato de 2-butyl-1-(3-((cyclopropylamino) metil) bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (129) 1, 1-dióxido de 3- ( (3- ( (4-amino-2-butil-7-isopropoxi-1H-imidazo[4, 5-d]piridazin-1-yl) metil) bencil) amino) tietano; (130) sal diclorhidrato de 2-butil-7-isopropoxi-1- (3- ( (1-metilciclobutil) amino) metil) bencil) -1H-imidazo[4, 5-d]piridazin-4-amine; (132) (E) -1- (4- (aminomethyl) bencyl) -2-butyl-7- (3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (133) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopentyl-1H-imidazo[4,5-d]pyridazin-4-amine; (135) 2,2,2-trifluoroacetate of 1-(4-(aminomethyl)benzyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (141) 1-( ( (1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (144) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-(2,5-dihydro-1H-pyrrol-3-yl)imidazo[4,5-d]pyridazin-4-amine; (145) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-pyrrolidine-3-yl-imidazo[4,5-d]pyridazin-4-amine; (147) dihydrochloride salt of 2-butyl-4-isopropoxy-3-[6-(tetrahydropyran-4-ylamino)hexyl]imidazo[4,5-d]pyridazin-7-amine; (150) hydrochloride salt of 2-butyl-4-isopropoxy-3-[4-(tetrahydropyran-4-ylamino)butyl]imidazo[4,5-d]pyridazin-7-amine; (154) 2-Butyl-3-[6-[(1,1-dioxothiethan-3-yl)amino]hexyl]-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (156) hydrochloride salt of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)methyl]-2-methyl-propane-1,3-diol; (157) hydrochloride salt of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)methyl]propane-1,3-diol; (160) 1-(4-(aminomethyl)benzyl)-7-isopropoxy-2-methyl-1H-imidazo[4,5-d]pyridazin-4-amine; (161) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfanyl-imidazo[4,5-d]pyridazin-7-amine; (163) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-N2-propyl-imidazo[4,5-d]pyridazine-2,7-diamine; (164) 3-[[4-(aminomethyl)phenyl]methyl]-2-(ethylaminomethyl)-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine or a pharmaceutically acceptable salt thereof. Among the compounds listed above, the following compounds of interest can be cited, for example: (19) dichlorhydrate salt of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (20) 2, 2, 2-trifluoroacetate of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (21) 1-(4-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (22) 2, 2, 2-trifluoroacetate de 1-(4-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (23) 1- (((1S, 3R)-3-aminocyclohexyl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine (y enantiómero) ; (24) 1-(4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)-2-methylpropan-2-ol; (25) Trans 1-(4-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo [4, 5-d]pyridazin-4-amine; (26) 1-((5-(aminomethyl)pyridin-2-yl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (28) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl)methyl)bencyl)acetamide; (33) 2, 2, 2-trifluoroacetate de 1-(3-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (35) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) phenyl) methanol; (36) 2-butyl-1-(4-((cyclopropylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (39) 2-butyl-7-isopropoxy-1-(4-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (40) 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (43) 2-butyl-N7-(4-((dimethylamino)methyl)bencyl)-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (47) 2-butyl-N7-(4-(((2-methoxyethyl)(methyl)amino)methyl)bencyl)-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (144) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-(2, 5-dihydro-1H-pyrrol-3-yl) imidazo[4, 5-d]pyridazin-4-amine; (156) sal chloride hydrate of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) methyl]-2-methyl-propane-1, 3-diol; (157) sal chloride hydrate of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4, 5-d]pyridazin-3-yl) methyl]propane-1, 3-diol; (159) 1-(4-(aminomethyl)bencyl)-2-(ethoxymethyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (161) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfanyl-imidazo[4, 5-d]pyridazin-7-amine; (163) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-N2-propyl-imidazo[4, 5-d]pyridazine-2, 7-diamine; (164) 3-[[4-(aminomethyl)phenyl]methyl]-2-(ethylaminomethyl)-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine or a pharmaceutically acceptable salt of the same. Among the compounds listed above, the following compounds of interest can be cited, for example: (91) 2-butyl-1-methyl-N7-(4-((4-methylpiperazin-1-yl)methyl)benzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (93) 4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-ol; (95) 2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (96) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrazol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (97) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (98) 2-butyl-N7-isopropyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (123) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2- [ (141) 1-( ((1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (144) 1-[[4-(aminomethyl)fenil]metil]-2-butil-7-(2,5-dihydro-1H-pyrrol-3-yl)imidazo[4,5-d]pyridazin-4-amine; (145) 1-[[4-(aminomethyl)fenil]metil]-2-butyl-7-pyrrolidin-3-yl-imidazo[4,5-d]pyridazin-4-amine; (160) 1-(4-(aminomethyl)benzyl)-7-isopropoxy-2-methyl-1H-imidazo[4,5-d]pyridazin-4-amine; (163) 3-[[4-(aminomethyl)fenil]metil]-4-isopropoxy-N2-propyl-imidazo[4,5-d]pyridazine-2,7-diamine; (164) 3-[[4-(aminomethyl)phenyl]methyl]-2-(ethylaminomethyl)-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine or a pharmaceutically acceptable salt of the same. According to this disclosure, compounds of formula (I) can be prepared, for example, by the following processes, corresponding to Schemes 1 (Synthesis Method 1), 2 (including Synthesis Methods 2, 2a and 2b), 3 (Synthesis Method 3) and 4 (Synthesis Method 4). These processes are also part of this disclosure and are detailed below. Compounds of formula (I) and other related compounds having different substituents are synthesized using the techniques and materials described below or otherwise known to the skilled worker. Furthermore, the solvents, temperatures, and other reaction conditions presented below may be varied as deemed appropriate by the skilled worker. SCHEME 1: Preparation of compounds of formula (I) - General process (Synthesis Method 1) The general methods below for the preparation of disclosure compounds are optionally modified by the use of reagents and conditions appropriate for the introduction of the various residues found in formula (I) as described below. According to SCHEME 1, a process in accordance with this disclosure comprises at least the following steps: (iB) provide a compound of formula (II) , (iiB) cyclization of the compound of formula (II) provided in step (iB) by reaction with R2-C (OCH3) 3 or R2-COCl where R2 is as defined herein to obtain a compound of formula (III), where R2 is as defined in this disclosure; (iiiB) hydrolysis of nitrile groups of the compound of formula (III) obtained from step (iiB) in order to obtain a compound of formula (IV), where R2 is as defined in this disclosure; (ivB) esterification of the carboxylic acid functional groups of the compound of formula (IV) obtained from step (iiiB) in order to obtain a compound of formula (V), where R is an alkyl (C1-C4) group - for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group and R2 is as defined in this disclosure; (vB) optionally reacting the compound of formula (V) obtained from step (ivB) with R1-X where R1 is as defined in this disclosure, and X represents a halogen atom, for example, a chlorine, iodine, or bromine atom, in order to obtain a compound of formula (Vb), where R is an alkyl group (C1-C4), for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group, and R1 and R2 are as defined in this disclosure; (viB) cyclization of the compound of formula (Vb) obtained from step (vB) or the compound of formula (V) (in which R1 is a hydrogen atom) obtained from step (ivB) in order to obtain a compound of formula (VIb), where R1 and R2 are as defined in this disclosure; (viiB) dihalogenation of the compound of formula (VIb) obtained from step (VIb) in order to obtain a compound of formula (VIIa), where R1 and R2 are as defined in this disclosure and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, for example, the two HALs are the same and are chlorine atoms; (viiiB) nucleophilic aromatic substitution of the compound of formula (VIIa) obtained from step (viiB) in order to obtain a compound of formula (VIIIa), wherein R1 and R2 are as defined in this disclosure and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom, or a bromine atom; (ixB) substitution and / or coupling of the compound of formula (VIIIa) obtained from step (viiiB) to obtain a compound of formula (Ia), where R1 and R2 are as defined in this disclosure, and R3a represents R3 as defined in this disclosure which may or may not comprise a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group; (xB) when R3a is different from R3 as defined in this disclosure, then react the compound of formula (Ia) obtained from step (ixB) with any suitable reagents and under any suitable conditions to obtain a compound of formula (I) as defined in this disclosure. This route allows the preparation of, for example, the following compounds of formula (I) in accordance with this disclosure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 86, 92, 93, 94, 95, 96, 97, 98 and 99. SCHEME 2: Preparation of compounds of formula (I) - General process (Synthesis Method 2, 2a and 2b) According to SCHEME 2, a process in accordance with this disclosure comprises at least the following steps: (i) provide a compound of formula (II) , (ii) cyclization of the compound of formula (II) provided in step (i) by reaction with R2-C(OCH3)3 or R2-COCl where R2 is as defined in this disclosure or is a hydrogen atom in order to obtain a compound of formula (III), where R2 is as defined in this disclosure or is a hydrogen atom; (iii) hydrolysis of nitrile groups of the compound of formula (III) obtained from step (ii) in order to obtain a compound of formula (IV), where R2 is as defined in this disclosure or is a hydrogen atom; (iv) esterification of the carboxylic acid functional groups of the compound of formula (IV) obtained from step (iii) in order to obtain a compound of formula (V), where R is an alkyl (C1-C4) group, for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group, and R2 is as defined in this disclosure or is a hydrogen atom; (v) cyclization of the compound of formula (V) obtained from step (iv) in order to obtain a compound of formula (VI), where R2 is as defined in this disclosure or is a hydrogen atom; (vi) dihalogenation of the compound of formula (VI) obtained from step (v) in order to obtain a compound of formula (VII), where R2 is as defined in this disclosure or is a hydrogen atom and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, for example, the two HALs are the same and are chlorine atoms; (vii) nucleophilic aromatic substitution of the compound of formula (VII) obtained from step (vi) with a compound of formula (AA) where the two G1s independently represent a hydrogen atom or a methoxy group, for example, the two G1s are a methoxy group, in order to obtain a compound of formula (VIII), where R2 is as defined in this disclosure or is a hydrogen atom, HAL is a halogen atom, e.g. a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, e.g. a chlorine atom, and the two G1s independently represent either a hydrogen atom or a methoxy group, e.g. the two G1s are a methoxy group; (viii) substitution and / or coupling reaction of the compound of formula (VIII) obtained from step (vii) in order to obtain a compound of formula (IX), where R2 is as defined in this disclosure or is a hydrogen atom, R3a represents R3 as defined in this disclosure comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group and the two G1s independently represent a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group; then either (ixAlpha, also referred to as ix) react the compound of formula (IX) obtained from step (viii) with R1a-X where R1a is R1 as defined herein comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, and X represents a halogen atom, a tosylate or a mesylate in order to obtain a compound of formula (X), where R2 is as defined in this disclosure or is a hydrogen atom, R3a represents R3 as defined in this disclosure comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, the two G1s independently represent a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group, and R1a is as defined above in this stage (ixAlpha); or (ixBeta, also called ixß) react the compound of formula (IX) obtained from step (viii) with an epoxide of formula where R' and R" are independently a hydrogen atom or an alkyl group (C1-C6), such as a methyl group, in order to obtain a compound of formula (X), where R2 is as defined in this disclosure or is a hydrogen atom, R3a represents R3 as defined in this disclosure comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, the two G1s independently represent a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group, and R1a is as defined above in step (ixAlpha); and either (x) deprotecting the compound of formula (X) obtained from step (ixAlpha) or (ixBeta) in order to obtain a compound of formula (I) as defined herein; and where R2 is a hydrogen atom in the compound of formula (X), prior to deprotection, the hydrogen was transformed into R2 as defined in formula (I) through chemical modification, such as metalation, followed, for example, either by reaction with alkyl disulfide, or dimethylformamide, or N-bromosuccinimide, which was further subjected to another chemical reaction, if necessary, such as oxidation, or reduction amination or nucleophilic substitution, to provide the required R2; or (x) deprotect the compound of formula (X) obtained from step (ixAlpha) or (ixBeta) in order to obtain a compound of formula (XI) wherein R3a represents R3 as defined herein, comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group, R2 is as defined herein, and R1b is R1a as defined herein or R1a with a function group such as an amino group, an alcohol, and an aldehyde; and thereafter (xi) reducing, reductively aminating, nucleophilically substituting, and / or oxidizing the compound of formula (XI) obtained from this step (x) to obtain a compound of formula (I) as defined herein; or (Gamma, also called) reduce, aminate in a reductive manner, substitute in a nucleophilic manner and / or oxidize the compound of formula (X) obtained from step (ixAlpha) or (ixBeta) in order to obtain a compound of formula (XII) wherein R3a represents R3 as defined herein comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, R2 is as defined herein, the two G1s independently represent either a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group, and R1b is a derivative of R1a as defined herein through reductive amination, reduction, substitution and / or oxidation; and thereafter (x) deprotecting the compound of formula (XII) obtained from step (Gamma) in order to obtain a compound of formula (I) as defined herein. As shown in scheme 2, there are three options available from compounds of formula (X). The first option is referred to in this disclosure as Synthesis Method 2. It comprises only step (x) starting from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. The second option is referred to in this disclosure as Synthesis Method 2a. It comprises step (x) from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (XI) as defined in this disclosure and then step (xi) from a compound of formula (XI) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. The third option is referred to in this disclosure as Synthesis Method 2b. It comprises step (Gamma) (also referred to as step ) from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (XII) as defined in this disclosure and then step (x) from a compound of formula (XII) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. This synthesis method 2 allows the preparation, for example, of the following compounds of formula (I) according to this disclosure: 19, 20, 21, 22, 23, 24, 25, 27, 32, 33, 34, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 165. This synthesis method 2a allows the preparation, for example, of the following compounds of formula (I) according to this disclosure: 38, 39, 40, 84, 103, 104, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 119. 148, 151, 153 and 155. This method of synthesis 2b allows the preparation, for example, of the following compounds of formula (I) according to this disclosure: 26, 28, 29, 30, 31, 35, 36, 37, 100 to 102, 105, 120 to 131, 146, 147, 149, 150, 152, 154 and 156 to 160 SCHEME 3: Preparation of compounds of formula (I) - General process (Synthesis Method 3) According to SCHEME 3, a process in accordance with this disclosure comprises at least the following steps: (iA) provide a compound of formula (II) (iiA) cyclization of the compound of formula (II) provided in step (iA) by reaction with R2-C (OCH3) 3 or R2-COCl where R2 is as defined herein to obtain a compound of formula (III), where R2 is as defined in this disclosure; (iiiA) hydrolysis of nitrile groups of the compound of formula (III) obtained from step (iiA) in order to obtain a compound of formula (IV), where R2 is as defined in this disclosure; (ivA) esterification of the carboxylic acid functional groups of the compound of formula (IV) obtained from step (iiiA) in order to obtain a compound of formula (V), where R is an alkyl group (C1-C4), for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group, and R2 is as defined in this disclosure; (vA) cyclization of the compound of formula (V) obtained from step (ivA) in order to obtain a compound of formula (VI), where R2 is as defined in this disclosure; (viaA) dihalogenation of the compound of formula (VI) obtained from step (vA) in order to obtain a compound of formula (VII); where R2 is as defined in this disclosure, and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom, or a bromine atom, for example, the two HALs are the same and are chlorine atoms; (viiA) optionally reacting the compound of formula (VII) obtained from step (viA) with R1-X where R1 is as defined in this disclosure, and X represents a halogen atom, for example, a chlorine atom, an iodine atom, or a bromine atom, in order to obtain a compound of formula (VIIa), where R1 and R2 are as defined in this disclosure, and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom, or a bromine atom, for example, the two HALs are the same and are chlorine atoms; (viiiA) nucleophilic aromatic substitution of the compound of formula (VIIa) obtained from step (viiA) or of the compound of formula (VII) (in which R1 is a hydrogen atom) obtained from step (viA) in order to obtain a compound of formula (VIIIa), wherein R1 and R2 are as defined in this disclosure and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom, or a bromine atom; (ixA) substitution and / or coupling of the compound of formula (VIIIa) obtained from step (viiiA) to obtain a compound of formula (Ia), where R3a represents R3 as defined in this disclosure, which may or may not include a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group, and R1 and R2 are as defined in this disclosure; (xA) When R3a is different from R3 as defined herein, then react the compound of formula (Ia) obtained from step (ixA) with any suitable reagents and under any suitable conditions to obtain a compound of formula (I) as defined herein. Such a method of Synthesis 3 allows the preparation, for example, of the following compounds of formula (I) according to herein: 41, 42, 43, 44, 45, 46, 47, 85, 87, 88, 89, 90, and 91. SCHEME 4: Preparation of compounds of formula (I) - General process (Synthesis Method 4) According to SCHEME 4, a process in accordance with this disclosure comprises at least the following steps: (i) provide a compound of formula (II) , (ii) cyclization of the compound of formula (II) provided in step (i) by reaction with R2-C (OCH3) 3 or R2-COCl where R2 is as defined herein in order to obtain a compound of formula (III), where R2 is as defined in this disclosure; (iii) hydrolysis of nitrile groups of the compound of formula (III) obtained from step (ii) in order to obtain a compound of formula (IV), where R2 is as defined in this disclosure; (iv) esterification of the carboxylic acid functional groups of the compound of formula (IV) obtained from step (iii) in order to obtain a compound of formula (V), where R is an alkyl group (C1-C4), for example, a methyl group, an ethyl group, a propyl group or a butyl group, such as a methyl group, and R2 is as defined in this disclosure; (v) cyclization of the compound of formula (V) obtained from step (iv) in order to obtain a compound of formula (VI), where R2 is as defined in this disclosure; (vi) dihalogenation of the compound of formula (VI) obtained from step (v) in order to obtain a compound of formula (VII), where R2 is as defined in this disclosure and HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, for example, the two HALs are the same and are chlorine atoms; then either (vialpha, also referred to as vii) react the compound of formula (VII) obtained from step (vi) with R1a-X where R1a is R1 as defined herein comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, and X represents a halogen atom, a tosylate or a mesylate in order to obtain a compound of formula (VIIIaa), where R2 is as defined in this disclosure, HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, for example, the two HALs are the same and are chlorine atoms, and R1a is as previously defined in this stage (viialfa); or (viiBeta, also called viiß) react the compound of formula (VII) obtained from step (vi) with an epoxide of formula where R' and R" are independently a hydrogen atom or an alkyl group (C1-C6), such as a methyl group, in order to obtain a compound of formula (VIIIaa), where R2 is as defined in this disclosure, HAL is a halogen atom, for example, a chlorine atom, a fluorine atom, an iodine atom, or a bromine atom, for example, the two HALs are the same and are chlorine atoms, and R1a is as defined above in step (viialfa); (viiiAA) nucleophilic aromatic substitution of the compound of formula (VIIIaa) obtained from step (viialpha) or step (viibeta) with a compound of formula (AA) where the two G1s independently represent a hydrogen atom or a methoxy group, for example, the two G1s are a methoxy group, in order to obtain a compound of formula (IXaa), where R2 is as defined in the present disclosure, HAL is a halogen atom, e.g. a chlorine atom, a fluorine atom, an iodine atom or a bromine atom, e.g. a chlorine atom, R1a is as defined above in step (viialfa), and the two G1s independently represent either a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group; (ixAA) substitution and / or coupling reaction of the compound of formula (IXaa) obtained from step (viiiAA) in order to obtain a compound of formula (X), where R2 is as defined in this disclosure, R1a is as defined above in step (viialfa), R3a represents R3 as defined in this disclosure comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group and the two G1s independently represent either a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group; and either (x) deprotecting the compound of formula (X) obtained from step (ixAA) in order to obtain a compound of formula (I) as defined in this disclosure; or (x) deprotect the compound of formula (X) obtained from step (ixAA) in order to obtain a compound of formula (XI) wherein R3a represents R3 as defined herein, comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group, R2 is as defined herein, and R1b is R1a or R1a with an al function as an amino group, an alcohol, and an aldehyde; and then (xi) reducing, reductively aminating, nucleophilically substituting, and / or oxidizing the compound of formula (XI) obtained from this step (x) to obtain a compound of formula (I) as defined herein; or (Gamma, also called) reduce, aminate in a reductive manner, substitute in a nucleophilic manner and / or oxidize the compound of formula (X) obtained from step (ixAA) in order to obtain a compound of formula (XII) wherein R3a represents R3 as defined herein comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group or a ketone protecting group, R2 is as defined herein, the two G1s independently represent either a hydrogen atom or a methoxy group, e.g., the two G1s are a methoxy group, and R1b is a derivative of R1a through reductive amination, reduction, substitution and / or oxidation; and thereafter (x) deprotecting the compound of formula (XII) obtained from step (Gamma) in order to obtain a compound of formula (I) as defined herein. As shown in scheme 4, there are three options available from compounds of formula (X). The first option is referred to in this disclosure as Synthesis Method 4. It comprises only step (x) from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. The second option is referred to in this disclosure as Synthesis Method 4a. It comprises step (x) from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (XI) as defined in this disclosure and then step (xi) from a compound of formula (XI) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. The third option is referred to in this disclosure as Synthesis Method 4b. It comprises step (Gamma) (also referred to as step ) from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (XII) as defined in this disclosure and then step (x) from a compound of formula (XII) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure. This Synthesis Method 4 allows the preparation, for example, of the following compounds of formula (I) according to this disclosure: 132 to 135, 137 to 145. With regard to stages (i), (iA) and (iB) (not shown in diagrams 1, 2, 3 and 4): The compound of formula (II) is a commercially available compound, for example from Fisher or Merck-Sigma, or it can be prepared by any method well known to the expert. With regard to stages (ii), (iiA) and (iiB) (respectively, schemes 2 (or 4), 3 and 1): The cyclization steps (ii), (iiA) and (iiB) of a compound (II) as defined in this disclosure allow obtaining a compound of formula (III) as defined in this disclosure. For example, the cyclization steps (ii), (iiA) and (iiB) of compound (II) can be carried out using as a reagent R2-C (OCH3) 3 where R2 is as defined in this disclosure (steps (ii), (iiA) and (iiB)) or is a hydrogen atom (step (ii)) and furthermore in the presence of a solvent such as xylene, acetonitrile, dioxane, toluene or mixtures thereof, for example, a mixture of xylene and acetonitrile, with heat, i.e. at a temperature ranging from 25 °C to 200 °C, for example, from 85 °C to 150 °C. The cyclization steps (ii), (iiA) and (iiB) of compound (II) can also be carried out using R2-COCl as a reagent where R2 is as defined in this disclosure (steps (ii), (iiA) and (iiB)) or is a hydrogen atom (step (ii)) in ethyl acetate (EtOAc) at room temperature and then treatment with sodium hydride (NaH) in dimethylformamide (DMF), followed by reflux heating. With regard to stages (iii) , (iiiA) and (iiiB) (respectively, schemes 2 (or 4) , 3 and 1) : The hydrolysis steps (iii), (iiiA) and (iiiB) of the nitrile groups present in a compound of formula (III) as defined in this disclosure allow obtaining a compound of formula (IV) as defined in this disclosure. For example, the hydrolysis steps (iii), (iiiA) and (iiiB) of the nitrile groups of the compound of formula (III) can be carried out in the presence of an acid such as sulfuric acid, hydrochloric acid or mixtures thereof, in the presence of water (water reflux) or in the presence of water and another organic solvent, such as dioxane, for example, in the presence of sulfuric acid in water, with heat, i.e., at a temperature ranging from 25 °C to 150 °C, for example, to 100 °C. The hydrolysis steps (iii), (iiiA) and (iiiB) of the nitrile groups of the compound of formula (III) can also be carried out in refluxing sodium hydroxide followed by acidification with hydrochloric acid. With regard to stages (iv), (ivA) and (ivB) (respectively, schemes 2 (or 4), 3 and 1): The esterification steps (iv), (ivA) and (ivB) of the carboxylic acid functions present in the compound of formula (IV) as defined in this disclosure allow obtaining a compound of formula (V) as defined in this disclosure. For example, the esterification steps (iv), (ivA), and (ivB) of the carboxylic acid functional groups present in the compound of formula (IV) can be carried out in the presence of a chlorinating agent such as thionyl chloride (SOCl2), phosphorus trichloride (PCl3), phosphorus pentachloride (PCl5), oxalyl chloride, or mixtures thereof, for example, SOCl2, and in the presence of a primary alcohol R-OH in which R is a C1-C4 alkyl group (for example, a methyl group, an ethyl group, a propyl group, or a butyl group, such as a methyl group), such as methanol, ethanol, propanol, or butanol, for example, methanol, for example, in SOCl2 and methanol, at a temperature ranging from 25 °C to 100 °C, for example, at 60 °C. The esterification steps (iv), (ivA) and (ivB) of the carboxylic acid functional groups present in the compound of formula (IV) can also be carried out in the presence of H2SO4, H2O, MeOH (methanol) at 100 °C. Regarding stage (vB) (scheme 1): Step (vB) from a compound of formula (V) as defined herein allows obtaining a compound of formula (Vb) as defined herein. Step (vB) is an optional step that can be performed if a compound of formula (Vb) is required in which R1 is as defined herein (i.e., R1 is not just a hydrogen atom). In other words, a compound of formula (V) (corresponding to R1 is a hydrogen atom): may be directly subjected to step (viB) in order to provide a compound of formula (VIb) wherein R1 and R2 are as defined in this disclosure, either can be subjected to step (vB) in order to provide a compound of formula (Vb) wherein R1 and R2 are as defined in this disclosure and then the compound of formula (Vb) obtained in this way is subjected to step (viB) in order to provide a compound of formula (VIb) wherein R1 and R2 are as defined in this disclosure. Depending on the desired compound, the expert will choose the most appropriate step to perform. For example, step (vB) can be carried out in the presence of R1-X where R1 and X are as defined in this disclosure, and furthermore in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, for example, in potassium carbonate, in a solvent such as dimethylformamide, acetone, acetonitrile, 1,4-dioxane, tetrahydrofuran (THF) , or mixtures thereof, for example, in dimethylformamide, such as in the presence of potassium carbonate and dimethylformamide from 0 °C to 150 °C, for example, from 25 °C to 130 °C. With regard to stages (v) , (vA) and (viB) (respectively, schemes 2 (or 4) , 3 and 1) : The cyclization steps (v) , (vA) and (viB) , respectively, from a compound of formula (V) , (V) or (Vb) as defined in this disclosure allow obtaining respectively a compound of formula (VI) , (VI) and (VIb) as defined in this disclosure. For example, the cyclization steps (v), (vA) and (viB) can be carried out in the presence of a reagent such as hydrazine hydrate, in the presence of a solvent such as methanol, ethanol or mixtures thereof, for example, methanol, such as in the presence of hydrazine, water and methanol, with heat, i.e., at a temperature ranging from 25 °C to 150 °C, for example, from 60 °C to 85 °C. With regard to stages (vi), (via) and (viib) (respectively, schemes 2 (or 4), 3 and 1): The dihalogenation steps (vi), (viA) and (viiB), respectively, from a compound of formula (VI), (VI) or (VIb) as defined in this disclosure allow obtaining a compound of formula (VII), (VII) and (VIIa) respectively as defined in this disclosure. For example, dihalogenation steps (vi), (viA), and (viiB) can be carried out in the presence of a reagent such as phosphorus oxychloride (POCl3), phosphorus pentachloride (PCl5), or mixtures thereof, e.g., POCl3, in the presence of a solvent such as N,N-dimethylaniline, or in the presence of phosphorus oxychloride and N,N-dimethylaniline, with heat, i.e., at a temperature ranging from 80 °C to 160 °C, e.g., from 100 °C to 110 °C. Dihalogenation steps (vi), (viA), and (viiB) can also be carried out in the presence of a mixture of phosphorus oxychloride and phosphorus pentachloride at reflux temperature. With regard to stage (vii) (scheme 2): Step (vii) from a compound of formula (VII) as defined in this disclosure allows obtaining a compound of formula (VIII) as defined in this disclosure. Step (vii) is a nucleophilic aromatic substitution that, for example, can be carried out in the presence of a solvent such as butanol, isoamyl alcohol, isopropanol, or mixtures thereof, for example, butanol, in the presence of a base such as N,N-diisopropylethylamine (DIEA), triethylamine (TEA), 1,8-diazabiclo[5.4.0]undec-7-ene DBU, for example, N,N-diisopropylethylamine, with heat, i.e., at a temperature ranging from 80 °C to 200 °C, for example, from 120 °C to 130 °C, or also in the presence of N-methylpyrrolidone, at 130 °C, or in the presence of TEA, dimethylacetamide from room temperature to 50 °C, and in the presence of a compound of formula (AA), where G1 represents a hydrogen atom or a methoxy group. Advantageously, to increase the reaction rate, the two G1 radicals in the formula (AA) are each a methoxy group. With regard to stage (viiA) (scheme 3): Step (viiA) from a compound of formula (VII) as defined in this disclosure allows obtaining a compound of formula (VIIa) as defined in this disclosure. Step (viiA) is an optional step that can be performed if a compound of formula (VIIa) is required in which R1 is as defined in this disclosure (i.e., R1 is not just a hydrogen atom). In other words, a compound of formula (VII) (corresponding to R1 is a hydrogen atom): may be directly subjected to step (ViiiA) in order to provide a compound of formula (VIIIa) wherein R1, R2 and HAL are as defined in this disclosure, or can be subjected to step (viiA) in order to provide a compound of formula (VIIa) wherein R1, R2 and HAL are as defined in this disclosure and then the compound of formula (VIIa) obtained in this manner is subjected to step (viiiA) in order to provide a compound of formula (VIIIa) wherein R1, R2 and HAL are as defined in this disclosure. Depending on the desired compound, the expert will choose the most appropriate step to perform. Step (viiA) can be carried out in the presence of R1-X where R1 and X are as defined in this disclosure, such as in the presence of methyl iodide (MeI), in acetone and K2CO3, at room temperature (25 °C), or in the presence of R1-X as defined in this disclosure, in Cs2CO3, 1,4-Dioxane, from room temperature (25 °C) to 120 °C. With respect to stage (viialpha, also called vii) and stage (viibeta, also called viiß) (scheme 4): The (viialpha) step or the (viibeta) step of a compound of formula (VII) as defined in this disclosure allows obtaining a compound of formula (VIIIaa) as defined in this disclosure. Step (viialpha) can be carried out in the presence of R1a-X, where R1a is R1 as defined herein, comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group, and X represents a halogen atom, a tosylate, or a mesylate. Step (viibeta) can be carried out in the presence of an epoxide of formula wherein R' and R" are independently a hydrogen atom or an alkyl group (C1-C6), such as a methyl group. With regard to stage (viiiAA) (scheme 4): Step (viiiAA) from a compound of formula (VIIIaa) as defined in this disclosure allows obtaining a compound of formula (IXaa) as defined in this disclosure. Step (viiiAA) is a nucleophilic aromatic substitution that, for example, can be carried out in the presence of a solvent such as butanol, isoamyl alcohol, isopropanol, or mixtures thereof, for example, butanol, in the presence of a base such as N,N-diisopropylethylamine (DIEA), triethylamine (TEA), 1,8-diazabiclo[5.4.0]undec-7-ene DBU, for example, N,N-diisopropylethylamine, with heat, i.e., at a temperature ranging from 80 °C to 200 °C, for example, from 120 °C to 130 °C, or also in the presence of N-methylpyrrolidone, at 130 °C, or in the presence of TEA, dimethylacetamide from room temperature to 50 °C, and in the presence of a compound of formula (AA), where G1 represents a hydrogen atom or a methoxy group. Advantageously, to increase the reaction rate, the two G1 radicals in the formula (AA) are each a methoxy group. With regard to stages (viiiA) and (viiiB) (respectively, schemes 3 and 1): In Scheme 1, step (viiiB) is applied to a compound of formula (VIIa) as defined herein to obtain a compound of formula (VIIIa) as defined herein. In scheme 3, depending on the desired compound, step (viiiA) can be applied to a compound of formula (VIIa) in which HAL, R1 and R2 are as defined in this disclosure, obtained from step (viiA) as defined in this disclosure or to a compound of formula (VII) in which HAL and R2 are as defined in this disclosure, obtained from step (viA) as defined in this disclosure in order to obtain a compound of formula (VIIIa) as defined in this disclosure. For example, the nucleophilic aromatic substitution steps (viiiA) and (ViiiB) can be carried out in the presence of a base such as ammonia (NH3), for example, in the presence of water, alcohol, dioxane or mixtures thereof, such as in the presence of ammonia and water, with heat, i.e., at a temperature ranging from 25 °C to 200 °C, for example, at 150 °C. With regard to stage (viii) (scheme 2): Step (viii) from a compound of formula (VIII) as defined in this disclosure allows obtaining a compound of formula (IX) as defined in this disclosure. For example, step (viii) can be carried out in the presence of a reagent such as alcoholates, for example, sodium propan-2-olate (iPrONa), for example, sodium propan-2-olate, in a solvent such as isopropanol, for example, in sodium propan-2-olate / isopropanol, with heat, i.e., at a temperature ranging from 50 °C to 200 °C, for example, from 150 °C to 170 °C. With regard to stage (ixAA) (scheme 4): Step (ixAA) from a compound of formula (IXaa) as defined in this disclosure allows obtaining a compound of formula (X) as defined in this disclosure. For example, step (ixAA) can be carried out in the presence of a reagent such as alcoholates, for example, sodium propan-2-olate (iPrONa), for example, sodium propan-2-olate, in a solvent such as isopropanol, for example, in sodium propan-2-olate / isopropanol, with heat, i.e., at a temperature ranging from 50 °C to 200 °C, for example, from 150 °C to 170 °C. With regard to stages (ixA) and (ixb) (respectively, schemes 3 and 1): The substitution and / or coupling steps (ixA) and (ixB) from a compound of formula (VIIIa) as defined in this disclosure allow obtaining a compound of formula (Ia) as defined in this disclosure. The substitution and / or coupling steps (ixA) and (ixB) can be any appropriate chemical reaction involving dehalogenation of the molecule, for example, such as alkylation, nucleophilic aromatic substitution, and / or coupling such as Suzuki coupling, for example, a reaction with the presence of R3a-Y where R3a represents R3 as defined in formula (I) according to this disclosure or is a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde and ketone protecting group, and Y represents hydroxyl, amine, boronic acid. With respect to stages (xA) and (xB): (respectively, schemes 3 and 1): Steps (xA) and (xB) from a compound of formula (Ia) as defined herein allow obtaining a compound of formula (I) as defined herein. It is understood that if in the compound of formula (Ia) obtained from, respectively, step (ixA) and steps (ixB), R3a is R3 then it is not necessary to perform step (xA) or step (xB) respectively. Therefore, compounds of formula (Ia) in which R3a is other than R3 as defined herein may be reacted with any suitable reagent and under any suitable conditions to obtain a compound of formula (I) as defined herein. For example, these steps may be selected from reduction steps, deprotection steps, hydrolysis steps, oxidation steps, and combinations thereof, it being understood that these steps may be carried out once or several times, if necessary. All of these steps are well known to those skilled in the art. Regarding stage (ixAlpha, also called ix) and stage (ixBeta, also called ixß) (scheme 2): The (ixAlpha) step or the (ixBeta) step of a compound of formula (IX) as defined in this disclosure allows obtaining a compound of formula (X) as defined in this disclosure. Step (ixAlpha) can be carried out in the presence of R1a-X, where R1a is R1 as defined herein, comprising or not comprising a hydroxyl protecting group, an amino protecting group, a carboxylic acid protecting group, an aldehyde protecting group, or a ketone protecting group, and X represents a halogen atom, a tosylate, or a mesylate. Step (ixBeta) can be carried out in the presence of an epoxide of formula wherein R' and R" are independently a hydrogen atom or an alkyl group (C1-C6), such as a methyl group. With respect to the stage (Gamma, also called) (scheme 2, Synthesis Method 2b or scheme 4, Synthesis Method 4b): The (Gamma) step from a compound of formula (X) as defined in this disclosure allows obtaining a compound of formula (XII) as defined in this disclosure. The (Gamma) step can be a reduction, a reductive amination, a nucleophilic substitution and / or an oxidation. With respect to stage (x) (scheme 2 or scheme 4): The deprotection step (x) can be performed in order to deprotect the amino group attached to the pyridazine portion of the imidazopyridazine ring and optionally, if appropriate, the protected group corresponding to R1a and / or R3a. In other words, step (x) can be carried out from a compound of formula (X) as defined in this disclosure or from a compound of formula (XII) as defined in this disclosure to obtain a compound of formula (I) as defined in this disclosure, or it can be carried out from a compound of formula (X) as defined in this disclosure to obtain a compound of formula (XI) as defined in this disclosure. For example, step (x) can be carried out in the presence of an acid such as trifluoroacetic acid (TFA), hydrochloric acid or mixtures thereof, for example, TFA, in the presence of a solvent such as dichloromethane (DCM), dioxane, tetrahydrofuran (THF), or mixtures thereof, for example, DCM, for example, in TFA and DCM. With regard to step (xi) (scheme 2, Synthesis Method 2a or scheme 4, Synthesis Method 4a): Step (xi) from a compound of formula (XI) as defined in this disclosure allows obtaining a compound of formula (I) as defined in this disclosure. Step (xi) can be a reduction, a reductive amination, a nucleophilic substitution, and / or an oxidation. Specific compounds of formula (I), as defined herein, are listed in Table 1 (number, chemical name, and formula) and are further detailed herein. Table 2 also lists 1H NMR, retention time, and liquid chromatography / mass spectra. The 1H NMR in Table 2 refers to 1H NMR spectra (400 MHz, ppm, DMSO-d6) as defined in the Experimental Part. The liquid chromatography / mass spectra (LC / MS) in Table 2 were obtained according to one of the seven methods described in the Experimental Part. The Retention Time (RT) in Table 2 is defined in minutes. Table 1: 22 Table 2 Among the intermediate compounds of formulas (VIIa), (VIII), (VIIIa) and (IX) or a pharmaceutically acceptable salt thereof, which are the subject of this disclosure, mention may be made, for example, of the following compounds as shown in Table 3 below: Table 3: Table 4 below also indicates 1H NMR, retention time and liquid chromatography / mass spectra. The 1H NMR in Table 4 is 1H NMR spectra (400 MHz, ppm, DMSO-d6) as defined in the Experimental Part. The liquid chromatography / mass spectra (LC / MS) in Table 4 were obtained according to one of the seven methods described in the Experimental Part. The Retention Time (RT) in Table 4 is defined in minutes. Table 4: The examples below describe the preparation of some compounds according to the disclosure. The numbers of the compounds exemplified below correspond to those provided in Tables 1 and 3 above. All reactions are carried out in an inert atmosphere unless otherwise stated. In the following examples, when the source of the starting products is not specified, it should be understood that these products are known compounds. EXAMPLES In the Preparations and Examples, the following abbreviations are used: ACN, MeCN or CH3CN: acetonitrile CDCl3: deuterated chloroform DCM: dichloromethane DIPEA: diisopropylethylamine DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide EDCI: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide Et2O: diethyl ether EtOAc: ethyl acetate EtOH: ethanol HBTU: (2-(1H-benzotriazol-1-yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate HOBt: hydroxybenzotriazole iPrOH: isopropanol mCPBA: Meta-chloroperoxybenzoic acid MeOH: methanol Me-THF: methyl tetrahydrofuran MgSO4: magnesium sulfate MS: mass spectrometry MTBE: methyl tert-butyl ether NaCl: sodium chloride NBS: N-bromosuccinimide nBuLi: n-Butyl-lithium ta: ambient temperature TR: Retention time MRI: nuclear magnetic resonance NMP: N-methyl-2-pyrrolidone TEA: triethylamine TFA: trifluoroacetic acid THF: tetrahydrofuran Ti (iPrO) 4: Titanium (IV) isopropoxide TLC: thin layer chromatography TMS: tetramethylsilane hoh (s) : hour (s) MATERIALS AND METHODS The progress of the synthesis reactions is monitored by TLC. The plates are made of glass and coated with Merck 60 F254 silica gel. After elution, the plates are observed under ultraviolet light at 254 nm. Microwave reactions were performed using a Biotage Initiator 8 EXP microwave machine. Products were purified, when necessary, on a Biotage Isolera chromatograph or a Merck Spot 2 chromatograph. The columns used were Merck silica columns of 15–40 µm (2.5 g to 800 g). ANALYSIS Mass spectrometry (MS): Method A: The spectra were obtained on a Waters UPLC-SQD. Ionization: electronebulization in positive and / or negative mode (ES+ / -) Column: ACQUITY CORTECS C18+-1, 6 µm - 2, 1 x 50 mm Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid) Column temperature: 40 °C Flow rate: 1 ml / min Gradient (3 min): from 2 to 100% of B in 2.0 min; 2.6 min: 100% of B; 2.7 min: 2% of B. Method A has been used for compounds: 2, 9, 35, 65, 69, 86, 87 and 91. Method B: The spectra were obtained on a Waters UPLC-SQD. Ionization: electronebulization in positive and / or negative mode (ES+ / -) Column: ACQUITY CORTECS C18+-1, 6 µm - 2, 1 x 50 mm Solvents: A: H2O (0.1% TFA) B: CH3CN (0.1% TFA) Column temperature: 40 °C Flow rate: 1 ml / min Gradient (10 min): 1 min at 2% B, from 2 to 100% B in 6.5 min; 1.7 min: 100% B; from 100% B to 2% B in 0.1 min; 1.7 min: 2% B Method B has been used for the following compounds: 68. Method N: The spectra were obtained on a Waters UPLC-SQD2: Ionization: electronebulization in positive and / or negative mode (ES+ / -). ACQUITY CSH C1 column.- 1, 7 µm - 2, 1 x 50 mm Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid) Column temperature: 60 °C Flow rate: 1 ml / min Gradient (2.5 min): from 3 to 100% of B in 2.1 min; 2.45 min: 100% of B; 2.50 min: 3% of B Method N has been used for the following compounds: 1, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 66 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 88, 89, 90, 92, 93, 94, 95, 96, 97, 101, 102, 103, 104, 105, 107 to 117, 120, 121, 124 to 135, 137 to 146, 149, 150, 152 to 161, 163 to 165; intermediate products: (IA) , (IB) , (J) , (K) , (L) , (M) and (N) . Method N1: The spectra were obtained on a Waters UPLC-SQD2: Ionization: electronebulization in positive and / or negative mode (ES+ / -). ACQUITY CSH C1 column.- 1, 7 µm - 2, 1 x 50 mm Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid) Column temperature: 60 °C Flow rate: 1 ml / min Gradient (10 min): from 3 to 100% of B in 8.6 min; 9.6 min: 100% of B; 9.8 min: 3% of B Method N1 has been used for compound: 106. Method O: The spectra were obtained in a WATERS QUATTRO PREMIER Ionization: electronebulization in positive and / or negative mode (ES+ / -) Column: ACQUITY MSS T3 - 1.8 µm - 2.1 x 50 mm Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid) Column temperature: 55 °C Flow rate: 0.9 ml / min Gradient (3, 7 min): from 5 to 100% of B in 3 min; 3, 1 min: 5% of B Method O has been used for compounds: 80, 81, 82, 83, 84, 100, 118, 119, 147 and the intermediate product (O). Method P: The spectra were obtained on a Waters Xevo - QTof Ionization: electronebulization in positive mode (ES+). ACQUITY BEH C1 column.- 1, 7 µm - 2, 1 x 100 mm Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid) Column temperature: 45 °C Flow rate: 0.6 ml / min Gradient (5, 3 min): 0, 3 min from 5% B, from 5 to 100% B in 3, 7 min; 0, 6 min: 100% B; 0, 7 min: 5% B Method P has been used for compounds: 16, 42 and 85. Method M: The spectra were obtained on an Agilent 1200 and 6110B Ionization: electronebulization in positive mode (ES+). Kinetex C1850*2, 1 mm, 5 µm Solvents: A: H2O+TFA 0.037% (v / v) B: ACN+TFA 0.018% (v / v) Column temperature: 40 °C Flow rate: 1 ml / min Gradient (5 min): from 5 to 95% of B in 3 min; 1 min: 95% of B; 1.50 min: 5% of B Method M has been used for the intermediate products: (A), (B) and (E) and for the compounds: 122, 123, 148, 151 and 162. Method Z: The spectra were obtained using a Waters Acquity UPLC system with a PDA detector Ionization: electronebulization in positive and / or negative mode (ES+ / -) Acquity BEH C18 Column (50mm x 2.1mm) 1.7µm Solvents: A: H2O (0.05% formic acid) B: CH3CN (0.05% formic acid) Column temperature: 35 °C Flow rate: 0.6 ml / min Gradient (4 min): 0.4 min: 3% B; from 3 to 98% B in 1.6 min; 1.5 min: 98% B; 0.50 min: 3% B The Z method has been used for the intermediate products: (F), (G) and (H). 1H nuclear magnetic resonance (NMR) The 1H NMR spectra were recorded on a Brüker Avance and / or Varian G spectrometer (300 MHz, 400 MHz, 500 MHz, or 600 MHz) on deuterated DMSO. Chemical shifts are expressed in ppm using tetramethylsilane (TMS) as the internal standard. The following abbreviations were used for the interpretation of the spectra: S = singlet, d = doublet, t = triplet, c = quartet, quint = quintet, sext = sextet, dd = double doublet, ddd = doublet of double doublets, m = multiplet, ax. = axial, equat. = equatorial. PREPARATION All of the following compounds were synthesized according to the protocols described below. Preparation of the intermediate product (E): Preparation 1: Intermediate product (A) 2-butyl-1H-imidazole-4,5-dicarbonitrile A suspension of (Z)-2,3-diaminobut-2-enenitrile (45.0 g, 416 mmol, 1.00 eq) and 1,1,1-trimethoxypentane (67.5 g, 416 mmol, 1.00 eq) in MeCN (90.0 mL) was stirred in an oil bath and maintained at 85 °C for 6 h. At the end of this time, the reaction mixture was concentrated by evaporation under reduced pressure. The entire mixture was dissolved in xylene (90.0 mL), and the resulting solution was stirred in an oil bath maintained at 150 °C for 8 h. The mixture was concentrated to yield a residue, which was filtered and washed with methylbenzene. The filter cake was then dried to yield the expected product. The product was used in the next stage without further purification. Intermediate product (A) (63.0 g, 87% yield) 1H NMR (400 MHz, in ppm, CDCl3) : 2.82 (t, J= 7.6 Hz, 15.2 Hz, 2H), 1.72-1.80 (m, 2H), 1.36-1.45 (m, 2H), 0.93-0.97 (m, 3H) MS M method: TR = 1.019 min, m / z 175.1 (M+H) + Preparation 2: Intermediate product (B) 2-butyl-1H-imidazole-4,5-dicarboxylic acid A solution of compound (A) (63.0 g, 362 mmol, 1.00 eq) in H₂SO₄ (284 mL) and H₂O (126 mL) was stirred at 100 °C for 8 h. A new main spot with lower polarity was observed by TLC. The pH of the solution was adjusted to 9–10 using 10% sodium hydroxide solution. The mixture was filtered, and the filter cake was concentrated to provide the expected product, which was used in the next step without further purification. The intermediate product (B) (76.5 g, 99.7% yield) was obtained as a dark brown solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 2.59 (t, J = 7.6 Hz, 2H), 1.57-1.63 (m, 2H), 1.19-1.28 (m, 2H), 1.27-1.33 (m, 2H), 0.86 (t, J= 7.2 Hz, 14.8 Hz, 2H) . MS M method: TR = 1, 163 min, m / z 213, 1 (M+H) +. Preparation 3: Intermediate Product (C) 2-butyl-1H-imidazole-4,5-dimethyl dicarboxylate A mixture of compound (B) (76.5 g, 361 mmol, 1.00 eq) in MeOH (230 mL) was slowly mixed with SOCl2 (214 g, 1.80 mol, 131 mL, 5.00 eq), degassed, and purged with N2 three times. The mixture was then stirred at 40–45 °C for 12 h in a N2 atmosphere. It was cooled and then slowly poured into cooled water (500 mL). Neutralization was achieved by adding 10% sodium hydroxide solution. The mixture was then extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine (1.00 L), dried over Na2SO4, filtered, and concentrated under reduced pressure to provide a residue. The crude product was used in the next stage without further purification. The intermediate product (C) (81.0 g, 93.5% yield) was obtained as a dark brown solid. 1H RMN (400 MHz, en ppm, DMSO-d6): 3.87 (s, 6H), 2.77 (t, J = 8.0 Hz, 2H), 1.68-1.76 (m, 2H), 1.30-1.40 (m, 2H), 0.90 (t, J = 7.6 Hz, 3H). Preparation 4: Product intermedio (D) 2-butil-5, 6-dihydro-1H-imidazo[4, 5-d]piridazina-4, 7-diona A mixture of compound (C) (81.0 g, 337 mmol, 1.00 eq) and NH₂NH₂·H₂O (51.7 g, 1.01 mol, 50.2 mL, 98.0% purity, 3.00 eq) in MeOH (243 mL) was degassed and purged with N₂ three times. The mixture was then stirred at 60 °C for 1 hour in a N₂ atmosphere. The reaction mixture was filtered and washed with methanol. This material was resuspended in water (1.00 L), heated to 85 °C, and then acidified by the addition of concentrated HCl (100 mL). After stirring for 12 hours at 85 °C, the mixture was cooled, and the white product was filtered by suction and washed with water. The crude product was used in the next stage without further purification. The intermediate product (D) (49.5 g, 70.5% yield) was obtained as a whitish solid. Preparation 5: Intermediate product (E) 2-butyl-4,7-dichloro-1H-imidazo[4,5-d]pyridazine To a cooled solution of compound (D) (49.5 g, 238 mmol, 1.00 eq) in POCl3 (248 mL) N,N-Dimethylaniline (50.0 mL) was added, and the reaction mixture was stirred at 110 °C for 90 min. The reaction mixture was concentrated under reduced pressure to provide a residue. The residue was poured into cold water (2.00 L), the pH was adjusted to 7 with solid sodium bicarbonate, and the mixture was extracted with EtOAc (2 x 1 L). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to provide a residue. The residue in MTBE (200 mL) was stirred for 2 h. The suspension was filtered, and the filter cake was collected. The intermediate product (E) (54.5 g, 92.0% yield) was obtained in the form of a yellow solid. 1H NMR (400 MHz, in ppm, CDCl3) : 3.18 (t, J = 7.6 Hz, 2H), 1.90-1.97 (m, 2H), 1.40-1.49 (m, 1H), 0.92 (t, J= 7.2 Hz, 3H). MS M method: TR = 2.161 min, m / z 245.0 (M+H) +. Preparation of the intermediate product (H): Preparation 6: Intermediate Product (F) 2-butyl-1-[(4-methoxyphenyl)methyl]imidazole-4,5-dimethyl dicarboxylate To a solution of the intermediate product (C) (300 g, 1.25 mol) in DMF (3.5 L), K2CO3 (260 g, 1.88 mol) was added and the mixture was stirred at room temperature for 1 h, then 4-methoxybenzyl chloride (244.6 g, 1.56 mol) was added and the mixture was stirred at room temperature for 16 h. The reaction mixture was poured into water (5 L), extracted with EtOAc (2 x 3 L), the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide the intermediate product (F) (450 g, crude) in the form of a pale yellow oil which was taken as is in the next step. 1H NMR (400 MHz, in ppm, CDCl3) : 6.95 (d, J = 8.8 Hz, 2H) 6.84 (d, J = 8.6 Hz, 2H) 5.31 (s, 2H) 3.91 (s, 3H) 3.81 (s, 3H) 3.78 (s, 3H) 2.6.- 2.64 (t, 2H) 1.3.- 1.63 (m, 2H) 1.3.- 1.31 (m, 2H) 0.89-0.84 (t, 3H) . MS: Z method, TR = 1.97 min, m / z 361.1 (M+H) + Preparation 7: Intermediate product (G) 2-butyl-3-[(4-methoxyphenyl)methyl]-5,6-dihydroimidazo[4,5-d]pyridazine-4,7-dione. A solution of the intermediate product (F) (450 g, 1.25 mol) in methanol (1.3 L) was mixed with NH2NH2.H2O (175.2 g, 3.49.8 mol) and the mixture was heated to 75 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with Et2O (1 L) and the precipitated solid was filtered and dried to provide the intermediate product (G) (250 g, 61.7% yield) as a whitish solid. 1H RMN (400 MHz, en ppm, DMSO-d6): 7.17 (d, J = 8.8 Hz, 2H) 6.89 (d, J = 8.4 Hz, 2H) 6.8-6.64 (sa, 2H) 5.68 (s, 2H) 3.72 (s, 3H) 2.6-2.65 (t, 2H) 1.5-1.54 (m, 2H) 1.3-1.23 (m, 2H) 0.83-0.8 (t, 3H). MS: Método Z, TR = 1, 59 min m / z 329, 1 (M+H) +. Preparation 8: Intermediate product (H)2-butil-4, 7-dichloro-3-[ (4-metoxifenil)metil]imidazo[4, 5-d]piridazina. To a cooled solution of the intermediate product (G) (70 g, 213.4 mmol) in POCl3 (620 mL, 8.8 vol), N,N-dimethylaniline (140 mL, 2 vol) was added, and the reaction mixture was stirred at 110 °C for 4 h. The reaction mixture was cooled to room temperature, poured into cold water (5 L), and the pH was adjusted to 7 with solid Na2CO3 and extracted with EtOAc (2 x 3 L). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was ground with Et2O (200 mL) for 2 h, filtered, and dried to give the intermediate product (H) (38 g, 48.5% yield) as a pale yellow solid. 1H NMR (400 MHz, in ppm, CDCl3) : 6, 9.- 6, 85 (m, 4H) 5, 68 (s, 2H) 3, 79 (s, 3H) 2, 91-2, 87 (t, 2H) 1, 8.- 1, 78 (m, 2H) 1, 4.- 1, 38 (m, 2H) 0.93-0.89 (t, 3H) MS: Z method, m / z 365.3 (M+H) + Preparation 9: Intermediate Product (IA) 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine and Intermediate product (IB) 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride Intermediate product (IA) 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine A mixture of the intermediate product (H) (5 g, 13.7 mmol) and ammonia solution (10 mL, 35%) was introduced into a microwaveable vial. The suspension was heated at 150 °C for 6 hours in a microwave oven. The resulting mixture was filtered and washed with water to provide 5 g of crude product, which was purified by crystallization in EtOH to give the intermediate product (IA) (2.15 g, 45% yield) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 84 (t, J=7, 4 Hz, 3 H) ; 1.32 (m, 2 H) ; 1.64 (m, 2 H) ; 2.83 (m, 2 H) ; 3, 72 (s, 3 H) ; 5, 65 (s, 2 H) ; 6, 71 (s wide, 2 H) ; 6.91 (d, J=8.9 Hz, 2 H) ; 6.96 (d, J=8.9 Hz, 2 H) MS method N: TR (min) : 1, 22; [M+H]+ 346; ES-[MH-+HCO2H]-: m / z 390 Intermediate product (IB) hydrochloride of 2-butyl-7-chloro-1- (4-methoxybenzyl) -1H-imidazo[4, 5-d]pyridazine-4-amine A mixture of the intermediate product (H) (5 g, 13.7 mmol) and ammonia solution (25 mL, 35%) was placed in an autoclave. The suspension was heated at 150 °C for 6 h at an internal pressure of 2.5 MPa (25 bar) and then held overnight without heating. The resulting precipitates were filtered, and the filter cake was dissolved in dioxane HCl (200 mL, 4 N), which was concentrated under reduced pressure to a volume of 1 / 10. The new precipitates were filtered, washed with EtOAc, and dried overnight at 30 °C under vacuum to obtain the intermediate product (Ib) (3.65 g, 54% yield), which was used directly in the subsequent steps. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.83 (t, J=7 Hz, 3 H) , 1.32 (sxt, J=7 Hz, 2 H) , 1.63 (quin, J=8 Hz, 2 H) , 2.90 (t, J=8 Hz, 2 H) , 3.73 (s, 3 H) , 5.75 (s, 2 H) , 6.92 (d, J=9 Hz, 2 H) , 7.07 (d, J=9 Hz, 2 H) , 8.97 (sa, 2 H) , 15.13 (sa, 1 H) MS Method N: TR (min) : 1, 22; [M+H]+ 346; ES-[MH-+HCO2H]-: m / z 390 Preparation 10: Intermediate product (J) 2-butyl-4,7-dichloro-1-methyl-1H-imidazo[4,5-d]pyridazine Potassium carbonate (8.29 mL, 60 mmol) was added to a solution of the intermediate product (E) (4.9 g, 20 mmol) in acetone (200 mL). The suspension was stirred for 30 min at room temperature. Methyl iodide (1.9 mL, 30 mmol) was then added, and the mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered and washed with acetone (2 x 20 mL) and DCM (2 x 20 mL). The filtrate was concentrated under reduced pressure to yield 6.75 g of a yellow solid. The solid was dissolved in EtOAc (250 mL) and washed with water (150 mL) and brine (150 mL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 5.1 g of yellow solid. The product was purified by silica gel column chromatography in a Merck cartridge (300 g 15-40 µm silica) using a DCM / MeOH / CH3CN (96 / 2 / 2) mixture as eluent to yield the expected product (J) (3.64 g, 70% yield) as a yellow solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.95 (t, J=7.4 Hz, 3 H) ; 1, 43 (m, 2 H) ; 1, 79 (m, 2 H) ; 3.00 (m, 2H) ; 4, 04 (s, 3H) MS N method: TR (min): 1.32; [M+H]+ 259 Preparation 11: Intermediate product (K) 2-butyl-7-chloro-1-methyl-1H-imidazo[4,5-d]pyridazin-4-amine A mixture of the intermediate product (J) (3.64 g, 14 mmol) and ammonia solution (100 mL, 35%) was placed in an autoclave and heated for 6 hours at 150 °C under 3.5 MPa (35 bar). The solid was dissolved in 100 mL of MeOH and concentrated under vacuum to yield 4.16 g of crude product. The product was poured into water (100 mL) and stirred for 1 hour. The suspension was filtered, washed with water, and dried to yield the expected product (K) (1.44 g, 43% yield) as a beige solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.93 (t, J=7.4 Hz, 3 H) ; 1, 41 (m, 2 H) ; 1, 74 (m, 2 H) ; 2, 90 (m, 2 H) ; 3, 95 (s, 3 H) ; 6, 63 (s wide, 2 H) MS N method: TR (min): 0.84; [M+H]+ 240 Preparation 12: Intermediate Product (L) 2-butyl-7-chloro-N,N-bis(2,4-dimethoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine To a solution of the intermediate product (E) (15 g, 61.20 mmol) in n-butanol (150 mL) were added DIPEA (107 mL, 612.63 mmol) and bis(2,4-dimethoxybenzyl)amine (7 g, 22.1 mmol). The reaction mixture was refluxed for 1 hour. An additional 5 g (15.8 mmol) of bis(2,4-dimethoxybenzyl)amine was added, and heating continued for another 1 hour. This operation was repeated twice more (2 x 5 g, 31.5 mmol). The resulting mixture was heated overnight. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure to remove most of the n-butanol. The residue was diluted with DCM (500 ml), then washed with H2O (250 ml), brine (200 ml), dried over anhydrous MgSO4, filtered and the filtrate was concentrated at reduced pressure to provide 38.8 g of crude product.The residue was purified by chromatography in a Merck cartridge (800 g of 15-40 µm silica) using DCM / acetone 96 / 4 to 90 / 10 as eluent to provide compound (L) (12 g, 37% yield) in the form of a pale yellow solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.85 (t, J=7.4 Hz, 3 H) ; 1, 28 (m, 2 H) ; 1, 68 (m, 2 H) ; 2, 82 (t, J=7, 6 Hz, 2 H) ; 3, 72 (s, 12 H) ; 5, 07 (s wide, 4 H) ; 6, 39 (dd, J=2, 4 and 8, 4 Hz, 2 H) ; 6, 54 (d, J=2, 4 Hz, 2 H) ; 6, 95 (d, J=8, 4 Hz, 2 H) ; 13, 35 (s wide, 1 H) MS method N: TR (min): 1.59; [M+H]+ 526 Preparation 13: Intermediate product (M) 2-butyl-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine. A suspension of the intermediate product (L) (4 g, 7.60 mmol) in dioxane (30 mL) was mixed with sodium isopropoxide (3.74 g, 45.62 mmol) and 2-propanol (30 mL, 1.05 mol). The mixture was heated at 170 °C at 1.8 MPa (18 bar) for 7 hours. The reaction mixture was cooled and filtered, and the cake was washed with EtOAc (100 mL). The filtrate was concentrated under reduced pressure. The crude product was dissolved with EtOAc (150 mL), then washed with H₂O (2 x 75 mL), brine (75 mL), dried over anhydrous MgSO₄, filtered, and the filtrate was concentrated under reduced pressure to yield 4.37 g of product. The residue was purified by chromatography in a Merck cartridge (200 g of 15-40 µm silica) with an EtOAc / Heptane (55 / 45) elution. The compound (M) (2.11 g, 50% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 84 (t, J=7, 4 Hz, 3 H) ; 1.26 (m, 2 H) ; 1.37 (d, J=6.2 Hz, 6 H) ; 1.66 (m, 2 H) ; 2.77 (t, J=7.6 Hz, 2 H) ; 3, 70 (s, 6 H) ; 3, 71 (s, 6 H) ; 5, 00 (s wide, 4 H) ; 5, 41 (sept, J=6, 2 Hz, 1 H) ; 6.38 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.94 (d, J=8.4 Hz, 2 H) ; 13, 01 (s width, 1 H) MS method N: TR (min) : 1.58; [M+H]+ 550 Preparation 14: Intermediate (N) 2-butyl-7-chloro-N, N-bis (4-methoxybenzyl) -1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of the intermediate product (E) (1.6 g, 6.53 mmol) in n-butanol (8 ml) in a microwaveable vial, DIPEA (3.42 ml, 19.58 mmol) and bis(4-methoxybenzyl)amine (1.68 g, 6.53 mmol) were added. The resulting mixture was stirred for 5 min at room temperature and then heated at 150 °C for 6 h in a microwave. After cooling to room temperature, the reaction mixture was filtered. The filtrate was then vacuum concentrated to provide 3.75 g of crude product, which was purified by chromatography in a Merck cartridge (150 g of 15-40 µm silica) using Heptane / EtOAc 90 / 10 to 20 / 80 as eluent to provide compound (N) (1.25 g, 41% yield) in the form of a pale yellow solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0, 86 (t, J=7 Hz, 3 H) , 1, 31 (sxt, J=7 Hz, 2 H) , 1, 72 (quin, J=8 Hz, 2 H) , 2, 86 (t, J=7 Hz, 2 H) , 2, 86 (t, J=7 Hz, 3 H) (s, 6 H) , 5, 08 (sa, 4 H) , 6, 86 (d, J=9 Hz, 4 H) , 7, 19 (d, J=9 Hz, 4 H) , 13, 45 (sa, 1 H) MS method N: TR (min) : 1, 78; [M+H]+ 466 Preparation 15: Intermediate (R) 2-butyl-N, N-bis, 4-methoxybenzyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine. To an isopropanol solution (11 mL), sodium (418.6 mg, 18.03 mmol) was added with stirring. The mixture was heated to 70 °C until the end of hydrogen bubbling. The hot sodium isopropoxide solution was rapidly added to a microwaveable vial containing 2-butyl-7-chloro-N,N-bis(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine intermediate (N) (1.2 g, 2.58 mmol) in dioxane (8 mL). The mixture was heated at 170 °C at 0.5 MPa (5 bar) for 6 hours and held overnight. The reaction mixture was filtered and washed with EtOAc to yield 1.94 g of crude product. The crude product was dissolved with EtOAc (100 ml) with stirring to provide a suspension, which was filtered and washed with EtOAc. The filtrate was concentrated under reduced pressure to provide 1.63 g of crude material, which was purified by chromatography on a Merck cartridge (150 g of 15-40 µm silica) with 20 / 80 to 80 / 20 EtOAc / Heptane eluent.Compound (R) (0.76 g, 60% yield) was obtained in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.86 (t, J=7 Hz, 3 H) , 1.30 (sxt, J=7 Hz, 2 H) , 1.39 (d, J=6 Hz, 6 H) , 1.71 (quin, J=7 Hz, 2 H) , 2.82 (t, J=7 Hz, 2 H), 3.71 (s, 6 H), 4.98 (s, 4 H), 5.44 (spt, J=6 Hz, 1 H), 6.84 (d, J=9 Hz, 4 H), 7.16 (d, J=8 Hz, 4 H), 13.11 (s, 1 H) MS O Method: TR (min) : 2, 79; [M+H]+ 490 EXAMPLES Example (1): Preparation of Compound 1: 2-butyl-7-isopropoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine To a suspension of potassium hydroxide (250 mg, 3.79 mmol) in anhydrous CH3CN (2 mL) was added 2-propanol (500 µL, 6.50 mmol). The mixture was stirred for 5 min at room temperature. Then, 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride, intermediate product (IB) (200 mg, 0.52 mmol), was added. The mixture was heated for 2 hours at 150 °C in a microwave oven. The mixture was cooled, filtered, and then washed with 2-propanol and ethyl acetate. The filtrate was concentrated under reduced pressure to yield 836 mg of the crude product. The residue was dissolved in EtOAc (100 ml), washed with H2O, brine, dried over anhydrous MgSO4, filtered, and the filtrate was concentrated under reduced pressure to provide 242 mg of crude material, which was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with an EtOAc / EtOH elution of 99 / 1 to 95 / 5. Example (1) (27 mg, 14% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.85 (t, J=7.4 Hz, 3 H) ; 1, 25 (d, J=6, 2 Hz, 6 H) ; 1, 33 (m, 2 H) ; 1, 63 (m, 2 H) ; 2, 81 (m, 2 H) ; 3, 71 (s, 3 H) ; 5, 36 (Sept, J=6, 2 Hz, 1 H) ; 5, 51 (s, 2 H) ; 5, 91 (s, 2 H) ; 6, 90 (d, J=8, 8 Hz, 2 H) ; 7, 06 (d, J=8, 8 Hz, 2 H) MS N method: TR (min): 1, 2; [M+H]+ 370. The following compounds can be prepared by analogy to Example 1: 48, 50, 52, 54, 56, 57, 58, 65, 68, 69, 72 and 86. Example (2): Preparation of Compound 2: 2-butyl-N7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamine Isopropylamine (1.8 ml, 20.85 mmol) was added to a solution of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (200 mg, 0.58 mol) in 1,4-dioxane (10 ml). The reaction mixture was heated to 230 °C in a microwave oven for 3 h. The mixture was concentrated under reduced pressure to provide 208 mg of crude product, which was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with a DCM / MeOH / NH4OH elution of 98 / 2 / 0.5 to 90 / 10 / 0.5. Example (2) (8 mg, 4% yield) was obtained as an amorphous white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.87 (t, J=7.4 Hz, 3 H) ; 1, 03 (d, J=6, 3 Hz, 6 H) ; 1, 36 (m, 2 H) ; 1, 67 (m, 2 H) ; 2, 87 (m, 2 H) ; 3, 71 (s, 3 H) ; 4.00 (m, 1H) ; 4, 79 (d, J=6, 5 ​​Hz, 1 H) ; 5, 59 (s, 2 H) ; 6, 10 (s, 2 H) ; 6, 90 (d, J=8, 9 Hz, 2 H) ; 7.00 (d, J=8.9 Hz, 2 H) MS Method A: TR (min): 0.82; [M+H]+ 369. The following compounds can be prepared by analogy to Example 2: 49, 53, 71, 94, 98. Example (3): Preparation of Compound 3: 2-butyl-7-(isopropylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine To a suspension of potassium hydroxide (150 mg, 2.27 mmol) in acetonitrile (2 mL), 2-propanethiol (400 µL, 4.18 mmol) was added. The mixture was stirred for 5 min at room temperature, and then 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (180 mg, 0.52 mmol), was added. The reaction mixture was heated for 2 h at 150 °C in a microwave oven. The mixture was filtered and washed with EtOAc. The filtrate was concentrated under reduced pressure to provide 695 mg of crude product, which was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with an 80 / 20 to 50 / 50 elution, DCM / DCM-MeOH (90 / 10). Example (3) (26 mg, 13% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.81 (t, J=7.4 Hz, 3 H) ; 1, 22 (d, J=6, 8 Hz, 6 H) ; 1, 29 (m, 2 H) ; 1, 60 (m, 2 H) ; 2, 74 (m, 2 H) ; 3, 71 (s, 3 H) ; 5, 85 (Sept, J=6, 8 Hz, 1 H) ; 5, 74 (s, 2 H) ; 6, 46 (s, 2 H) ; 6.90 (m, 4 H) MS method N: TR (min): 1.23; [M+H]+ 386 The following compounds can be prepared by analogy to Example 3: 99. Example (4): Preparation of Compound 4: 2-butyl-1-(4-methoxybenzyl)-7-(2-methoxyethoxy)-1H-imidazo[4,5-d]pyridazin-4-amine To a suspension of potassium hydroxide (90 mg, 1.36 mmol) in anhydrous acetonitrile (4 mL) was added 2-methoxyethanol (460.71 µL, 5.78 mmol). The mixture was stirred for 5 min at room temperature, then 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (200 mg, 0.58 mmol). The reaction mixture was heated for 2 h at 170 °C in a microwave oven. The mixture was filtered and washed with 2-propanol and EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with a 100 / 0 to 0 / 100 elution cartridge of DCM / DCM-MeOH (95-5). Example (4) (46 mg, 21% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.85 (t, J=7, 4 Hz, 3 H); 1, 33 (m, 2 H); 1, 63 (m, 2 H); 2, 82 (m, 2 H); 3, 25 (s, 3 H); 3, 65 (m, 2 H); 3, 71 (s, 3 H); 4, 50 (m, 2 H); 5, 52 (s, 2H); 5, 98 (s, 2H); 6, 89 (d, J=8, 7 Hz, 2 H); 7, 13 (d, J=8, 7 Hz, 2 H) MS method N: TR (min) : 1, 13; [M+H]+ Example (5) : Preparation of Compound 5: 2-butyl-1- (4-methoxybenzyl)-7-propoxy-1H-imidazo[4, 5-d]pyridazin-4-amine Sodium (43 mg, 1.87 mmol) was added to 1-propanol (3 mL, 39.73 mmol), and the mixture was stirred until the end of hydrogen bubbling. The sodium propoxide solution was added to a mixture of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride, intermediate product (IB) (200 mg, 0.52 mmol), and triethylamine (150 µL, 1.07 mmol) in a microwave reactor, and the reaction mixture was heated to 150 °C for 2 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc, washed with water, and then with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure to provide 147 mg of crude product, which was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with a DCM / DCM-MeOH-MeCN elution of 90 / 10 to 80 / 20 (80-10-10). Example (5) (73 mg, 38% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.84 (t, J=7, 4 Hz, 3 H); 0.89 (t, J=7, 4 Hz, 3 H); 1, 32 (m, 2 H); 1, 61 (m, 2 H); 1, 70 (m, 2 H); 2, 79 (m, 2 H); 3, 71 (s, 3 H); 4, 32 (t, J=6, 4 Hz, 2 H); 5, 54 (s, 2H); 5, 97 (s, 2H); 6, 90 (d, J=8, 8 Hz, 2 H); 7, 06 (d, J=8, 8 Hz, 2 H) MS method N: TR (min) : 1, 2; [M+H]+ Example (6) : Preparation of Compound 6: 7-(allyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine Sodium (43 mg, 1.87 mmol) was added to allyl alcohol (3 mL, 43.47 mmol), and the mixture was stirred until the end of hydrogen bubbling. The sodium allyl oxide solution was added to 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (200 mg, 0.58 mmol), in a microwave reactor, and the reaction mixture was heated to 150 °C in a microwave. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with EtOAc, washed with water, and then with brine. The organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to provide 496 mg of crude product, which was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with an elution of DCM / DCM-MeOH (90-10) from 80 / 20 to 0 / 100. Example (6) (43 mg, 20% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.84 (t, J=7, 4 Hz, 3 H); 1, 32 (m, 2 H); 1, 61 (m, 2 H); 2, 80 (m, 2 H); 3, 71 (s, 3 H); 4, 93 (td, J=1, 6 and 5, 21 Hz, 2 H); 5, 19 (cd, J=1, 6 and 10, 5 Hz, 1 H); 5, 30 (cd, J=1, 6 and 17, 3 Hz, 1 H); 5, 54 (s, 2H); 6.00 (s, 2H); 6, 06 (m, 1 H); 6, 89 (d, J=8, 9 Hz, 2 H); 7.07 (d, J=8.9Hz, 2H) MS method N: TR (min) : 1, 17; [M+H]+ Example (7) : Preparation of Compound 7: 7-(sec-butoxy)-2-butyl-1-(4-methoxybenzyl)-1H-midazo[4, 5-d]pyridazin-4-amine Sodium (43 mg, 1.87 mmol) was added to 2-butanol (3 mL, 32.46 mmol), and the mixture was stirred until the end of hydrogen bubbling. The sodium 2-butoxide solution was added to a mixture of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride, intermediate product (IB) (200 mg, 0.52 mmol), and triethylamine (150 µL, 1.07 mmol) in a microwave reactor, and the reaction mixture was heated to 150 °C in a microwave. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with EtOAc, washed with water, and then with brine. The organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to provide 165 mg of crude product, which was purified on a Gilson GX271 system, using a CSH 50x250 mm, 5 µm column (Waters™) operating at 150 ml / min and room temperature.The following A / B gradient was used: t = 0 min: 18% solution B, t = 5 min: 18% solution B, t = 25 min: 38% solution B, with A: water / formic acid 0.1% (v / v) and B: acetonitrile / formic acid 0.1% (v / v). Example (7) (82 mg, 41% yield) was obtained as an amorphous white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.81 (t, J=7.4 Hz, 3 H) ; 0.85 (t, J=7, 4 Hz, 3 H) ; 1, 22 (d, J=6, 2 Hz, 3 H) ; 1, 33 (m, 2 H) ; 1.55 to 1.67 (m, 4 H) ; 2, 79 (m, 2 H) ; 3, 71 (s, 3 H) ; 5, 23 (m, 1 H) ; 5, 50 (d, J=16, 2 Hz, 1 H) ; 5, 55 (d, J=16, 2 Hz, 1 H) ; 5, 97 (s, 2 H) ; 6, 78 (d, J=8, 9 Hz, 2 H) ; 7, 03 (d, J=8, 9 Hz, 2 H) MS N method: TR (min): 1.28; [M+H]+ 384 Example (8): Preparation of Compound 8: 7-butoxy-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine Sodium (86 mg, 3.74 mmol) was added to 1-butanol (3 mL, 32.46 mmol), and the mixture was stirred until the end of hydrogen bubbling. The sodium butoxide solution was added to a mixture of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride, intermediate product (IB) (200 mg, 0.52 mmol), and triethylamine (150 µL, 1.07 mmol) in a microwave reactor, and the reaction mixture was heated to 150 °C in a microwave reactor. The mixture was concentrated under reduced pressure, and the residue was dissolved with EtOAc, washed with water, and then with brine. The organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to provide 156 mg of crude product, which was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with a DCM / DCM80-MeOH10-MeCN10 elution of 90 / 10 to 80 / 20. Example (8) (59 mg, 29% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 84 (t, J=7, 4 Hz, 3 H) ; 0.85 (t, J=7.4 Hz, 3 H) ; 1.31 (m, 4 H) ; 1.63 (m, 4 H) ; 2.80 (m, 2 H) ; 3, 71 (s, 3 H) ; 4.36 (t, J=6.5 Hz, 2 H) ; 5, 53 (s, 2 H) ; 5, 96 (s, 2 H) ; 6.90 (d, J=8.8 Hz, 2 H) ; 7.03 (d, J=8.8 Hz, 2 H) MS method N: TR (min) : 1, 25; [M+H]+ 384; ES-: [M-H+HCO2H]-: m / z 428 Example (9) : Preparation of Compound 9: 2-butyl-7- (cyclopentyloxy) -1- (4-methoxybenzyl) -1H-imidazo[4, 5-d]pyridazine-4-amine. A mixture of cyclopentanol (1.5 ml, 16.34 mmol) and sodium (93.11 mg, 4.05 mmol) was stirred at 80 °C for 1 h. Then, a solution of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (0.2 g, 58 mmol) in 1,4-dioxane (4 ml) was added and the mixture was microwaved at 170 °C for 6 h. The reaction mixture was concentrated under reduced pressure to provide 310 mg of crude product, which was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with elution of DCM / MeOH (95 / 5), to provide 63 mg (26.5% yield) of Example (9) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.83 (t, J=7, 40 Hz, 3 H) 1.32 (sxt, J=7.60, 2 H) 1.4.- 1.76 (m, 8 H) 1.7.- 1.94 (m, 2 H) 2.78 (t, J=7, 60 Hz, 2 H) 3, 70 (s, 3 H) 5, 4.- 5, 57 (m, 3 H) 5, 92 (s, 2 H) 6, 89 (d, J=8, 78 Hz, 2 H) 7, 01 (d, J=8, 78 Hz, 2 H) MS method A: TR (min): 0.96; [M+H]+ 396 Example (10): Preparation of Compound 10: 2-butyl-1-(4-methoxybenzyl)-7-(pyrrolidine-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine. A mixture of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (0.2 g, 0.58 mmol) in pyrrolidine (2 ml, 23.72 mmol) and water (1 ml) was stirred at 160 °C in a microwave for 4 h. The reaction mixture was concentrated under reduced pressure to provide 347 mg of crude product, which was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with elution of DCM / MeOH (90 / 10), to provide 20 mg (9.1% yield) of Example (10) in the form of a white foam. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.83 (t, J=7, 5 Hz, 3 H); 1, 31 (m, 2 H); 1, 63 (m, 2 H); 1, 82 (m, 4 H); 2, 70 (m, 2 H); 3, 15 (m, 4 H); 3, 71 (s, 3 H); 5, 62 (s, 2H); 6, 11 (s, 2H); 6, 88 (d, J=8, 9 Hz, 2 H); 6, 96 (d, J=8, 9 Hz, 2 H) MS method N: TR (min) : 1, 26; [M+H]+ Example (11) : Preparation of Compound 11: 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-3-yl)-1H-imidazo[4, 5d]pyridazin-4-amine In a microwaveable vial, a solution of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (250 mg, 0.72 mmol) in 1,4-dioxane (5 ml) was added, followed by the addition of Pd(dppf)Cl2.DCM (88.55 mg, 0.11 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H pyrrole (224.55 mg, 1.08 mmol) and finally 2 M aqueous solution of Cs2CO3 (1.45 ml, 2.89 mmol). The mixture was heated to 135 °C for 60 min in a microwave oven. The solvent was evaporated under reduced pressure, and the residue was dissolved in DCM and washed with a saturated aqueous solution of NaHCO3. The organic layer was separated, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified by silica gel chromatography using a CHCl3 / iPrOH (90 / 10) mixture as the eluent to provide 18.3 mg (6.5% yield) of Example (11) as a creamy solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.83 (t, J=7.4 Hz, 3 H) ; 1, 31 (m, 2 H) ; 1, 63 (m, 2 H) ; 2, 71 (m, 2 H) ; 3, 60 (s, 3 H) ; 3, 68 (m, 3 H) ; 5, 32 (s, 2 H) ; 6.08 (dd, J=1.9 and 2.5 Hz, 1 H) ; 6, 28 (s, 2H) ; 6, 68 (d, J=8, 9 Hz, 2 H) ; 6, 72 (m, 2 H) ; 6, 81 (d, J=8, 3 Hz, 2 H) MS N method: TR (min): 1, 18; [M+H]+ 391 The following compounds can be prepared by analogy to Example 11: 55, 62, 63, 64, 67, 70, 92, 93, 95, 96, and 97. Example (12 A): Preparation of Compound 12: (E)-2-butyl-1-(4-methoxybenzyl)-7-(3-methylbut-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine and Example (12 B): Preparation of Compound 13: 2-butyl-7-isopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine Step 1: Example (12 A): Preparation of Compound 12: (E) -2-butyl-1-(4-methoxybenzyl) -7-(3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine In a microwave vial, 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (500 mg, 1.45 mmol) was added to 1,4-Dioxane (10 ml), followed by the addition of Pd(dppf)Cl2.DCM (177.10 mg, 0.22 mmol), (E)-4,4,5,5-tetramethyl-2-(3-methylbut-1-en-1-yl)-1,3,2-dioxaborolane (567 mg, 2.89 mmol) and finally, a 2 M aqueous solution of Cs2CO3 (2.89 ml, 5.78 mmol). The mixture was heated at 120 °C for 1 h 30 min in a microwave oven. The solvent was evaporated under reduced pressure, and the residue was dissolved with DCM and washed with a saturated aqueous solution of NaHCO3. The organic layer was separated, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified by silica gel chromatography using a mixture of DCM / NH3 in (2 N) MeOH (97 / 3) as the eluent to provide 70 mg (12.7% yield) as a beige solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.86 (t, J=7, 5 Hz, 3 H); 0.92 (d, J=6.8Hz, 6H); 1, 35 (m, 2 H); 1, 68 (m, 2 H); 2, 34 (m, 1H); 2, 87 (m, 2 H); 3, 70 (s, 3 H); 5, 55 (s, 2H); 6, 37 (s, 2H); 6, 44 (dd, J=5, 9 and 15, 5 Hz, 1 H); 6, 51 (d, J=15, 5 Hz, 1 H); 6, 86 (d, J=9, 1Hz, 2H); 6.90 (d, J=9, 1Hz, 2H) MS method N: TR (min) : 1, 33; [M+H]+ Step 2: Example (12B) Preparation of Compound 13: 2-butyl-7-isopentyl-1- (4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine To a solution of (E)-2-butyl-1-(4-methoxybenzyl)-7-(3-methylbut-1-en-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine Example (12A) (40 mg, 0.11 mmol) in MeOH (7 mL) 10% Pd / C (23 mg) was added. The mixture was maintained in a hydrogen atmosphere (0.4 MPa (4 bar)) at 30 °C for 1 h 30 min. The mixture was filtered through a 0.2 µm filter membrane and the filtrate was evaporated under reduced pressure to give 28 mg (67% yield) of Example (12B) as a cream-colored solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.79 (d, J=6.6 Hz, 6 H) ; 0.85 (t, J=7, 4 Hz, 3 H) ; 1, 29 to 1, 40 (m, 4 H) ; 1, 48 (m, 1 H) ; 1, 68 (m, 2 H) ; 2, 74 to 2, 84 (m, 4 H) ; 3, 70 (s, 3 H) ; 5, 52 (s, 2 H) ; 6, 20 (s, 2 H) ; 6, 79 (d, J=8, 7 Hz, 2 H) ; 6, 91 (d, J=8, 7 Hz, 2 H) MS N method: TR (min): 1.41; [M+H]+ 382 The following compounds can be prepared by analogy to Examples 12:51, 59, 60, 61, 66 and 73. Example (13): Preparation of Compound 14: 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrole-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine In a microwaveable vial, a solution of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (150 mg, 0.43 mmol) in 1,4-dioxane (3 ml) was added, followed by the addition of Pd(dppf)Cl2.DCM (53.13 mg, 0.065 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H pyrrole (167.47 mg, 0.87 mmol) and finally 2 M aqueous solution of Cs2CO3 (867.48 µl, 1.73 mmol). The mixture was heated at 110 °C for 60 min in a microwave oven and at 130 °C for 45 min. The solvent was then evaporated under reduced pressure, and the residue was dissolved in DCM and washed with a saturated aqueous solution of NaHCO3. The organic layer was separated, dried over MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified by silica gel chromatography using a 97:3 DCM / NH3 mixture in 2 N MeOH as the eluent to yield 41.24 mg (25.5% yield) of Example (13) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.82 (t, J=7.5 Hz, 3 H) ; 1, 29 (m, 2 H) ; 1, 61 (m, 2 H) ; 2, 69 (m, 2 H) ; 3, 68 (s, 3 H) ; 5, 31 (s, 2 H) ; 6, 16 (dt, J=1, 8 and 2, 5 Hz, 1 H) ; 6, 26 (s, 2H) ; 6, 69 (d, J=9, 0 Hz, 2 H) ; 6, 80 (m, 3 H) ; 6.85 (td, J=1.8 and 2.5 Hz, 1 H) ; 11, 00 (s, 1 H) MS Method N: TR (min) : 1, 15; [M+H]+ 377; ES-: [M-H+HCO2H]-: m / z 421 Example (14 A) : Preparation of Compound 15: 2-butyl-7-(cyclopent-1-en-1-yl) -1-(4-methoxybenzyl) -1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride and Example (14 B): Preparation of Compound 16: 2-butyl-7-cyclopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine Step 1: Example (14 A): Preparation of Compound 15: 2-butyl-7-(cyclopent-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride In a microwaveable vial, a solution of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) (250 mg, 0.72 mmol) was added to a mixture of Me-THF / DMF (8 / 2.4 ml), followed by the addition of Pd(dppf)Cl2.DCM (88.55 mg, 0.11 mmol), cyclopent-1-en-1-ylboronic acid (121.38 mg, 1.08 mmol), and finally a 2 M aqueous solution of Cs2CO3 (1.45 ml, 2.89 mmol). The mixture was heated at 100 °C for 2 h in a microwave. The sample was then diluted with Me-THF and washed with H₂O and a saturated aqueous solution of NaCl. The organic layer was separated, dried over MgSO₄, filtered, and evaporated under reduced pressure. The raw material was purified by silica gel chromatography using a 98 / 2 DCM / MeOH mixture as the eluent. The first fractions containing the expected compound were evaporated to dryness and then dissolved in Et₂O. At 0 °C, a 2 M HCl solution in Et₂O was added.The resulting solid was filtered and vacuum dried to provide 37 mg (12.4% yield) of Example (14A). A second fraction containing the expected compound was evaporated to dryness to provide 70 mg as free base and was committed to the next step as is. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.86 (t, J=7.5 Hz, 3 H) ; 1, 36 (m, 2 H) ; 1, 70 (m, 2 H) ; 1, 80 (m, 2 H) ; 2, 31 (m, 2 H) ; 2, 47 (m, 2 H) ; 2, 91 (m, 2 H) ; 3, 71 (s, 3 H) ; 5, 51 (s, 2 H) ; 6.00 (m, 1H) ; 6, 81 (d, J=8, 9 Hz, 2 H) ; 6, 89 (d, J=8, 9 Hz, 2 H) ; 8, 82 (m wide, 2 H) ; 14, 60 (width, 1 H) MS N method: TR (min): 1.27; [M+H]+ 378 Step 2: Example (14 B): Preparation of Compound 16: 2-butyl-7-cyclopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine To a solution of 2-butyl-7-(cyclopent-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine (70 mg, 0.19 mmol) from Step 1, in MeOH (6 mL), platinum(IV) oxide hydrate (13 mg) was added. The mixture was maintained in a hydrogen atmosphere (0.2 MPa (2 bar)) at 25 °C for 1 h 50 min. The mixture was filtered through a 0.2 µm filter membrane, and the filtrate was evaporated under reduced pressure. The resulting crude material was purified by silica gel chromatography using a DCM / MeOH (98 / 2) mixture as eluent to provide 46 mg (63.8% yield) of Example (14B) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.85 (t, J=7.5 Hz, 3 H) ; 1, 35 (m, 2 H) ; 1, 52 (m, 2 H) ; 1, 61 to 1, 83 (m, 8 H) ; 2, 88 (m, 2 H) ; 3, 45 (m, 1 H) ; 3, 72 (s, 3 H) ; 5, 66 (s, 2 H) ; 6, 92 (s, 4 H) ; 8, 15 (m, 2 H) MS P method: TR (min): 2.36; [M+H]+ 380 Example (15 A): Preparation of Compound 17: 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine and Example (15 B): Preparation of Compound 18: 2-butyl-7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine Step 1: Example (15 A): Preparation of Compound 17: 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine To a suspension of 2-butyl-7-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (IA) , (200 mg, 0.58 mmol) in 1,4-Dioxane (6 ml) were added Pd(dppf)Cl2.DCM (47.3 mg, 0.58 mmol) , 4,4,5,5-Tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (228.85 µl, 1.16 mmol) and finally a 2 M aqueous solution of Cs2CO3 (809.64 µl, 1.62 mmol). The mixture was heated under reflux for 6 h, then diluted with EtOAc and washed with H₂O. The organic layer was separated and washed with a saturated aqueous NaCl solution. The organic layer was separated, dried over MgSO₄, filtered, and evaporated under reduced pressure. The crude material was purified by silica gel chromatography using a DCM / MeOH (97 / 3) mixture as eluent to yield 88 mg as a creamy foam. The resulting product was ground with Et₂O, filtered, and dried to yield 71.2 mg (35% yield) of Example (15A). 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.86 (t, J=7, 5 Hz, 3 H); 1, 35 (m, 2 H); 1, 69 (m, 2 H); 1, 83 (s width, 3 H) ; 2, 82 (m, 2 H); 3, 69 (s, 3H); 4, 94 (s width, 1 H) ; 5, 36 (s width, 1 H) ; 5, 48 (s, 2H); 6, 42 (s, 2H); 6, 72 (d, J=8, 9 Hz, 2 H); 6, 86 (d, J=8, 9 Hz, 2 H) MS method N: TR (min) : 1, 22; [M+H]+ Step 2: Example (15B) Preparation of Compound 18: 2-butyl-7-isopropyl-1- (4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine To a solution of 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine (55 mg, 0.16 mmol), Example (15A), in MeOH (6 mL) platinum(IV) oxide hydrate (7 mg) was added. The mixture was maintained in a hydrogen atmosphere (0.2 MPa (2 bar)) at 25 °C for 2 h. Then platinum(IV) oxide hydrate (7 mg) was added and the mixture was maintained in a hydrogen atmosphere (0.2 MPa (2 bar)) at 25 °C for 4 h 30 min. The mixture was filtered through a 0.2 µm filter membrane and the filtrate was evaporated at reduced pressure to provide 65 mg of crude product, which was purified by silica gel chromatography using a CHCl3 / iPrOH (94 / 6) mixture as eluent to provide 25 mg (44.2% yield) of Example (15B), in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.85 (t, J=7.5 Hz, 3 H) ; 1, 11 (d, J=6, 7 Hz, 6 H) ; 1, 35 (m, 2 H) ; 1, 68 (m, 2 H) ; 2, 83 (m, 2 H) ; 3, 26 (Sept, J= 6, 7 Hz, 1 H) ; 3, 70 (s, 3 H) ; 5, 53 (s, 2 H) ; 6, 19 (s, 2H) ; 6, 82 (d, J=9, 0 Hz, 2 H) ; 6, 91 (d, J=9, 0 Hz, 2 H) MS method N TR (min): 1.23; [M+H]+ 354 The following compound can be prepared by analogy to Example 15: 159. Example (16 A): Preparation of Compound 19: 1-(((1r,4r)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine dihydrochloride Step 1: (4- (4- (bis (2,4-dimethoxybenzyl)amino) -2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl) methyl) cyclohexyl) methyl) tert-butyl carbamate To a suspension of 2-butyl-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (M) (1 g, 1.82 mmol) in Me-THF (20 mL) Cs2CO3 (1.78 g, 5.46 mmol) was added. The mixture was stirred at room temperature for 30 min. Then, n-([(1r,4r)-4-(bromomethyl)cyclohexyl]methyl) tert-butyl carbamate (879 mg, 2.73 mmol) in Me-THF (12 mL) was added. The mixture was stirred for 5 min at room temperature and then refluxed for 24 hours. The reaction mixture was then diluted with EtOAc (150 ml), washed with water and brine, and concentrated under reduced pressure to provide 1.73 g of crude product, which was purified by chromatography in a Merck cartridge (70 g of 15-40 µm silica) with an EtOAc / heptane elution from 0 / 100 to 50 / 50. The expected product (1.03 g, 73% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 75 (m.2 H) ; 0.83 (t. J=7 Hz.3 H) ; 1.08 (m.2 H) ; 1.24 to 1.40 (m.18 H); 1, 48 (d. J=12 Hz.2 H) ; 1.58 to 1.81 (m.5 H); 2, 73 (t. J=6 Hz.2 H) ; 2, 77 (t. J=7 Hz.2 H) ; 3.66 to 3.76 (m.12 H); 4, 10 (d. J=6 Hz.2 H) ; 5, 00 (s width.4 H) ; 5, 37 (spt. J=6 Hz.1 H) ; 6, 39 (dd. J=2 and 8 Hz.2 H) ; 6, 52 (d. J=2 Hz.2 H) ; 6, 78 (t. J=6 Hz.1 H) ; 6.96 (d, J=8 Hz, 2 H) MS method N: TR (min) : 1.87; [M+H]+ 775 Step 2: Example (16 A) : Preparation of Compound 19: dichlorhydrate of 1- ( ( (1r, 4r) -4- (aminomethyl) cyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of (4-((4-(bis(4-methoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl)methyl)tert-butyl carbamate from Step 1 (1.03 g, 1.33 mmol) in DCM (6 mL) were added 2,2,2-trifluoroacetic acid (6 mL, 77.9 mmol) and 1,3-dimethoxybenzene (522 µL, 3.99 mmol). The mixture was stirred for 24 h. The reaction was diluted with DCM (50 mL) and H2O (10 mL). The pH of the mixture was adjusted to pH 10-12 with 30% NaOH with stirring in an ice bath. The product was extracted with DCM (4 x 50 ml), the combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to yield 3.1 g of crude product. The residue was purified by chromatography in a Macherey Nagel cartridge (40 g of 15-40 µm diol) with DCM-DCM / MeOH / H2O (80 / 10 / 1) from 100 / 0 to 50 / 50 to yield an oil.The oil was treated with iPr₂O (10 mL), a white solid was filtered and washed with iPr₂O (3 x 5 mL), and vacuum dried to yield 617 mg of powder. 500 mg of this product were purified using a C1819 x 150 mm 5 µm column, eluted with 10 mM ammonium bicarbonate (pH 10) / acetonitrile to yield 188 mg of material, which was dissolved in HCl in MeOH (1.25 N) and the mixture was evaporated under reduced pressure. The residue was then dissolved in water, filtered over a 0.22 µm membrane, and the filtrate was lyophilized to yield 190 mg (39.5% yield) of Example 16A, in the form of hydrochloric acid (2HCl). 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 87 (c. J=13 Hz.2 H) ; 0.94 (t. J=7 Hz.3 H) ; 1, 12 (c. J=13 Hz.2 H) ; 1.33 to 1.48 (m. 8 H) ; 1.51 to 1.63 (m, 3 H); 1.66 to 1.92 (m, 5 H); 2, 63 (t, J=6 Hz, 2 H) ; 2.93 (t, J=8 Hz, 2 H) ; 4, 21 (d, J=7 Hz, 2 H) ; 5, 24 (quin, J=6 Hz, 1 H) ; 7, 90 (s wide, 3 H) ; 8, 57 (s wide, 2 H) ; 13, 89 (s, 1 H) MS method N: TR (min) : 0.83; [M+H]+ 375 Example (16 B) : Preparation of Compound 20: 2, 2, 2-Trifluoroacetate of trans 4- (aminomethyl) cyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine Step 1: (4- (4- (bis (4-methoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) cyclohexyl) methyl) tert-butyl carbamate To a suspension of 2-butyl-7-isopropoxy-N,N-bis(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, Intermediate Product (R) (414 mg, 0.85 mmol) in THF (23 mL) Cs2CO3 (827 mg, 2.54 mmol) was added. The mixture was stirred for 30 min at room temperature. Then, tert-butyl N-([(1r,4r)-4-(bromomethyl)cyclohexyl]methyl)carbamate (545 mg, 1.69 mmol) and DMF (6 mL) were added. The mixture was stirred for 5 min at room temperature and then heated for 1 h at 100 °C in a microwave. The reaction mixture was filtered, the filtrate was diluted with EtOAc (200 mL), washed with water and brine, and concentrated under reduced pressure to provide 820 mg of crude product. The residue was purified by chromatography in a Merck cartridge (50 g of 15–40 µm silica) with an EtOAc / heptane elution of 10 / 90 to 80 / 20. The expected product (233 mg, 39% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 78 (m, 2 H) ; 0.86 (t, J=7.5 Hz, 3 H) ; 1.08 (m, 2 H) ; 1.23 to 1.41 (m, 3 H) ; 1, 36 (s, 9 H) ; 1.37 (d, J=6.2 Hz, 6 H) ; 1.49 (m, 2 H) ; 1.63 to 1.82 (m, 5 H); 2, 73 (t, J=6, 1 Hz, 2 H) ; 2.83 (t, J=7.6 Hz, 2 H) ; 3, 71 (s, 6 H) ; 4, 14 (d, J=7, 2 Hz, 2 H) ; 4, 97 (s, 4 H) ; 5, 41 (sept, J=6, 2 Hz, 1 H) ; 6.78 (t, J=6, 1 Hz, 1 H) ; 6.84 (d, J=8.8 Hz, 4 H) ; 7, 17 (d, J=8, 8 Hz, 4 H) MS method N: TR (min) : 1.82; [M+H]+ 715; ES-[MH-+HCO2H]-: m / z 759 Step 2: Example (16 B) : Preparation of Compound 20: 2, 2, 2-trifluoroacetate of 4- (aminomethyl) cyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of (4-((4-(bis(4-methoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl)methyl)tert-butyl carbamate from Step 1 (230 mg, 0.32 mmol) in DCM (4 ml) 2,2,2-trifluoroacetic acid (4 ml, 0.32 mmol) was added. The mixture was stirred for 6 days at room temperature. The reaction was diluted with EtOAc (120 ml) and extracted with H2O (100 ml). The aqueous phase was lyophilized to provide 123 mg of crude product. The residue was poured into a saturated NaHCO3 solution and extracted with EtOAc (3 x 50 mL), dried over anhydrous MgSO4, filtered, and the filtrate was concentrated under reduced pressure. Example (16B) (50 mg, 37% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 80 (m, 2 H) ; 0.93 (t, J=7.5 Hz, 3 H) ; 1.10 (m, 2 H) ; 1.30 (m, 1 H) ; 1.36 (d, J=6.2 Hz, 6 H) ; 1.41 (m, 2 H) ; 1.50 (m, 2 H) ; 1.71 to 1.82 (m, 5 H); 2.46 (d, J=6.9 Hz, 2 H) ; 2.83 (m, 2 H) ; 4.13 (d, J=7.4 Hz, 2 H) ; 4.74 (m, 3 H) ; 5, 39 (sept, J=6, 2 Hz, 1 H) ; 5, 87 (s, 2 H) MS method N: TR (min): 0.80; [M+H]+ 375; ES+ [M+2H-iPr]2+: m / z 167 Example (17 A) : Preparation of Compound 21: 1- (4- (aminomethyl) benzyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine Step 1: (4- ( (4- (bis (2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) tert-butyl carbamate To a suspension of 2-butyl-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (M) (1 g, 1.82 mmol) in Me-THF (30 ml) Cs2CO3 (1.78 g, 5.46 mmol) was added. The mixture was stirred for 30 min at room temperature, then tert-butyl 4-(bromomethyl)benzylcarbamate (819 mg, 2.73 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with 150 mL of Me-THF and washed with water and brine, dried over anhydrous MgSO4, filtered, and the filtrate concentrated under reduced pressure to yield 1.73 g of crude product. The residue was purified by chromatography in a Merck cartridge (50 g of 15–40 µm silica) with DCM-DCM / MeOH (90 / 10) dilutions from 100 / 0 to 50 / 50. The expected product (1.34 g, 96% yield) was obtained as a white foam.1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 76 (t, J=7 Hz, 3 H) ; 1, 21 (m, 8 H) ; 1, 37 (s, 9 H) ; 1.55 (quin, J=7 Hz, 2 H) ; 2, 74 (t, J=7 Hz, 2 H) ; 3, 71 (s, 12 H) ; 4.07 (d, J=6 Hz, 2 H) ; 5, 01 (s, 4 H) ; 5, 31 (quin, J=6 Hz, 1 H) ; 5, 55 (s, 2 H) ; 6, 39 (dd, J=2 et y 8 Hz, 2 H) ; 6.52 (d, J=2 Hz, 2 H) ; 6.97 (d, J=8 Hz, 2 H) ; 7.03 (d, J=8 Hz, 2 H) ; 7, 19 (d, J=8 Hz, 2 H) ; 7, 34 (t, J=6 Hz, 1 H). MS method N: TR (min) : 1.87; [M+H]+ 769 Step 2: Example (17 A) : Preparation of Compound 21: 1- (4- (aminomethyl) benzyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of (4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl) tert-butyl carbamate from Step 1 (684 mg, 0.889 mmol) in DCM (10 ml) cooled in an ice bath, 1,3-dimethoxybenzene (349 µl, 2.67 mmol) and 2,2,2-trifluoroacetic acid (10 ml, 129.8 mmol) were added. After 15 minutes, the ice bath was removed and the mixture was stirred for 16 hours at room temperature. The reaction mixture was diluted with DCM (100 ml) and H2O (50 ml), and the aqueous phase was washed with DCM (2 x 50 ml). The pH of the aqueous layer was adjusted to pH 11 with 30% NaOH with stirring in an ice bath.The product was extracted with DCM (4 x 50 ml), the combined organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to provide 306 mg of crude product, which was purified by chromatography on a Macherey Nagel cartridge (26 g of 15-40 µm diol) with DCM-DCM / MeOH (90 / 10) from 100 / 0 to 0 / 100, to provide 91 mg of purified compound, which was further purified with C1819 x 150 mm 5 µm column, eluted with 10 mM ammonium bicarbonate (pH 10) / acetonitrile to provide 64 mg (19.5% yield) of Example (17A). 1H NMR (400 MHz, in ppm, DMSO-d6): 0.84 (t, J=7 Hz, 3 H) ; 1, 21 (s, 3 H) ; 1, 23 (s, 3 H) ; 1, 33 (m, 2 H) ; 1, 63 (m, 2 H) ; 1, 97 (m, 2 H) ; 2, 79 (d, J=15 Hz, 2 H) ; 3, 66 (s, 2 H) ; 5, 33 (spt, J=6 Hz, 1 H) ; 5, 54 (s, 2H) ; 5, 91 (s, 2 H) ; 7, 01 (d, J=8 Hz, 2 H) ; 7.28 (d, J=8 Hz, 2 H) MS N method: TR (min): 0.76; [M+H]+ 369 The following compounds can be prepared by analogy to Example 17A: 158 and 160. Example (17 B): Preparation of Compound 22: 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine trifluoroacetate Step 1: tert-butyl (4-((4-(bis(4-methoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)carbamate To a suspension of 2-butyl-7-isopropoxy-N,N-bis(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine, intermediate product (R) (133 mg, 0.27 mmol) in THF (7 ml) Cs2CO3 (266 mg, 0.81 mmol) was added. The mixture was stirred for 15 min at room temperature, then tert-butyl 4-(bromomethyl)benzylcarbamate (163 mg, 0.52 mmol) was added. The mixture was stirred at room temperature for 20 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to provide 269 mg of crude product, which was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with an elution of EtOAc / heptane from 10 / 90 to 60 / 40. The expected product (83 mg, 43% yield) was obtained in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 78 (t, J=7, 4 Hz, 3 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1.28 (m, 2 H) ; 1, 36 (s, 9 H) ; 1.60 (m, 2 H) ; 2.79 (t, J=7.6 Hz, 2 H) ; 3, 71 (s, 6 H) ; 4.07 (d, J=6, 2 Hz, 2 H) ; 4, 98 (s, 4 H) ; 5, 34 (sept, J=6, 2 Hz, 1 H) ; 5, 59 (s, 2 H) ; 6.85 (d, J=8.8 Hz, 4 H) ; 7.04 (d, J=8, 2 Hz, 2 H) ; 7.18 (d, J=8.8 Hz, 4 H) ; 7, 20 (d, J=8, 2 Hz, 2 H) ; 7.35 (t, J=6, 2 Hz, 1 H) MS method N: TR (min) : 1.67; [M+H]+ 709; ES-[2MH-+HCO2H]-: m / z 1462; ES-[MH-+HCO2H]-: m / z 753 Step 2: Example (17B) Preparation of Compound 22: 2, 2, 2-trifluoroacetate of 1- (4- (aminomethyl) benzyl) -2-butyl-7-isopropoxy-1H-imidate-pyridine, 4-4-amine To a solution of tert-butyl (4-((4-(bis(4-methoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)carbamate from Step 1 (70 mg, 0.099 mmol) in DCM (1.2 mL) 2,2,2-trifluoroacetic acid (1.2 mL, 15.51 mmol) was added. The mixture was stirred for 8 days at room temperature. The reaction was diluted with DCM (80 mL) and extracted with H2O (200 mL). The aqueous phase was washed with EtOAc (2 x 50 mL). The aqueous phase was lyophilized overnight. Example (17B) (75 mg, 93% yield) was obtained in the form of a white lyophilized powder. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.85 (t, J=7.4 Hz, 3 H) ; 1, 22 (d, J=6, 2 Hz, 6 H) ; 1, 33 (m, 2 H) ; 1, 66 (m, 2 H) ; 2, 87 (m, 2 H) ; 4, 02 (m, 2 H) ; 5, 16 (m, 1 H) ; 5, 67 (s, 2 H) ; 7, 18 (d, J=8, 5 Hz, 2 H) ; 7, 42 (d, J=8, 5 Hz, 2 H) ; 8, 13 (s, 3 H) ; 8, 47 (m, 2 H) MS N method: TR (min): 0.68; [M+H]+ 369 Example (18): Preparation of Compound 23: 1-(((1S,3R)-3-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (and enantiomer) Step 1: ( (1R, 3S) -3- ( (4- (bis (2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) cyclohexyl) tert-butyl carbamate (and enantiomer) A suspension of the intermediate product (M) (500 mg, 0.91 mmol) in Me-THF (15 mL) was mixed with Cs₂CO₃ (449.05 mg, 1.36 mmol). The mixture was stirred at room temperature for 30 min. Then, tert-butyl [cis-3-(bromomethyl)cyclohexyl]carbamate (419.70 mg, 1.36 mmol) was added, and the mixture was stirred at room temperature for 20 min and then heated at 60 °C for 5 days. The mixture was diluted with Me-THF (250 mL), washed with H₂O (2 x 80 mL), brine (80 mL), dried over anhydrous MgSO₄, and filtered. The filtrate was concentrated under reduced pressure to provide 940 mg of crude product, which was purified by chromatography in a Merck cartridge (50 g of 15-40 µm silica) with an EtOAc / heptane elution of 10 / 90 to 80 / 20. The expected compound (490 mg, 71% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0. 80 to 1. 44 (m, 7 H); 0.83 (t, J=7.5 Hz, 3 H) ; 1, 34 (s, 9 H) ; 1.35 (d, J=6.2 Hz, 3 H) ; 1.38 (d, J=6.2 Hz, 3 H) ; 1.57 (m, 1 H) ; 1.61 to 1.76 (m, 4 H); 1.85 (m, 1 H) ; 2.78 (t, J=7.4 Hz, 2 H) ; 3.12 (m, 1 H) ; 3, 70 (s, 6 H) ; 3, 71 (s, 6 H) ; 4.12 (m, 2 H) ; 5, 00 (s, 4 H) ; 5, 38 (sept, J=6, 2 Hz, 1 H) ; 6.38 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.76 (d, J=7.9 Hz, 1 H) ; 6.95 (d, J=8;4 Hz, 2 H) MS method N: TR (min) : 1.83; [M+H]+ 761 Step 2: Example (18) Preparation of Compound 23: 1- ( ( (1S, 3R) -3-aminocyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine (and enantiomer) To a solution of ((1R, 3S)-3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl) tert-butyl carbamate (and enantiomer) from Step 1 (480 mg, 0.63 mmol) in DCM (2.5 mL) 2,2,2-trifluoroacetic acid (2.5 mL, 32.65 mmol) was added. The mixture was stirred at room temperature for 24 hours. The reaction was poured into DCM (100 mL) and washed with H2O (2 x 80 mL). The aqueous phase was neutralized by the addition of 5 M sodium hydroxide and extracted using EtOAc (3 x 75 mL). The organic phase was washed with H2O, brine, dried over anhydrous MgSO4, filtered and the filtrate was concentrated under reduced pressure to provide 115 mg (50.7% yield) of Example (18) in the form of a white powder. 1H NMR (400 MHz, in ppm, DMSO-d6): 0. 75 to 1. 00 (m, 2 H); 0.93 (t, J = 7.4 Hz, 3 H) ; 1, 15 (m, 1 H) ; 1.33 to 1.54 (m, 9 H); 1.63 to 1.89 (m, 5 H); 2, 07 (m wide, 2 H) ; 2.45 (m, 3 H) ; 2.83 (m, 2 H) ; 4.11 (m, 2 H) ; 5, 38 (sept, J = 6, 2 Hz, 1 H) ; 5, 85 (s, 2 H) MS method N: TR (min) : 0.85; [M+H]+ 361; ES+ [M+2H]2+: m / z 181 Example (19) : Preparation of Compound 24: 1- (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) -2-methylpropan-2-ol Step 1: 1- (4-(bis(2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) -2-methylpropan-2-ol To a suspension of the intermediate product (M) (500 mg, 91 mmol) in Me-THF (15 mL), Cs₂CO₃ (900 mg, 2.73 mmol) was added. The mixture was stirred for 30 min at room temperature. Then, 2,2-dimethyloxirane (125 µL, 1.37 mmol) was added. The mixture was microwaved for 20 h at 60 °C and then concentrated under reduced pressure. The residue was diluted in MeCN (15 mL), 2,2-dimethyloxirane (250 µL, 2.74 mmol) was added, and the mixture was microwaved for 48 h at 90 °C. The reaction mixture was then diluted with Me-THF (250 ml), washed with water and brine, dried over MgSO4, filtered and concentrated under reduced pressure to provide 533 mg of crude product, which was purified by chromatography in a Merck cartridge (40 g of 15-40 µm silica) with an EtOAc / heptane elution from 10 / 90 to 60 / 40. The expected product (236 mg, 42% yield) was obtained as a white amorphous solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 83 (t, J=7, 4 Hz, 3 H) ; 1.09 (s wide, 6 H) ; 1, 29 (m, 2 H) ; 1.36 (d, J=6.2 Hz, 6 H) ; 1.64 (m, 2 H) ; 2.95 (t, J=7.6 Hz, 2 H) ; 3, 70 (s, 6 H) ; 3, 71 (s, 6 H) ; 4, 29 (s wide, 2 H) ; 4, 76 (s, 1 H) ; 5, 01 (s, 4 H) ; 5, 38 (sept, J=6, 2 Hz, 1 H) ; 6.39 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.96 (d, J=8, 4 Hz, 2 H) MS method N: TR (min) : 1.59; [M+H]+ 622; ES-[M-H+HCO2H]-: m / z 666 Step 2: Example (19) : Preparation of Compound 24: 1- (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) -2-methylpropan-2-ol To a solution of 1-(4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)-2-methylpropan-2-ol from Step 1 (230 mg, 0.37 mol) in DCM (2 ml) 2,2,2-trifluoroacetic acid (1.5 ml, 20.19 mmol) was added. The mixture was stirred for 5 h. The reaction mixture was diluted with DCM (100 ml) and extracted with H2O (2 x 80 ml). The aqueous phase was neutralized with NaOH (5 M) to pH 10, extracted with EtOAc (3 x 75 ml), the organic phase was washed with water and brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Example (19) (37 mg, 31% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.92 (t, J=7.3 Hz, 3 H) ; 1, 09 (s wide, 6 H) ; 1, 36 (d, J=6, 2 Hz, 6 H) ; 1, 39 (m, 2 H) ; 1, 75 (m, 2 H) ; 3, 01 (m, 2 H) ; 4, 28 (s, 2 H) ; 4, 78 (s, 1 H) ; 5, 36 (Sept, J=6, 2 Hz, 1 H) ; 6, 24 (s, 2 H) MS method N: TR (min): 1, 1; [M+H]+ 322 The following compounds can be prepared by analogy to Example 19: 74, 75, 76, 80, 81. Example (20): Preparation of Compound 25: Trans 1-(4-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine Step 1: 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl) tert-butyl carbamate To a suspension of the intermediate product (M) (400 mg, 0.73 mmol) in Me-THF (15 ml) was added Cs2CO3 (720 mg, 2.19 mmol). The mixture was stirred for 30 min at room temperature. Then, 4-(bromomethyl)cyclohexyl) tert-butyl carbamate (320 mg, 1.10 mmol) was added. The mixture was stirred at room temperature for 24 h, then heated at 90 °C in a microwave for 18 h. The reaction mixture was then diluted with Me-THF (methyltetrahydrofuran) (250 ml), washed with water and brine, dried over MgSO4, filtered, and concentrated under reduced pressure to provide 692 mg of crude product, which was purified by chromatography on a Merck cartridge (40 g of 15-40 µm silica) with an EtOAc / heptane elution of 10 / 90 to 100 / 00. The expected product (357 mg, 64% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 83 (t, J=7. 5 Hz, 3 H) ; 1.04 (m, 2 H) ; 1, 14 (m, 2 H) ; 1.09 (m, 2 H) ; 1, 36 (s, 9 H) ; 1.37 (d, J=6.2 Hz, 6 H) ; 1.47 (m, 2 H) ; 1.60 to 1.79 (m, 5 H); 2.77 (t, J=7.4 Hz, 2 H) ; 3, 17 (m, 1 H) ; 3, 70 (s, 6 H) ; 3, 71 (s, 6 H) ; 4, 10 (d, J=7, 2 Hz, 2 H) ; 5, 00 (s, 4 H) ; 5, 38 (sept, J=6, 2 Hz, 1 H) ; 6.39 (dd, J=2.5 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.5 Hz, 2 H) ; 6.68 (d, J=7.9 Hz, 1 H) ; 6.96 (d, J=8, 4 Hz, 2 H) MS method N: TR (min) : 1.79; [M+H]+ 761 Step 2: Example (20) : Preparation of Compound 25: Trans 1- (4-aminocyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl)tert-butyl carbamate from Step 1 (345 mg, 0.45 mmol) in DCM (2 ml) 2,2,2-trifluoroacetic acid (2 ml, 26.66 mmol) was added. The mixture was stirred for 24 hours at room temperature. The reaction mixture was diluted with DCM (100 ml) and extracted with H2O (2 x 80 ml). The aqueous phase was neutralized with NaOH (5 M) to pH 10, extracted with EtOAc (3 x 75 ml), the organic phase was washed with water and brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Example (20) (142 mg, 87% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.92 (t, J=7.3 Hz, 3 H) ; 0.94 (m, 2H) ; 1, 12 (m, 2 H) ; 1, 34 to 1, 48 (m, 5 H) ; 1, 36 (d, J=6, 2 Hz, 6 H) ; 1.65 to 1.81 (m, 5 H) ; 2, 82 (m, 2 H) ; 2.95 (m wide, 2 H) ; 4, 10 (d, J=7, 5 Hz, 2 H) ; 5, 39 (Sept, J=6, 2 Hz, 1 H) ; 5, 85 (s, 2 H) MS Method N: TR (min) : 0, 78; [M+H]+ 361; ES+ [M+2H]2+: m / z 181 ) The following compounds can be prepared by analogy to Example 20: 77, 78, 79, 146, 149, 165. Example (21 A): Preparation of Compound 261- ( (5- (aminomethyl) pyridin-2-yl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine and Example (21 B): Preparation of Compound 27.- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)nicotinonitrile Step 1: 6-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)nicotinonitrile To a suspension of the intermediate product (M) (500 mg, 0.91 mmol) in Me-THF (15 mL), Cs2CO3 (898 mg, 2.73 mmol) was added. The mixture was stirred for 30 min at room temperature, then 6-(bromomethyl)nicotinonitrile (285 mg, 1.37 mmol) was added. The mixture was stirred for 1 h at room temperature. The reaction mixture was then diluted with Me-THF, washed with water and brine, dried over MgSO4, filtered, and concentrated under reduced pressure to provide 661 mg of crude product, which was purified by chromatography on a Merck cartridge (50 g of 15-40 µm silica) with an elution of EtOAc / heptane from 10 / 90 to 80 / 20. The expected product (467 mg, 77% yield) was obtained in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.80 (t, J=7, 5 Hz, 3 H); 1, 06 (d, J=6, 2 Hz, 6 H) ; 1, 28 (m, 2 H) ; 1, 61 (m, 2 H) ; 2, 81 (t, J=7, 6 Hz, 2 H) ; 3, 71 (s, 6 H) ; 3, 72 (s, 6 H) ; 5, 02 (s, 4 H) ; 5, 18 (Sept, J=6, 2 Hz, 1 H) ; 5, 75 (s, 2 H) ; 6, 40 (dd, J=2, 4 and 8, 4 Hz, 2 H); 6, 53 (d, J=2, 4 Hz, 2 H) ; 6, 98 (d, J=8, 4 Hz, 2 H) ; 7, 49 (dd, J=0.9 and 8, 3 Hz, 1 H); 8, 33 (dd, J=2, 2 and 8, 3 Hz, 1 H); 8, 90 (dd, J=0.9 and 2, 2 Hz, 1 H) MS O method: TR (min) : 2, 96; [M+H]+ 666 Stage 2: 1- ( (5- (aminomethyl) pyridine-2-yl)methyl) -2-butyl-N, N-bis (2, 4-dimethoxybenzyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of 6-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)nicotinonitrile from Step 1 (460 mg, 0.69 mmol) in EtOH (10 ml) Pd / C 10% (46 mg, 0.43 mmol) was added. The mixture was hydrogenated at 1.7 MPa (17 bar) at 25 °C for 6 h and filtered. The filtrate was concentrated under vacuum to provide 413 mg of crude product, which was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with elution of DCM / MeOH / NH4OH from 99 / 1 / 0.1 to 93 / 7 / 0.1. The expected product (178 mg, 38% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 79 (t, J=7, 4 Hz, 3 H) ; 1, 17 (d, J=6, 2 Hz, 6 H) ; 1.27 (m, 2 H) ; 1.61 (m, 2 H) ; 1, 95 (m wide, 2 H) ; 2.83 (t, J=7.6 Hz, 2 H) ; 3, 67 (s, 2 H) ; 3, 71 (s, 6 H) ; 3, 72 (s, 6 H) ; 5, 01 (s, 4 H) ; 5, 24 (sept, J=6, 2 Hz, 1 H) ; 5, 61 (s, 2 H) ; 6.39 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.97 (d, J=8, 4 Hz, 2 H) ; 7, 16 (dd, J=0, 8 y 8, 1 Hz, 1 H) ; 7.73 (dd, J=2.3 y 8.1 Hz, 1 H) ; 8.37 (dd, J=0.8 y 2.3 Hz, 1 H) MS method N: TR (min) : 1, 32; [M+H]+ 670; ES+ [M+2H]2+: m / z 335, 7 Step 3 (I) : Example (21 A) : Preparation of Compound 26: 1- ( (5- (aminomethyl) pyridin-2-yl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of 1-((5-(aminomethyl)pyridin-2-yl)methyl)-2-butyl-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine, from Step 2 (175 mg, 0.26 mmol) in DCM (1.2 ml) 2,2,2-trifluoroacetic acid (1.20 ml, 15.68 mmol) was added. The mixture was stirred for 24 h. The reaction mixture was diluted with DCM (100 ml) and extracted with H2O (2 x 80 ml). The aqueous phase was adjusted to pH 10 with a 5 N sodium hydroxide solution, extracted with EtOAc (3 x 75 ml), the organic phase was washed with water and brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Example (21A) (79 mg, 82% yield) was obtained as a white solid.1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 86 (t, J=7, 4 Hz, 3 H) ; 1, 16 (d, J=6, 2 Hz, 6 H) ; 1.35 (m, 2 H) ; 1.68 (m, 2 H) ; 2.67 (m, 2 H) ; 2.87 (m, 2 H) ; 3, 70 (s, 2 H) ; 5, 25 (sept, J=6, 2 Hz, 1 H) ; 5, 61 (s, 2 H) ; 5, 89 (s, 2 H) ; 7, 12 (d, J=8, 1 Hz, 1 H) ; 7.73 (dd, J=2.3 y 8.1 Hz, 1 H) ; 8.38 (d, J=2.3 Hz, 1 H) MS method N: TR (min): 0.46; [M+H]+ 370. Step 3 (II) : Example (21-B) : Preparation of Compound 27: 6- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) nicotinonitrile To a solution of 6-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)nicotinonitrile, from Step 1 (225 mg, 0.34 mmol) in DCM (1.5 ml) 2,2,2-trifluoroacetic acid (1.50 ml, 19.59 mmol) was added. The mixture was stirred for 24 hours. The reaction mixture was diluted with DCM (100 ml) and extracted with H2O (2 x 80 ml). The aqueous phase was adjusted to pH 12 with a 5 N sodium hydroxide solution saturated with NaCl, extracted with EtOAc (3 x 75 ml), the organic phase was washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. Example (21B) (110 mg, 89% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.86 (t, J=7 Hz, 3 H); 1, 05 (d, J=6 Hz, 6 H) ; 1, 35 (dc, J=7 and 15 Hz, 2 H); 1, 68 (dt, J=8 and 15 Hz, 2 H); 2, 87 (t, J=8 Hz, 2 H) ; 5, 19 (e.g., J=6 Hz, 1 H) ; 5, 75 (s, 2 H) ; 5, 92 (s, 2 H) ; 7, 45 (dd, J=1 and 8 Hz, 1 H); 8, 33 (dd, J=2 and 8 Hz, 1 H); 8, 90 (dd, J=1 and 2 Hz, 1 H) MS method N: TR (min) : 1.10; [M+H]+ m:z 366 Example (22) : Preparation of Compound 28: N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl) methyl) benzyl) acetamide To a solution of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (Example (17A)) (200 mg, 0.54 mmol) in DMF (6 ml) were added DIPEA (95 µl, 0.54 mmol) and acetic anhydride (61 µl, 0.65 mmol). The solution was stirred at room temperature for 2 min and then poured into a mixture of water (30 ml) and ice (30 g) which was stirred at room temperature for 30 min. Then, solid NaHCO3 was added until pH 8. The solution was extracted with EtOAc (3 x 40 ml). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 139 mg of white solid, which was dissolved in MeOH (10 mL). Potassium carbonate (108 mg) was added, and the suspension was stirred at room temperature for 18 h. The reaction mixture was concentrated under vacuum, dissolved in DCM (10 mL), washed with water (5 mL), and brine (5 mL).The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to provide the crude product, which was stirred for 15 min at room temperature in diisopropyl ether (2 ml). The suspension was filtered. The solid was washed with diisopropyl ether (2 x 1 ml) and dried under vacuum. Example (22) (70 mg, 65% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.84 (t, J=7.5 Hz, 3 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1, 32 (m, 2 H) ; 1, 63 (m, 2 H) ; 1, 83 (s, 3 H) ; 2, 79 (m, 2 H) ; 4, 19 (d, J=6, 0 Hz, 2 H) ; 5, 32 (Sept, J=6, 2 Hz, 1 H) ; 5, 55 (s, 2 H) ; 5, 91 (s, 2 H) ; 7, 03 (d, J=8, 4 Hz, 2 H) ; 7, 20 (d, J=8, 4 Hz, 2 H) ; 8, 29 (t, J=6, 0 Hz, 1 H) MS method N: TR (min): 1.09; [M+H]+ 411 Example (23): Preparation of Compound 29: N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)undecanamide To a solution of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (Example (17A)) (127 mg, 0.35 mmol) in DMF (3 ml) were added undecanoic acid (65 µl, 0.35 mmol) and TEA (345 µl, 0.35 mmol). The solution was stirred for 5 min at room temperature. Then, HBTU (167 mg, 0.43 mmol) was added. The mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into a mixture of water (30 ml) and ice (30 g) and stirred at room temperature for 30 min, then extracted with EtOAc (3 x 30 ml). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 200 mg of the crude product, which was purified by chromatography on a Merck cartridge (10 g of 15–40 µm silica) with DCM / MeOH (93 / 7) elution to obtain a colorless gum. This gum was dissolved in MeOH (2.5 mL) and filtered through an Amberlist A-26 OH column.The MeOH filtrate was concentrated under vacuum to provide a gum (48 mg), which was stirred at room temperature for 15 min with diisopropyl ether. The supernatant solution was discarded and the gum was dried under vacuum. Example (23) was obtained (31 mg, 15% yield) as a colorless gum. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.84 (t, J=7.4 Hz, 3 H) ; 0.85 (t, J=6.9 Hz, 3 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1, 22 (s wide, 14 H) ; 1, 32 (m, 2 H) ; 1, 48 (m, 2 H) ; 1, 62 (m, 2 H) ; 2, 08 (t, J=7, 4 Hz, 2 H) ; 2, 79 (m, 2 H) ; 4, 20 (d, J=6, 1 Hz, 2 H) ; 5, 32 (Sept, J=6, 2 Hz, 1 H) ; 5, 54 (s, 2H) ; 5, 91 (s, 2 H) ; 7, 02 (d, J=8, 4 Hz, 2 H) ; 7, 19 (d, J=8, 4 Hz, 2 H) ; 8, 24 (t, J=6, 1 Hz, 1 H) MS method N: TR (min): 1.59; [M+H]+ 537; ES- [M-H+HCO2H]-: m / z 581 The following compounds can be prepared by analogy to Example 23: 84, 103, 106 and 107. Example (24): Preparation of Compound 30: N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)pentanamide To a solution of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (Example (17A)) (200 mg, 0.42 mmol) in THF (5 ml) were added valeric acid (51 µl, 0.46 mmol), EDCI (238 mg, 1.24 mmol), HOBt (95 mg, 1.5 eq), and DIPEA dropwise (290 µl, 4 eq). The solution was shaken at room temperature for 2 h. The reaction mixture was diluted with EtOAc (50 ml), washed with water (25 ml), saturated aqueous sodium bicarbonate (25 ml), and water (2 x 25 ml). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to provide 156 mg of crude product, which was purified by Merck cartridge chromatography (10 g of 15-40 µm silica) with DCM / MeOH / CH3CN (90 / 5 / 5) elution to provide Example (24) (94 mg, 50% yield) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 83 (t, J=7, 4 Hz, 6 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1, 23 (m, 2 H) ; 1.32 (m, 2 H) ; 1.47 (m, 2 H) ; 1.62 (m, 2 H) ; 2.09 (t, J=7.5 Hz, 2 H) ; 2.79 (m, 2 H) ; 4.20 (d, J=6.0 Hz, 2 H) ; 5, 31 (sept, J=6, 2 Hz, 1 H) ; 5, 55 (s, 2 H) ; 5, 96 (s, 2 H) ; 7.02 (d, J=8, 3 Hz, 2 H) ; 7, 19 (d, J=8, 3 Hz, 2 H) ; 8.25 (t, J=6.0 Hz, 1 H) MS method N: TR (min) : 1.23; [M+H]+ 453; ES- [M-H+HCO2H]-: m / z 497 Example (25) : Preparation of Compound 31: N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) -3- (2-methoxyethoxy) propanamide To a solution of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (Example (17A)) (200 mg, 0.42 mmol) in THF (5 ml) were added 3-(2-methoxyethoxy)propanoic acid (65 mg, 0.41 mmol), EDCI (238 mg, 1.24 mmol), HOBT (95 mg, 1.5 eq) and DIPEA drop (290 µl, 4 eq). The solution was shaken at room temperature for 2 hours. The reaction mixture was diluted with EtOAc (50 ml), washed with water (25 ml), saturated aqueous sodium bicarbonate solution (25 ml), and water (2 x 25 ml). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to provide 182 mg of crude product, which was purified by chromatography on a Merck cartridge (10 g silica 15-40 µm) with DCM / methanol / acetonitrile (85 / 7.5 / 7.5) elution to provide Example (25) (58.5 mg, 28% yield) in the form of a colorless gum. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 85 (t, J=7, 4 Hz, 3 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1.32 (m, 2 H) ; 1.63 (m, 2 H) ; 2.34 (t, J=6.5 Hz, 2 H) ; 2.78 (t, J=7.6 Hz, 2 H) ; 3, 16 (s, 3 H) ; 3.37 (m, 2 H) ; 3.46 (m, 2 H) ; 3.60 (t, J=6.5 Hz, 2 H) ; 4.23 (d, J=6, 1 Hz, 2 H) ; 5, 32 (sept, J=6, 2 Hz, 1 H) ; 5, 55 (s, 2 H) ; 5, 91 (s, 2 H) ; 7.02 (d, J=8, 3 Hz, 2 H) ; 7.20 (d, J=8.3 Hz, 2 H) ; 8.31 (t, J=6, 1 Hz, 1 H) MS method N: TR (min) : 1, 11; [M+H]+ 499 Example (26) : Preparation of Compound 32: 1- ( ( (1S, 3S) -3-aminocyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-]pyridazine-4-amine (and enantiomer) Step 1: N-[ (1S, 3S) -3- ( (4- (bis (2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) cyclohexyl) carbamate of tercanti-butyl omer (y Cs2CO3 (898 mg, 2.73 mmol) was added to a suspension of the intermediate product (M) (500 mg, 0.91 mmol) in Me-THF (15 ml). The mixture was stirred for 30 min at room temperature. Then, tert-butyl [trans-3-(bromomethyl)cyclohexyl]carbamate (410 mg, 1.36 mmol) was added. The mixture was stirred for 4 days at room temperature, then microwaved at 90 °C for 9 hours. The reaction mixture was diluted with Me-THF (250 ml), washed with water and brine, dried over MgSO4, filtered, and concentrated under reduced pressure to provide 1.23 g of crude product, which was purified by chromatography in a Merck cartridge (70 g of 15-40 µm silica) with an elution of EtOAc / heptane from 50 / 50 to 100 / 0. The expected product (434 mg, 63% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 84 (t, J=7. 5 Hz, 3 H) ; 1.08 (m, 1 H) ; 1.20 to 1.55 (m, 9 H); 1, 32 (s, 9 H) ; 1.36 (d, J=6.2 Hz, 3 H) ; 1.38 (d, J=6.2 Hz, 3 H) ; 1.66 (m, 2 H) ; 2.11 (m, 1 H) ; 2.78 (t, J=7.5 Hz, 2 H) ; 3, 68 (m partly occult, 1 H) ; 3, 70 (s, 6 H) ; 3, 71 (s, 6 H) ; 4, 11 (d, J=7, 2 Hz, 2 H) ; 5, 00 (s, 4 H) ; 5, 36 (sept, J=6, 2 Hz, 1 H) ; 6.38 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.73 (d, J=7, 2 Hz, 1 H) ; 6.95 (d, J=8, 4 Hz, 2 H) MS method N: TR (min) : 1.82; [M+H]+ 761 Step 2: Example (26) : Preparation of Compound 32: 1- ( ( (1S, 3S) -3-aminocyclohexyl) methyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-]pyridazine-4-amine (and enantiomer) To a solution of 3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)cyclohexyl)tert-butyl carbamate (435 mg, 0.57 mmol) in DCM (2.5 ml) 2,2,2-trifluoroacetic acid (2.5 ml, 32.65 mmol) was added. The mixture was stirred for 24 hours at room temperature. The reaction mixture was diluted with DCM (100 ml) and extracted with H2O (2 x 80 ml). The aqueous phase was adjusted to pH 10 with a 5 N sodium hydroxide solution, extracted with EtOAc (3 x 75 ml), the organic phase was washed with water and brine, dried over MgSO4, filtered and evaporated under reduced pressure. Example (26) (136 mg, 66% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.93 (t, J=7.4 Hz, 3 H) ; 1, 07 (m, 1 H) ; 1, 26 to 1, 62 (m, 15 H) ; 1, 78 (m, 2 H) ; 1.90 (m wide, 2 H) ; 2, 22 (m, 1 H) ; 2, 82 (m, 2 H) ; 3, 09 (m, 1 H) ; 4, 11 (m, 2 H) ; 5, 38 (Sept, J=6, 2 Hz, 1 H) ; 5, 84 (s, 2 H) MS N method: TR (min): 0.90; [M+H]+ 361; ES+ [M+2H]2+: m / z 181 Example (27): Preparation of Compound 33: 1-(3-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine trifluoroacetate Step 1: (3- ( (4- (bis (2,4-dimethoxybenzyl)amino) -2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl) methyl) benzyl) tert-butyl carbamate To a suspension of the intermediate product (M) (200 mg, 0.36 mmol) in THF (11 ml) Cs2CO3 (356 mg, 1.09 mmol) was added. The mixture was stirred for 30 min at room temperature. Then, tert-butyl 3-bromomethylbenzylcarbamate (230 mg, 0.73 mmol) was added. The mixture was stirred for 20 hours at room temperature, then filtered and the filtrate was concentrated under reduced pressure to provide 526 mg of crude product. The residue was dissolved in EtOAc, washed with water and brine, and concentrated under reduced pressure to provide 428 mg of crude product, which was purified by chromatography in a Merck cartridge (30 g of 15-40 µm silica) with an EtOAc / heptane elution of 10 / 90 to 80 / 20. The expected product (61 mg, 22% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 77 (t, J=7. 5 Hz, 3 H) ; 1.22 (d, J=6.2 Hz, 6 H) ; 1.24 (m, 2 H) ; 1, 34 (s, 9 H) ; 1.56 (m, 2 H) ; 2.75 (t, J=7.6 Hz, 2 H) ; 3, 71 (s, 12 H) ; 4.06 (d, J=6.4 Hz, 2 H) ; 5, 01 (s, 4 H) ; 5, 32 (sept, J=6, 2 Hz, 1 H) ; 5, 56 (s, 2 H) ; 6.39 (dd, J=2.5 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.5 Hz, 2 H) ; 6.94 (width, J=7.9 Hz, 1 H) ; 6.98 (d, J=8, 4 Hz, 2 H) ; 7.03 (s wide, 1 H) ; 7, 14 (width, J=7, 9 Hz, 1 H) ; 7.28 (t, J=7.9 Hz, 1 H) ; 7.32 (t, J=6;4 Hz, 1 H) MS method: TR (min) : 3.22; [M+H]+ 769 Step 2: Example (27) : Preparation of Compound 33: 2, 2, 2-trifluoroacetate of 1- (3- (aminomethyl) benzyl) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of tert-butyl (3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)carbamate from Step 1 (60 mg, 0.08 mmol) in DCM (1 ml) 2,2,2-trifluoroacetic acid (1 ml, 13 mmol) was added. The mixture was stirred for 8 hours at room temperature. The reaction was diluted with DCM (100 ml) and extracted with H2O (2 x 50 ml). The aqueous phase was neutralized with a saturated solution of K2CO3 to pH 8 and extracted by EtOAc (3 x 75 ml). The organic phase was dried over anhydrous MgSO4, filtered, and the filtrate was concentrated under reduced pressure. Example (27) (24 mg, 83% yield) was obtained in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 86 (t, J=7, 4 Hz, 3 H) ; 1.22 (d, J=6.2 Hz, 6 H) ; 1.34 (m, 2 H) ; 1.67 (m, 2 H) ; 2.80 (m, 2 H) ; 3, 94 (s, 2 H) ; 5, 32 (sept, J= 6, 2 Hz, 1 H) ; 5, 59 (s, 2 H) ; 5, 98 (s, 2 H) ; 7.11 (t, J=2.0 Hz, 1 H) ; 7, 14 (td, J=2, 0 and 7, 8 Hz, 1 H) ; 7.36 (td, J=2.0 and 7.8 Hz, 1 H) ; 7.41 (t, J=7.8 Hz, 1 H) ; 7.86 (m, 3 H) MS method N: TR (min) : 0.81; [M+H]+ 369 Example (28) : Preparation of Compound 34: 4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzaldehyde Step 1: 4- ( (4- (bis (2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzaldehyde To a suspension of the intermediate product (M) (2.2 g, 3.12 mmol) in Me-THF (21 ml) were added 4-(bromomethyl)benzaldehyde (847 mg, 4.26 mmol) and Cs2CO3 (1.32 g, 4.11 mmol). The mixture was stirred at room temperature for 24 h. The mixture was poured into Me-THF (15 ml), then washed with H2O (15 ml), dried over anhydrous MgSO4, filtered, and the filtrate was concentrated under reduced pressure to provide 3 g of crude product, which was purified by chromatography in a Merck cartridge (150 g of 15-40 µm silica) with elution from EtOAc / heptane (38 / 62). The expected product (1.5 g, 71% yield) was obtained in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 76 (t, J=7, 4 Hz, 3 H) ; 1, 13 (d, J=6, 2 Hz, 6 H) ; 1.24 (m, 2 H) ; 1.56 (m, 2 H) ; 2.77 (t, J=7.5 Hz, 2 H) ; 3, 71 (s, 12 H) ; 5, 02 (s, 4 H) ; 5, 26 (sept, J=6, 2 Hz, 1 H) ; 5, 69 (s, 2 H) ; 6.40 (dd, J=2.5 y 8.4 Hz, 2 H) ; 6.53 (d, J=2.5 Hz, 2 H) ; 6.99 (d, J=8, 4 Hz, 2 H) ; 7.25 (d, J=8.3 Hz, 2 H) ; 7.89 (d, J=8, 3 Hz, 2 H) ; 9.97 (s, 1 H) MS method N: TR (min): 1.66; [M+H]+ 668; ES- [2M-H+HCO2H]-: m / z 1379 Step 2: Example (28) Preparation of Compound 34: 4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzaldehyde To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 (110 mg, 0.17 mmol) in DCM (1.6 mL) 2,2,2-trifluoroacetic acid (1.6 mL, 21 mmol) was added. The mixture was stirred at room temperature for 24 h. The reaction was poured into DCM (10 mL) and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 96 mg of crude product. The crude product was purified by chromatography in a Merck cartridge (5 g of silica 15-40 µm) with elution of DCM / MeOH (96 / 4). Example (28) (23 mg, 36.8% yield) was obtained as a solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.84 (t, J=7.5 Hz, 3 H) ; 1, 12 (d, J=6, 2 Hz, 6 H) ; 1, 33 (m, 2 H) ; 1, 64 (m, 2 H) ; 2, 83 (m, 2 H) ; 5, 26 (m, 1 H) ; 5, 69 (s, 2 H) ; 5, 97 (s, 2 H) ; 7, 23 (d, J=8, 2 Hz, 2 H) ; 7, 89 (d, J=8, 2 Hz, 2 H) ; 9, 98 (s, 1 H) MS N method: TR (min): 1.21; [M+H]+ 368 Example (29): Preparation of Compound 35: (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)phenyl)methanol. To a solution of the compound 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 in Example (28) (200 mg, 0.30 mmol) in DCM (3 ml) were added 2,2,2-trifluoroacetic acid (1.6 ml, 21 mmol) and triethylsilane (145 µl, 0.90 mmol). The mixture was stirred at room temperature for 24 hours. The reaction was poured into DCM and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to provide 200 mg of crude product, which was purified by preparative HPLC at room temperature using a 250 x 50 mm, 5 µm CSH column (WATERS™) and a water / acetonitrile gradient with 0.1% formic acid (t = 0 min: 10% acetonitrile; t = 5 min: 10%; and t = 25 min: 30%). The compound was eluted at 18.8 min and lyophilized to provide 22 mg (19.8% yield) of Example (29) as a white foam. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.84 (t, J=7, 28 Hz, 3 H) 1.21 (d, J=6, 27 Hz, 6 H) 1.32 (sxt, J=7, 65 Hz, 2 H) H) 2, 79 (t, J=7, 81 Hz, 2 H) 4, 45 (s, 2 H) 5, 13 (sa, 1 H) 5, 32 (spt, J=6, 15 Hz, 1 H) 5, 56 (s, 2 H) 5, 92 (s, 27, 8, 8 H) Hz, 2 H) 7, 27 (d, J=8, 28 Hz, 2 H) MS A method: TR (min) : 0.73; [M+H]+ 370 Example (30) : Preparation of Compound 36: 2-butyl-1- (4- ( (cyclopropylamine) methyl) benzyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine Step 1: 2-butyl-1- (4- ( (cyclopropylamino) methyl) benzyl) -N, N-bis (2, 4-dimethoxybenzyl) -7-sopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 in Example (28) (200 mg, 0.30 mmol) in MeOH (2 ml) were added cyclopropylamine (25.41 µl, 0.36 mmol) and acetic acid (34.29 µl, 0.60 mmol). The mixture was stirred at room temperature for 10 min and then sodium cyanoborohydride (29.72 mg, 0.45 mmol) was added. The mixture was stirred at room temperature for 3 h. The reaction was carried out in H₂O and the pH was adjusted to 8 by adding a 35% ammonia solution. The mixture was then extracted with EtOAc. The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated under vacuum to yield 0.25 g of oil. The product was purified by chromatography in a Merck cartridge (20 g of 15–40 µm silica) with elution from [(EtOAc / EtOH 3 / 1) 40% - heptane 60%]. The expected product (154 mg, 72.4% yield) was obtained as a solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 19 (m, 2 H) ; 0.29 (m, 2 H) ; 0.76 (t, J=7.4 Hz, 3 H) ; 1, 21 (d, J=6, 2 Hz, 6 H) ; 1.24 (m, 2 H) ; 1.54 (m, 2 H) ; 1.97 (m, 1 H) ; 2.56 (m, 1 H) ; 2.75 (t, J=7.6 Hz, 2 H) ; 3.65 (d, J=5.4 Hz, 2 H) ; 3, 71 (s, 12 H) ; 5, 01 (s, 4 H) ; 5, 31 (sept, J=6, 2 Hz, 1 H) ; 5, 56 (s, 2 H) ; 6.39 (dd, J=2.5 y 8.5 Hz, 2 H) ; 6.52 (d, J=2.5 Hz, 2 H) ; 6.97 (d, J=8.5 Hz, 2 H) ; 7.02 (d, J=8, 3 Hz, 2 H) ; 7;27 (d, J=8, 3 Hz, 2 H) MS method N: TR (min) : 1.57; [M+H]+ 709; ES+ [M+2H]2+: m / z 355 Step 2: Example (30) Preparation of Compound 36: 2-butyl-1- (4- ( (cyclopropylamine) methyl) benzyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-4-amine To a solution of 2-butyl-1-(4-((cyclopropylamino)methyl)benzyl)-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine from Step 1 (140 mg, 0.20 mol) in DCM (2 mL) was added 2,2,2-trifluoroacetic acid (910 µL, 11.81 mmol). The mixture was stirred at room temperature for 24 h. The reaction was poured into DCM (10 mL) and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 90 mg of crude product. The crude product was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with elution of DCM / MeOH / NH4OH (95 / 5 / 0.2), to provide Example (30) (40 mg, 49% yield) in the form of a solid. 1H NMR (400 MHz, ppm, DMSO-d6): 0.17 to 0.32 (m, 4 H); 0.83 (t, J=7, 3 Hz, 3 H) ; 1, 20 (d, J=6, 2 Hz, 6 H) ; 1, 31 (m, 2 H) ; 1, 61 (m, 2 H) ; 1, 97 (m, 1 H) ; 2, 60 (m, 1 H) ; 2, 80 (m, 2 H) ; 3, 66 (s, 2 H) ; 5, 32 (Sept, J=6, 2 Hz, 1 H) ; 5, 55 (s, 2 H) ; 5, 92 (m, 2 H) ; 7.00 (d, J=8, 3 Hz, 2 H) ; 7, 27 (d, J=8, 3 Hz, 2 H) MS N method: TR (min): 0.83; [M+H]+ 409; ES+ [M+2H-iPr]2+: m / z 184 The following compounds can be prepared by analogy to Example 30: 82, 83, 100, 101, 102. Example (31): Preparation of Compound 37: 1, 1-dioxide of 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-yl) methyl) benzyl) amino) thiethane. Step 1: 3-((4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-]pyridazin-yl)methyl)benzyl)amino)thiethane 1,1-dioxide. To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 in Example (28) (810 mg, 1.21 mmol) in MeOH (10 ml) were added 1,1-3-aminothiethane hydrochloride (301.85 mg, 1.82 mmol), triethylamine (338.13 µl, 2.43 mmol) and acetic acid (208.31 µl, 3.64 mmol). The mixture was stirred at room temperature for 10 min, and then sodium cyanoborohydride (114.33 mg, 1.82 mmol) was added. The mixture was stirred at room temperature for 4 h. The reaction was poured into water, and the pH was adjusted to 8 by adding a 35% ammonia solution. The mixture was then extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 1 g of crude product, which was used in the next stage without further purification. Step 2: Example (31) Preparation of Compound 37: 1, 1-dioxide of 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-yl) methyl) benzyl) amino) thiethane. To a solution of 1,1-dioxide of 3-((4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)amino)thiethane from Step 1 (150 mg, 0.19 mmol) in DCM (5 mL) 2,2,2-trifluoroacetic acid (897.05 µL, 11.64 mmol) was added. The mixture was stirred at room temperature for 24 hours. The reaction was poured into DCM and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 99 mg of white foam. The crude product was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with elution of DCM / MeOH / NH4OH (95 / 5 / 0.2), to provide Example (31) (61 mg, 66% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.84 (t, J=7, 4 Hz, 3 H); 1, 20 (d, J=6, 2 Hz, 6 H) ; 1, 32 (m, 2 H) ; 1, 62 (m, 2 H) ; 2;80 (m, 2 H) ; 2, 91 (m, 1 H) ; 3, 44 (m, 1 H) ; 3, 59 (s, 2 H) ; 3, 84 and 3, 91 (m, 2 H) ; 4, 17 and 4, 25 (m, 2 H) ; 5, 32 (Sept, J=6, 2 Hz, 1 H) ; 5, 56 (s, 2 H) ; 5, 94 (s, 2 H) ; 7, 02 (d, J=8, 2 Hz, 2 H) ; 7, 28 (d, J=8, 2 Hz, 2 H) MS Method N: TR (min) : 0.99; [M+H]+ 473 Example (32) : Preparation of Compound 38: N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) -N- (1, 1-dioxidothioethane-3-yl) acetamide. Stage 1: N- (4- ( (4- (bis (2, 4-dimethoxybenzyl) amino) -2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazine-1-yl)methyl) benzyl) -N- (1, 1-dioxidothioethane-tam-3-yl) To a solution of 1,1-dioxide of 3-((4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)amino)thiethane from Step 1 in Example (31) (300 mg, 0.39 mmol) in Pyridine (3 ml), acetic anhydride (109.86 µl, 1.16 mmol) was added. The mixture was stirred at room temperature for 48 h. At the end of this time, the reaction mixture was concentrated by evaporation under reduced pressure. The residue was poured into EtOAc and washed with water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 308 mg of white foam. The crude product was purified by chromatography in a Merck cartridge (20 g of 15–40 µm silica) with DCM / MeOH (95 / 5) elution, to yield 275 mg of the expected product as a white foam. The compound was used in the next step without further purification.Step 2: Example (32) Preparation of Compound 38: N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)-N-(1,1-dioxythiethane-3-yl)acetamide. To a solution of N-(4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)-N-(1,1-dioxidothiethane-3-yl)acetamide from Step 1 (270 mg, 0.33 mol) in DCM (7 mL) 2,2,2-trifluoroacetic acid (1 mL, 12.98 mmol) was added. The mixture was stirred at room temperature for 24 h. The reaction was poured into DCM and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 220 mg of white foam. The crude product was purified by chromatography in a Merck cartridge (20 g of 15-40 µm silica) with elution of CH2Cl2 / MeOH / NH4OH (93 / 7 / 0.2), to provide 110 mg (64.5% yield) of Example (32) in the form of a white foam. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.82 (t, J=7 Hz, 3 H); 1, 17 (d, J=6 Hz, 6 H) ; 1, 30 (dc, J=7 and 15 Hz, 2 H); 1, 59 (quin, J=8 Hz, 2 H) ; 1, 96 (s, 2 H) ; 2, 19 (s wide, 1 H) ; 2, 81 (t, J=8 Hz, 2 H) ; 4.06 and 4.79 (m, 6 H) ; 5, 05 (m, 1 H) ; 5, 30 (quin, J=6 Hz, 1 H) ; 5, 57 (s wide, 2 H) ; 5, 92 (s, 2 H) ; 6, 94 and 7, 26 (m, 4 H) MS Method N: TR (min) : 1.08; [M+H]+ m / z 515, ES- [M-H+HCO2H]-: m / z 559 Example (33) : Preparation of Compound 39: 2-butyl-7-isopropoxy-1- (4- ( ( ( (1-methylcyclobutyl) amino) methyl) benzyl) -1H-imidazo[4, 5-d]pyridazin-4-amine. Stage 1: 2-butyl-N, N-bis (2, 4-dimethoxybenzyl) -7-isopropoxy-1- (4- ( ( (1-methylcyclobutyl) amino) methyl) benzyl) -1H-imidazo[4, 5-d]pyridazin-4-amine. To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 in Example (28) (300 mg, 0.45 mmol) in methanol (2 ml) were added 1-methylcyclobutanamine hydrochloride (86.26 mg, 0.67 mmol), triethylamine (125.23 µl, 0.90 mmol) and acetic acid (77.15 µl, 1.35 mmol). The mixture was stirred at room temperature for 10 min and then sodium cyanoborohydride (43.21 mg, 0.67 mmol) was added. The mixture was stirred at room temperature for 5 h. The reaction was poured into water and the pH was adjusted to 8 by adding a 35% ammonia solution. The mixture was then extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 0.45 g of oil.The crude product was purified by chromatography on a Merck cartridge (30 g silica 15-40 µm) with elution of [ (EtOAc / EtOH 3 / 1) 50 %- Heptane 50 %], to provide the expected product (146 mg, yield 44 %), in the form of a 1 % solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 76 (t, J=7. 5 Hz, 3 H) ; 1, 18 (s, 3 H) ; 1.23 (d, J=6.2 Hz, 6 H) ; 1.25 (m, 2 H) ; 1.55 (m, 2 H) ; 1.58 to 1.72 (m, 4 H); 1.85 to 2.01 (m, 3 H); 2.74 (t, J=7.6 Hz, 2 H) ; 3.56 (d, J=6.4 Hz, 2 H) ; 3, 71 (s, 12 H) ; 5;01 (s, 4 H) ; 5, 33 (sept, J=6, 2 Hz, 1 H) ; 5, 55 (s, 2 H) ; 6.39 (dd, J=2.4 y 8.4 Hz, 2 H) ; 6.52 (d, J=2.4 Hz, 2 H) ; 6.97 (d, J=8, 4 Hz, 2 H) ; 7.02 (d, J=8, 3 Hz, 2 H) ; 7, 30 (d, J=8, 3 Hz, 2 H) MS method N: TR (min) : 1, 32; [M+H]+ 737; ES+ [M+2H]2+: m / z 369 Step 2: Example (33) : Preparation of Compound 39: 2-butyl-7-isopropoxy-1- (4- ( ( (1-methylcyclobutyl) amino) methyl) benzyl) -1H-imidazo[4, 5-d]pyridazin-4-amine. To a solution of 2-butyl-N,N-bis(2,4-dimethoxybenzyl)-7-isopropoxy-1-(4-((1-methylcyclobutyl)amino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine from Step 1 (140 mg, 0.19 mmol) in DCM (4 mL) 2,2,2-trifluoroacetic acid (878 µL, 11.40 mmol) was added. The mixture was stirred at room temperature for 24 hours. The reaction was poured into DCM and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to give 83 mg of white solid. The crude product was purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with CH2Cl2 / MeOH / NH4OH (94 / 6 / 0.2) elution, to provide Example (33) (66 mg, 79.7% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.85 (t, J=7.4 Hz, 3 H) ; 1, 19 (s, 3 H) ; 1, 22 (d, J=6, 2 Hz, 6 H) ; 1, 33 (m, 2 H) ; 1, 58 to 1, 73 (m, 6 H) ; 1, 93 (m, 2 H) ; 2, 09 (m wide, 1 H) ; 2, 80 (m, 2 H) ; 3, 58 (s, 2 H) ; 5, 33 (Sept, J=6, 2 Hz, 1 H) ; 5, 56 (s, 2H) ; 5, 92 (s, 2 H) ; 7, 01 (d, J=8, 3 Hz, 2 H) ; 7, 31 (d, J=8, 3 Hz, 2 H) MS Method N: TR (min) : 0, 9; [M+H]+ 437; ES+ [M+C5H8]+: m / z 369 The following compounds can be prepared by analogy to Example 33: 85, 87, 88, 89, 90, 91. Example (34): Preparation of Compound 40: 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine Step 1: 4-(4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)piperazine-1-carboxylate tert-butyl To a solution of 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzaldehyde from Step 1 in Example (28) (200 mg, 0.30 mmol) in methanol (2.5 mL) were added 1-Boc-piperazine (85.38 mg, 0.45 mmol) and acetic acid (34.29 µL, 0.60 mmol). The mixture was stirred at room temperature for 10 min and then sodium cyanoborohydride (28.23 mg, 0.45 mmol) was added. Stirring at room temperature was continued for 4.5 h. The reaction was poured into water, and the pH was adjusted to 9 by adding a 35% ammonia solution. The mixture was then extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 0.45 g of oil. The crude product (289 mg), a white gum, was used directly in the next stage. Step 2: Example (34) Preparation of Compound 40: 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine To a solution of 4-(4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)piperazine-1-carboxylate tert-butyl from Step 1 (250 mg, 0.3 mmol) in DCM (6.3 ml) 2,2,2-trifluoroacetic acid (919.29 µl, 11.93 mmol) was added. The mixture was stirred at room temperature for 24 hours. The reaction was poured into DCM and washed with 1 M sodium hydroxide. The organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide 145 mg of crude product, which was purified by chromatography on a Merck cartridge (20 g of 15-40 µm silica) with CH2Cl2 / MeOH / NH4OH (90 / 10 / 0.2) elution, to provide Example (34) (45 mg, 35% yield) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 81 (t, J=7 Hz, 3 H) ; 1, 17 (d, J=6 Hz, 6 H) ; 1, 29 (dc, J=7 y 15 Hz, 2 H) ; 1, 59 (quin, J=8 Hz, 2 H) ; 2, 22 (s wide, 4 H) ; 2, 63 (t, J=5 Hz, 4 H) ; 2, 81 (t, J=7 Hz, 2 H) ; 3, 36 (s, 2 H) ; 5, 30 (spt, J=6 Hz, 1 H) ; 5, 55 (s, 2 H) ; 5, 94 (s, 2 H) ; 7.00 (d, J=8 Hz, 2 H) ; 7, 24 (d, J=8 Hz, 2 H) MS method N: TR (min): 0.80; [M+H]+ 438 Example (35) : Preparation of Compound 41: 2-butyl-N7, N7, 1-trimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine A mixture of the intermediate product (K) (95 mg, 0.40 mmol) in DMF (1 ml) and dimethylamine (7 ml, 40% in water) was placed in an autoclave and heated for 6 hours at 160 °C. The reaction mixture was poured into water (100 ml) and extracted with EtOAc (3 x 30 ml). The organic layer was collected and dried over anhydrous MgSO4, filtered, and concentrated under vacuum to provide 40 mg of crude product, which was purified by chromatography on a Merck cartridge (2.5 g, 15–40 µm silica) with a DCM / methanol (93 / 7) elution to give Example (34) (13 mg, 14% yield) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.94 (t, J=7.4 Hz, 3 H) ; 1, 43 (m, 2 H) ; 1, 77 (m, 2 H) ; 2, 77 (s, 6 H) ; 2, 86 (m, 2 H) ; 3, 95 (s, 3 H) ; 6, 06 (s, 2H) MS N method: TR (min): 0.88; [M+H]+ 249 Example (36): Preparation of Compound 42: 2-butyl-1-methyl-7-(pyrrolidine-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine A mixture of Intermediate Product (K) (50 mg, 0.21 mmol), water (1 mL), and pyrrolidine (1 mL) was introduced into a microwaveable vial. The suspension was heated at 160 °C for 7 hours in a microwave oven. The reaction mixture was concentrated under vacuum to provide 100 mg of crude product, which was purified by chromatography on a Merck cartridge (10 g of 15–40 µm silica) with an elution of DCM / MeOH / MeCN (85 / 7.5 / 7.5) to provide Example (36) (32 mg, 55% yield) as a yellow amorphous solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.94 (t, J=7.4 Hz, 3 H) ; 1, 43 (m, 2 H) ; 1, 77 (m, 2 H) ; 1, 89 (m, 4 H) ; 2, 88 (m, 2 H) ; 3, 30 (m, 4 H) ; 3, 96 (s, 3 H) ; 6, 88 (s, 2 H) MS P method: TR (min): 1.85; [M+H]+ 275 Example (37): Preparation of Compound 43: 2-butyl-N7-(4-((dimethylamino)methyl)benzyl)-N7, 1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine A mixture of Intermediate Product (K) (200 mg, 0.83 mmol), dimethyl((4-[(methylamino)methyl]phenyl)methyl)amine (783 mg, 4.17 mmol), 1-butanol (2 mL), and 3-chloropyridine hydrochloride (413 mg, 2.75 mmol) was introduced into a microwaveable vial. The suspension was heated at 160 °C for 3 hours in a microwave oven. The reaction mixture was concentrated under vacuum to provide 1.2 g of crude product. This material was dissolved in EtOAc (25 mL) and washed with water (20 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide 381 mg of crude compound, which was purified by chromatography on a Merck cartridge (20 g of 15-40 µm silica) with an elution of DCM / methanol (8 / 2), to provide Example (37) (83 mg, 26% yield) in the form of a yellow solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.94 (t, J=7.4 Hz, 3 H) ; 1.42 (m, 2 H) ; 1.76 (m, 2 H) ; 2.12 (s, 6 H) ; 2.67 (s, 3 H); 2.86 (m, 2 H) ; 3.34 (s, 2 H) ; 4.01 (s, 3 H) ; 4.31 (s, 2 H) ; 6.05 (s, 2 H) ; 7.22 (d, J=8.2 Hz, 2 H) ; 7.29 (d, J=8.2 Hz, 2 H) . MS method N: TR (min) : 0.84; [M+H]+ 382; ES+ [M+2H]2+: m / z 191, 5 Example (38) : Preparation of Compound 44: 2-butyl-N7, 1-dimethyl-N7- (4- (morpholinomethyl) benzyl) -1H-imidazo[4, 5-d]pyridazine-4, 7-diamine A mixture of the intermediate product (K) (100 mg, 0.42 mmol), methyl-(4-morpholin-4-ylmethylbenzyl)amine (484 mg, 2.09 mmol), 1-butanol (2 mL), and 3-chloropyridine hydrochloride (206.5 mg, 1.38 mmol) was introduced into a microwaveable vial. The suspension was heated at 160 °C for 6 hours in a microwave oven. The reaction mixture was concentrated under vacuum to provide 604 mg of crude product. This material was dissolved in EtOAc (50 mL) and washed with water (50 mL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under vacuum to yield 221 mg of yellow solid, which was purified by chromatography in a Merck cartridge (15 g of 15-40 µm silica) with a DCM / MeOH (9 / 1) elution to yield 75 mg as a beige solid, which was stirred for 1 hour with isopropyl ether (2 ml). After filtration and drying, Example (38) (55 mg, 35% yield) was obtained as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.94 (t, J=7.3 Hz, 3 H) ; 1, 42 (m, 2 H) ; 1, 76 (m, 2 H) ; 2, 32 (m, 4 H) ; 2, 66 (s, 3 H) ; 2, 86 (m, 2 H) ; 3, 41 (s, 2 H) ; 3, 56 (m, 4 H) ; 4, 00 (s, 3 H) ; 4, 30 (s, 2 H) ; 6, 02 (s, 2H) ; 7, 23 (d, J=8, 3 Hz, 2 H) ; 7, 29 (d, J=8, 3 Hz, 2 H) MS N method: TR (min): 0.73; [M+H]+ 424; ES+ [M+2H]2+: m / z 212.5 Example (39 A): Preparation of Compound 45: 4-(((4-amino-2-butyl-1-methyl-1H-imidazo[4,5-d]pyridazin-7-yl)(methyl)amino)methyl)benzenitrile and Example (39 B): Preparation of Compound 46: N7-(4-(aminomethyl)benzyl)-2-butyl-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine Step 1: Example (39 A) : Preparation of Compound 45: 4- ( ( (4-amino-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazin-7-yl) (methyl) amino) methyl) benzonitrile A mixture of Intermediate Product (K) (400 mg, 1.67 mmol), 4-(methylaminomethyl)benzenitrile (1.28 g, 8.34 mmol), 1-butanol (10 mL), and 3-chloropyridine hydrochloride (826 mg, 5.51 mmol) was introduced into a microwaveable vial. The suspension was heated at 160 °C for 5 hours in a microwave oven. The reaction mixture was concentrated under vacuum to provide 1.9 g of crude product. This material was dissolved in EtOAc (100 mL) and washed with water (100 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide 703 mg of yellow solid, which was purified by chromatography on a Merck cartridge (40 g of 15-40 µm silica) with an elution of DCM / methanol / acetonitrile (96 / 2 / 2) to provide Example (39A) (124 mg, 21% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.94 (t, J=7.4 Hz, 3 H) ; 1, 42 (m, 2 H) ; 1, 76 (m, 2 H) ; 2, 71 (s, 3 H) ; 2, 86 (m, 2 H) ; 4, 00 (s, 3 H) ; 4, 45 (s, 2 H) ; 6, 03 (s, 2H) ; 7, 55 (d, J=8, 5 Hz, 2 H) ; 7, 76 (d, J=8, 5 Hz, 2 H) MS N method: TR (min): 1, 12; [M+H]+ 350 Step 2: Example (39B) Preparation of Compound 46: N7-(4-(aminomethyl)benzyl)-2-butyl-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine To a solution of 4-(((4-amino-2-butyl-1-methyl-1H-imidazo[4,5-d]pyridazin 7yl)(methyl)amino)methyl)benzenitrile from Step 1 (104 mg, 0.30 mmol) in THF (4 mL) 1 M BH3-THF (893 µL, 0.89 mmol) was added dropwise. The solution was heated under reflux for 18 hours. Then 1 M methanol-HCl (3 mL) was added and the mixture was heated under reflux for 24 hours. The reaction mixture was concentrated under reduced pressure to give 414 mg of white solid. The residue was dissolved in DCM (10 mL) and washed with water (10 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide 114 mg of white solid, which was purified by chromatography on a Macherey Nagel Chromabond Sorbenz NH2 cartridge (16.4 g) with DCM / methanol (95 / 5) elution to obtain Example (39B) (13 mg, 12% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6): 0.94 (t, J=7.5 Hz, 3 H) ; 1, 42 (m, 2 H) ; 1, 76 (m, 2 H) ; 2, 09 (m, 2 H) ; 2, 66 (s, 3 H) ; 2, 85 (m, 2 H) ; 3, 66 (s, 2 H) ; 4, 00 (s, 3 H) ; 4, 29 (s, 2 H) ; 6, 00 (s, 2 H) ; 7:14 a.m. to 7:30 a.m. (m, 4 a.m.) MS N method: TR (min): 0.73; [M+H]+ 354; ES+ [M+2H-NH3]2+: m / z 169 Example (40): Preparation of Compound 47: 2-butyl-N7-(4-(((2-methoxyethyl)(methyl)amino)methyl)benzyl)-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine A mixture of Intermediate Product (K) (100 mg, 0.42 mmol), 2-methoxy-N-methyl-N-(4-((methylamino)methyl)benzyl)ethan-1-amine (464 mg, 2.09 mmol), 1-butanol (2 mL), and 3-chloropyridine hydrochloride (206.5 mg, 1.38 mmol) was introduced into a microwaveable vial. The suspension was heated at 160 °C for 3 hours in a microwave oven. The reaction mixture was concentrated under vacuum to provide 731 mg of crude product. This material was dissolved in EtOAc (25 mL) and washed with water (20 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide 244 mg of crude compound, which was purified by chromatography on a Merck cartridge (20 g of 15-40 µm silica) with DCM / MeOH (9 / 1) elution to provide Example (40) (32 mg, 18% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0. 94 (t, J=7, 4 Hz, 3 H) ; 1.41 (m, 2 H) ; 1.75 (m, 2 H) ; 2, 12 (s, 3 H) ; 2, 50 (m occult, 2 H) ; 2, 66 (s, 3 H) ; 2.85 (m, 2 H) ; 3, 21 (s, 3 H) ; 3.43 (t, J=6.0 Hz, 2 H) ; 3, 45 (s, 2 H) ; 4, 00 (s, 3 H) ; 4, 30 (s, 2 H) ; 6, 01 (s, 2 H) ; 7, 21 (d, J=8, 2 Hz, 2 H) ; 7, 28 (d, J=8, 2 Hz, 2 H) MS method N: TR (min): 0.72; [M+H]+ 426; ES+ [M+2H]2+: m / z 213, 5 Example (41) : Preparation of Compound 104: 2-butyl-7-isopropoxy-1- (4- ( ( (2-methoxyethyl) amino) methyl) benzyl) -1H-imidazo[4, 5-d]pyridazine-4-amine In argon, a solution of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (200 mg, 0.54 mmol) in 3 mL of DMF was mixed with Cs₂CO₃ (531 mg, 1.63 mmol) and the mixture was stirred for 30 min. Then, 2-bromomethyl methyl ether (80.00 µl, 0.80 mmol) was added and the mixture was stirred at room temperature for 24 h. The reaction mixture was poured into 50 mL of ice-cold water. The aqueous solution was extracted with EtOAc (3 x 25 mL), the organic layers were combined and washed with brine. The organic layer was dried over anhydrous MgSO₄, filtered, and... Concentrated under vacuum to provide 244 mg of crude compound, which was purified by chromatography on a Merck cartridge (20 g of 15-40 µm silica) with elution of DCM / DCM-MeOH (8-2) / NH3.H2O (90 / 10 / 0.015 to 80 / 200.015) to provide Example (41) (72 mg, 31% yield) in the form of a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.83 (t, J=7 Hz, 3 H) , 1.20 (d, J=6 Hz, 6 H) , 1.2.- 1.41 (m, 2 H) , 1.5.- 1.67 (m, 2 H) , 2.59 (t, J=6 Hz, 2 H) , 2, 7.- 2, 86 (m, 2 H) , 3, 20 (s, 3 H) , 3, 3.- 3, 41 (m partially hidden, 2 H) , 3, 67 (s, 2 H) , 5, 32 (spt, J=6 Hz, 1 H) , 5, 55 (s, 2 H), 5, 93 (s, 2 H), 7.01 (d, J=8 Hz, 2 H), 7.27 (d, J=8 Hz, 2 H) MS N method: TR (min): 0.80; [M+H]+ 427 The following compounds can be prepared by analogy to Example 41: 108, 109, 110, 116, 117, 119. Example (42): Preparation of Compound 105: 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-(2-methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo 4, 5-d]pyridazin-7-amine Step 1: N-[[4-[[7-[bis[ (2, 4-dimethoxyphenyl) methyl]amino]-2-butyl-4-propan-2-yloximidazo[4, 5-d]pyridazin-3-yl]methyl]phenyl]methyl]-N-[2-[2-[2-[2-[2- [2- (2 methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate tert-butyl In argon, a solution of tert-butyl (4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)carbamate from Step 1 in Example (17A) (200 mg, 0.26 mmol) in DMF (3 mL) was given sodium hydride (31 mg, 0.78 mmol) at room temperature and the mixture was stirred until the end of gas bubbling. Then m-PEG6 bromide (123 µL, 0.39 mmol) was added and the mixture was stirred at room temperature overnight. A second portion of sodium hydride (31 mg, 0.78 mmol) was added and the mixture was stirred again for 24 h. The reaction mixture was poured into 100 ml of ice water. The aqueous solution was extracted with DCM (100 ml) and MeTHF (100 ml), the organic layers were combined and concentrated under vacuum to provide 65 mg of crude compound.The aqueous phase was concentrated under vacuum to yield 404 mg of crude compound, which was treated with a mixture of EtOAc / EtOH. After filtering out insoluble residues, the filtrate was concentrated under vacuum and combined with the 65 mg of crude compound from the organic phase. The crude material was then purified by chromatography in a Merck cartridge (10 g of 15-40 µm silica) with elution of EtOAc / EtOH from 98:2 to 90:10 to yield the expected compound (54 mg, 20% yield) as a white solid. 1H NMR (400 MHz, in ppm, DMSO-d6) : 0.75 (t, J=7.4 Hz, 3 H) 1.1.- 1.47 (m, 17 H) 1.55 (m, 2 H) 2.77 (m, 2 H) 3.21 (m, 3 H) 3.3.- 3.55 (m, 24 H) 3.71 (s, 12 H) 4.38 (s, 2 H) 5.01 (s, 4 H) 5.31 (m, 1 H) 5.57 (s, 2 H) 6.39 (m, J=8, 3 Hz, 2 H) 6.53 (d, J=2, 3 Hz, 2 H) 6.97 (m, J=8, 3 Hz, 2 H) 7.05 (d, J=8, 3 Hz, 2 H) 7.19 (d, J=8, 3 Hz, 2 H) MS N method: TR (min): 1.79; [M+H]+ 1047 Step 2: Example (42): Preparation of Compound 105: 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-(2-methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo 4, 5-d]pyridazin-7-amine In argon, a solution of N-[[4-[[7-[bis[(2,4-dimethoxyphenyl)methyl]amino]-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl]methyl]phenyl]methyl]-N-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]tert-butyl carbamate from Step 1 (50 mg, 0.048 mmol) in DCM (0.2 ml) was given TFA (203 µl, 2.63 mmol) at room temperature, resulting in a purple solution, which was stirred for 48 h. The reaction mixture was then concentrated under vacuum and collected in MeOH (3 mL). The insoluble residues were filtered and washed with MeOH. The methanolic solution was concentrated and loaded onto a 5 g SCX cartridge, which was eluted with 100 mL of MeOH and 100 mL of MeOH / NH3 (2 M). The MeOH / NH3 phase was concentrated under vacuum to provide Example (42) (29.3 mg, 95% yield) as a white solid. 1H NMR (400 MHz, ppm, DMSO-d6): 0.84 (t, J=7 Hz, 3 H), 1.21 (d, J=6 Hz, 6 H), 1.2.- 1.38 (m, 2 H) , 1.63 (t, J=8 Hz, 2 H) , 2.59 (t, J=6 Hz, 2 H) , 2.7.- 2.90 (m, 2 H) , 3.2.- 3.25 (m, 3 H) , 3.3.- 3.55 (m, 22 H), 3.67 (s, 2 H), 5.78 (m, 1 H), 5.56 (s, 2 H), 5.90 (s, 2 H), 7.02 (d, J=8 Hz, 2 H), 7.28 (d, J=8 Hz, 2 H). MS method N: TR (min): 1.01; [M+...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 represents: - a hydrogen atom, or - a group selected from: a) - a (C1-C6) alkyl group -; - a (C1-C6) hydroxyalkyl group -; - a (C1-C6) NH2-alkyl group -; - a (C1-C6) NH-alkyl group -; - a (C1-C6) 2-alkyl group -; - a (C2-C6) alkenyl group -; - a (C2-C6) alkynyl group -; b) - a (C1-C6) phenylalkyl group - which is unsubstituted or substituted with at least one substituent selected from: b1.- a (C1-C6) alkoxy group -; b2.- a hydroxyl group; b3) a -C(O)-H group; and b4.- an alkyl (C1-C6) group - which is unsubstituted or substituted with at least one substituent selected from: b4.1.- a hydroxyl group; and b4.2.- an -NR4R5 group wherein R4 and R5 are selected independently of each other from: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl (C1-C16) group -;b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, an alkoxy (C1-C6)-alkyl (C1-C6) group or an alkoxy (C1-C6)-alkoxy (C1-C6)-alkyl (C1-C6) group; b4.2.4.- an alkyl (C1-C6)-S(O2)- group; b4.2.5.- an alkyl (C1-C6)-NH-C(O)- group; b4.2.6.- an alkyl (C1-C16)-C(O)- group; b4.2.7.- an alkyl (C1-C16)-OC(O)- group; b4.2.8.- a CH3-[O-(CH2)2]nC(O) group - where n is an integer from 1 to 30; b4.2.9.- a (C3-C10) cycloalkyl group - which is unsubstituted or substituted with at least one substituent selected from: - a hydroxyl group; and - a (C1-C6) alkyl group -; or b4.2.10.- a (C3-C10) member heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(O)- and -SO2-; b4.2.11.- a phenyl-C(O)- group; b4.2.12.- an alkoxy (C1-C6)-phenyl-alkyl (C1-C6)-OC(O)- group; b4.2.13.- a group alkyl (C1-C16) -C (O) -NH-phenyl-alkyl (C1-C6) -OC (O) -;b4.2.14.- an (C1-C16) alkyl group -OC(O)-C1-C6 alkyl-; or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group and a CH3-[O-(CH2)2]n group, n being an integer from 1 to 30; c) a (C3-C10) cycloalkyl group (C1-C6)-alkyl- which is unsubstituted or substituted with at least one substituent selected from -NH2 and an NH2-C1-C6 alkyl group;d) - a (C3-C10) alkyl-membered (C1-C6) heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group - and a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; and e) - a (C1-C6) alkyl-membered (C5-C10) heteroaryl group - comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur, said heteroaryl being unsubstituted or substituted with at least one substituent selected from: - a (C1-C6) alkyl group -; - a (C1-C6) NH2-alkyl group - and - a cyano group; f) - a (C3-C10) member-NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S (O) , SO2 and sulfur;(g) - a (C3-C10) member-N(C(O)-alkyl(C1-C6))-alkyl(C1-C16)-, said heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, S(O), SO2 and sulfur; R2 represents a halogen atom, or a group selected from: - a (C1-C6) alkyl group -; - a (C2-C6) alkenyl group -; - a (C2-C6) alkynyl group -; - a (C1-C6) alkylthio group -; - a (C1-C6) alkylthio (C1-C6)-alkyl (C1-C6) group -; - a (C1-C6) alkyl-S(O) group -; - a (C1-C6) alkyl-S(O2) group -; - an alkyl (C1-C6) group -S (O) -alkyl (C1-C6) -; - an alkyl (C1-C6) group -S (O2) -alkyl (C1-C6) -; - an alkoxy (C1-C6) group -; - an alkoxy (C1-C6) -alkyl (C1-C6) group -; - a haloalkoxy (C1-C6) -alkyl (C1-C6) group -; - a cycloalkyl (C3-C5) -O-alkyl (C1-C6) group -; - an alkyl (C1-C6) -NH-alkyl (C1-C6) group -; - a (alkyl (C1-C6) ) 2-N-alkyl (C1-C6) group -; - an alkyl (C1-C6) -NH- group; and - a (alkyl (C1-C6) ) 2N- group;R3 represents: - a deuterium atom; - a hydrogen atom or a group selected from: a) - an alkyl (C1-C6) group -; - an alkenyl (C2-C6) group -; - an alkynyl (C2-C6) group -; and - an alkylthio (C1-C6) group -; b) - an -OR6 group where R6 is selected from: - a hydrogen atom; - an alkyl (C1-C6) group -; - a CH3-[O-(CH2)2]n- group where n is an integer from 1 to 30; - an alkenyl (C2-C6) group -; - an alkynyl (C2-C6) group -; - a cycloalkyl (C3-C10) group -; - a phenyl group; - a phenylalkyl (C1-C6) group -; and - a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen, sulfur, -S(=O)- and -S(=O)2-; c) - an -NR7R8 group wherein R7 and R8 are selected independently of each other from: - a hydrogen atom; - a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30;- an (C1-C6) alkyl group - unsubstituted or substituted with - a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen, and sulfur; or - a phenyl group that is unsubstituted or substituted with at least one substituent selected from: - a cyano group and - an NR9R10 (C1-C6) alkyl group - wherein: R9 and R10 are selected, independently of each other, from: - a hydrogen atom; - a (C1-C6) alkyl group; - a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C3-C10) member heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from a (C1-C6) alkyl group and a CH3-[O-(CH2)2]n group, where n is an integer from 1 to 30;or R7 and R8 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent selected from: - a phenyl group and - a (C1-C6) hydroxyalkyl group -phenyl-; d) - a (C3-C10) member heterocycloalkyl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur; e) - a (C5-C10) member heteroaryl group comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur, said (C5-C10) member heteroaryl group being unsubstituted or substituted with at least one (C1-C6) alkyl group -; f) - a (C6-C10) member -aryl group;(g) - a cycloalkyl (C3-C10) group -, provided that at least one of R1 and R3 is other than a hydrogen atom.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 represents: - a hydrogen atom or - a group selected from: a) - a (C1-C6) alkyl group -; - a (C1-C6) hydroxyalkyl group - or - a (C1-C6) NH2alkyl group -; b) - a (C1-C6) phenylalkyl group - which is unsubstituted or substituted with a substituent, selected from: b1. - a (C1-C6) alkoxy group -; b3. - a -C(O)-H group and b4. - a (C1-C6) alkyl group - substituted with at least one substituent selected from: b4.

1. - a hydroxyl group; b4.2.- a -NR4R5 group wherein R4 and R5 are selected independently from each other, from: b4.2.1.- a hydrogen atom; b4.2.2.- an alkyl (C1-C16) group -;b4.2.3.- a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30, an alkoxy (C1-C6)-alkyl (C1-C6) group or an alkoxy (C1-C6)-alkoxy (C1-C6)-alkyl (C1-C6) group; b4.2.4.- an alkyl (C1-C6)-S(O2)- group; b4.2.5.- an alkyl (C1-C6)-NH-C(O)- group; b4.2.6.- an alkyl (C1-C16)-C(O)- group; b4.2.7.- an alkyl (C1-C16)-OC(O)- group; b4.2.8.- a CH3-[O-(CH2)2]nC(O) group - where n is an integer from 1 to 30; b4.2.9.- a (C3-C10) cycloalkyl group - which is unsubstituted or substituted with at least one (C1-C6) alkyl group or a hydroxyl group; b4.2.10.- a (C3-C10) member heterocycloalkyl group - comprising one to four heteroatoms selected from oxygen, nitrogen and -SO2-; b4.2.11.- a phenyl-C(O)- group; b4.2.12.- an alkoxy (C1-C6)-phenylalkyl (C1-C6)-OC(O)- group; b4.2.13.- an alkyl (C1-C16)-C(O)-NH-phenylalkyl (C1-C6)-OC(O)- group; b4.2.14.- an alkyl (C1-C16) -OC (O) -alkyl (C1-C6) - group;or R4 and R5 together with the nitrogen atom to which they are attached form a (C3-C10) member heterocycloalkyl group comprising one to two heteroatoms selected from oxygen and nitrogen; c) a (C3-C10) cycloalkyl (C1-C6) group that is unsubstituted or substituted with a substituent selected from -NH2 and a (C1-C6) NH2-alkyl group; d) an unsubstituted (C1-C6) member heterocycloalkyl (C3-C10) group comprising one to two nitrogen heteroatoms; e) a (C1-C6) member heteroaryl (C5-C10) group comprising a nitrogen heteroatom, said heteroaryl being unsubstituted or substituted with at least one substituent selected from: an (C1-C6) NH2-alkyl group and a cyano group; f) - a (C3-C10) member-NH-alkyl (C1-C16) heterocycloalkyl group -, said heterocycloalkyl group comprising a heteroatom selected from oxygen, nitrogen, S (O) , SO2 and sulfur;(g) - a (C3-C10) member-N(C(O)-alkyl(C1-C6))-alkyl(C1-C16)-, said heterocycloalkyl group comprising a heteroatom selected from oxygen, nitrogen, S(O), SO2, and sulfur.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claim 1 or claim 2, wherein R2 represents: - a (C1-C6) alkyl group -; - a (C1-C6) alkylthio group -; - a (C1-C6)-S(O)-alkyl group -; - a (C1-C6)-NH-alkyl(C1-C6)-alkyl group -; - a (C1-C6)-NH-alkyl group -; and - a (C1-C6)-alkyl(C1-C6)-alkoxy group.

4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R3 represents: - a hydrogen atom or - a group selected from: a) - an alkyl (C1-C6) group -; - an alkenyl (C2-C6) group -; - an alkylthio (C1-C6) group -;b) - an -OR6 group wherein R6 is selected from: - a hydrogen atom; - a (C1-C6) alkyl group; - a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; - a (C2-C6) alkenyl group; - a (C3-C10) cycloalkyl group; - a phenyl group; - a (C1-C6) phenylalkyl group; and - a (C3-C10) member heterocycloalkyl group comprising a heteroatom selected from oxygen, sulfur, -S(O)- and -SO2-; c) - an -NR7R8 group wherein R7 and R8 are selected independently of each other from: - a hydrogen atom; - a CH3-[O-(CH2)2]n- group, where n is an integer from 1 to 30; - an (C1-C6) alkyl group - unsubstituted or substituted with: - a (C5-C10) member heteroaryl group comprising an oxygen atom; or - a phenyl group that is unsubstituted or substituted with at least one substituent selected from: - a cyano group and - an (C1-C6) NR9R10-alkyl group - wherein R9 and R10 are selected, independently of each other, from: - a hydrogen atom;- an alkyl (C1-C6) group or - a CH3-[O-(CH2)2]n- where n is an integer from 1 to 30; or R9 and R10 together form with the nitrogen atom to which they are attached a (C3-C10) member heterocycloalkyl group comprising one to two heteroatoms selected from oxygen and nitrogen, said (C3-C10) member heterocycloalkyl group being substituted with at least one (C1-C6) alkyl group -, for example, one to three (C1-C6) alkyl groups -, such as a (C1-C6) alkyl group -; or R7 and R8 together with the nitrogen atom to which they are attached form a (C3C10) member heterocycloalkyl group comprising a nitrogen heteroatom, said heterocycloalkyl group being unsubstituted or substituted with at least one substituent, for example, one to three substituents, such as a substituent selected from: - a phenyl group and - a (C1-C6) hydroxyalkyl group;d) - a (C3-C10) member heterocycloalkyl group comprising a heteroatom selected from oxygen and nitrogen; e) - a (C5-C10) member heteroaryl group comprising one to two heteroatoms selected from oxygen, nitrogen and sulfur, said (C5-C10) member heteroaryl group being unsubstituted or substituted with at least one (C1-C6) alkyl group, for example, one to three (C1-C6) alkyl groups, such as a (C1-C6) alkyl group; f) - a (C6-C10) member aryl group and g) - a (C3-C10) cycloalkyl group.

5. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, said compound being selected from: (1) 2-butyl-7-isopropoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (2) 2-butyl-N7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (3) 2-butyl-7-(isopropylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine;(4) 2-butyl-1-(4-methoxybenzyl)-7-(2-methoxyethoxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (5) 2-butyl-1-(4-methoxybenzyl)-7-propoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (6) 7-(allyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (7) 7-(sec-butoxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (8) 7-butoxy-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (9) 2-butyl-7-(cyclopentyloxy)-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (10) 2-butyl-1-(4-methoxybenzyl)-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (11) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-3-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (12) (E)-2-butyl-1-(4-methoxybenzyl)-7-(3-methylbut-1-en-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (13) 2-butyl-7-isopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (14) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine;(15) 2-butyl-7-(cyclopent-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (16) 2-butyl-7-cyclopentyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (17) 2-butyl-1-(4-methoxybenzyl)-7-(prop-1-en-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (18) 2-butyl-7-isopropyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (19) 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine dihydrochloride; (20) 2,2,2-trifluoroacetate of 4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (21) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (22) 2,2,2-trifluoroacetate of 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (23) 1- ( ( (1S,3R)-3-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (and enantiomer) ;(24) 1-(4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)-2-methylpropan-2-ol; (25) Trans 1-(4-aminocyclohexyl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (26) 1-((5-(aminomethyl)pyridin-2-yl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (27) 6-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) nicotinonitrile; (28) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl) methyl) bencyl) acetamida; (29) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) undecanamide; (30) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) pentanamide; (31) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl)bencyl)-3-(2-methoxyethoxy)propanamida; (32) 1- (((1S, 3S)-3-aminocyclohexyl) methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-]pyridazin-4-amine (y enantiómero) ;(33) 2, 2, 2-trifluoroacetato de 1-(3-(aminometil) bencil)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (34) 4- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-1-yl) metil) benzaldehído; (35) (4- ((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-1-yl) metil) phenyl) methanol; (36) 2-butyl-1- (4- ( (cyclopropylamino) metil) bencil) -7-isopropoxy-1H-imidazo[4, 5-d]piridazin-4-amine; (37) 1, 1-dióxido de 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazinyl) metil) bencil) amino) thiethane; (38) N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]piridazin-1-yl) metil) bencil) -N- (1, 1-dioxidothietan-3-yl) acetamida; (39) 2-butyl-7-isopropoxy-1-(4-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (40) 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (41) 2-butyl-N7, N7, 1-trimethyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamine;(42) 2-butyl-1-methyl-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (43) 2-butyl-N7-(4-((dimethylamino)methyl)benzyl)-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (44) 2-butyl-N7,1-dimethyl-N7-(4-(morpholinometil)benzyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamine; (45) 4- ( ( (4-amino-2-butil-1-metil-1H-imidazo[4, 5-d]pyridazin-7-yl) (metil) amino) metil) benzonitrilo; (46) N7-(4-(aminomethyl)benzyl)-2-butyl-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (47) 2-butyl-N7-(4-(((2-methoxyethyl) (methyl)amino)methyl)benzyl)-N7,1-dimethyl-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (48) 2-butyl-7-ethoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazine-4-amina; (49) 2-butyl-1-(4-methoxybenzyl)-N7-(2-methoxyethyl)-1H-imidazo[4,5-d]pyridazine-4,7-diamina; (50) 2-butyl-7-methoxy-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (51) 2-butyl-7-cyclohexyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine;(52) 7-(benzyloxy)-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (53) 2-butyl-1-(4-methoxybenzyl)-N7-methyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamina; (54) (S)-2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (55) 2-butyl-7-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (56) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrofuran-3-yl)oxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (57) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydro-2H-pyran-4-yl)oxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (58) 2-butyl-1-(4-methoxybenzyl)-7-((tetrahydrothiophen-3-yl)oxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (59) 2-butyl-1-(4-methoxybenzyl)-7-(tetrahydrofuran-3-yl)oxy)-1H-imidazo[4, 5-d]pyridazin-4-amine; (60) 2-butyl-1-(4-methoxybenzyl)-7-(2-methylprop-1-en-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (61) 2-butyl-7-isobutyl-1-(4-methoxybenzyl)-1H-imidazo[4, 5-d]pyridazin-4-amine;(62) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (63) 2-butyl-1-(4-methoxybenzyl)-7-(thiophen-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (64) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride; (65) isomer A of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (66) 2-butyl-7-(cyclohex-1-en-1-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (67) 2-butyl-7-(furan-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (68) 1,1-dioxide of 3-((4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (69) isomer B of the 1-oxide of 3- ( (4-amino-2-butyl-1- (4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-yl)oxy)tetrahydrothiophene; (70) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrrol-2-yl)-1H-imidazo[4,5-d]pyridazin-4-amine hydrochloride;(71) 2-Butyl-1-(4-methoxybenzyl)-N7,N7-dimethyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (72) 2-butyl-1-(4-methoxybenzyl)-7-phenoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (73) 2-Butyl-7-(2,5-dihydrofuran-3-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (74) 2-butyl-7-isopropoxy-1-(pyridin-3-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (75) 2-butyl-7-isopropoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (76) 2,2,2-trifluoroacetate of 2-butyl-7-isopropoxy-1-(pyridin-4-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (77) 1-(5-aminopentyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (78) 2-butyl-7-isopropoxy-1-(2-(piperidin-4-yl)ethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (79) 2-butyl-7-isopropoxy-1-(2-(piperazin-1-yl)ethyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (80) 1-benzyl-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride;(81) 2-butyl-1-(cyclohexylmethyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (82) 2-butyl-7-isopropoxy-1-(4-(((tetrahydro-2H-pyran-4-yl) amino) methyl) bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine hydrochloride; (83) 2-butyl-7-isopropoxy-1-(4-((isopropylamino) methyl) bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine dichloride; (84) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) heptanamide; (85) hydrochloride de (4-(1-(4-amino-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazin-7-yl) pyrrolidin-3-yl) phenyl) methanol; (86) 2-butyl-7-isopropoxy-1-methyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (87) N7-(4-(aminomethyl) bencyl)-2-butyl-1-methyl-1H-imidazo[4, 5-d]pyridazin-4, 7-diamine; (88) 2-butyl-N7-isopropyl-1-methyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine; (89) 2-butyl-1-methyl-7-(3-phenylpyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (90) N7-bencyl-2-butyl-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine;(91) 2-Butyl-1-methyl-N7-(4-((4-methylpiperazin-1-yl)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (92) 2-butyl-1-(4-methoxybenzyl)-7-phenyl-1H-imidazo[4,5-d]pyridazin-4-amine; (93) 4-amino-2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-7-ol; (94) 2-butyl-N7-(3-(furan-2-yl)propyl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (95) 2-butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (96) 2-butyl-1-(4-methoxybenzyl)-7-(1H-pyrazol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (97) 2-butyl-1-(4-methoxybenzyl)-7-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (98) 2-butyl-N7-isopropyl-1H-imidazo[4,5-d]pyridazin-4,7-diamine; (99) 2-butyl-7-(isopropylthio)-1H-imidazo[4,5-d]pyridazin-4-amine; (100) dihydrochloride salt of (1R,3R)-3-( (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)amino)cyclobutan-1-ol;(101) 2-butyl-7-isopropoxy-1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (102) 2-butyl-7-isopropoxy-1-(4-(morpholinomethyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (103) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)methyl)benzyl)propionamide; (104) 2-butyl-7-isopropoxy-1-(4-( ((2-methoxyethyl)amino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (105) 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2- [2- (2-methoxyethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]methyl]imidazo[4, 5-d]pyridazin-7-amine; (106) N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) benzamide; (107) N- (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) -3-methoxypropanamide; (108) 2-butyl-7-isopropoxy-1-(4-(((2-(2-methoxyethoxy)ethyl)amino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine;(109) 2-butyl-1-(4-((hexylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (110) 2-butyl-1-(4-((decylamino)methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (111) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl)methyl)bencyl) ethyl carbamate; (112) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) carbamate de 4-methoxybencyl; (113) 1-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) -3-ethylurea; (114) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) carbamate de 4-acetamidobencyl; (115) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) methanesulfonamida; (116) 2-butyl-1-(4-((dimethylamino) methyl) bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (117) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) bencyl) tert-butyl glycinate;(118) 2-butyl-7-isopropoxy-1-(4-((methylamino)methyl)benzyl)-1H-imidazo[4,5-d]pyridazin-4-amine; (119) 3- ( (4- ( (4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) benzyl) amino) propanoato de tercbutilo; (120) 1-(4-(5,8,11-trioxa-2-azadodecyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (121) 2-butyl-4-isopropoxy-3-[[4-[[2-[2- [2- (2-methoxyethoxy) ethoxy] ethoxy] ethylamino] methyl] phenyl] methyl] imidazo[4, 5-d] pyridazin-7-amine; (122) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2- [2- [2- [2- [2- [2- [2- [2- [2- (2-methoxyethoxy) ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethylamino] methyl] phenyl] methyl] imidazo[4, 5-d] pyridazin-7-amine; (123) di2, 2, 2-trifluoroacetate of 2-butyl-4-isopropoxy-3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2- [(124) 2-butyl-7-isopropoxy-1- (3- ( (methylamino) methyl) bencyl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (125) 2-butyl-1- (3- ( (dimethylamino) methyl) bencyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (126) sal dichlorhidrato de 2-butyl-1- (3- ( (cyclobutylamino) methyl) bencyl) -7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (127) sal diclorhidrato de 2-butil-1- (3- ( (cyclopropilamino) metil) bencil) -7-isopropoxi-1H-imidazo[4, 5-d]piridazin-4-amine; (128) sal diclorhidrato de 2-butil-7-isopropoxi-1- (3- ( (isopropilamino) metil) bencil) -1H-imidazo[4, 5-d]piridazin-4-amine; (129) 1, 1-dióxido de 3- ( (3- ( (4-amino-2-butil-7-isopropoxi-1H-imidazo[4, 5-d]piridazin-1-yl) metil) bencil) amino) thiethane; (130) salt dichlorohydrate of 2-butyl-7-isopropoxy-1-(3-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (131) 2-butyl-7-isopropoxy-1-(3-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine;(132) (E) -1- (4- (aminomethyl) bencyl) -2-butyl-7- (3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (133) 1-(4-(aminomethyl)bencyl)-2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (134) 1-(4-(aminomethyl)bencyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (135) 2, 2, 2-trifluoroacetate de 1-(4-(aminomethyl)bencyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (137) 1-(((1R, 4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-((E)-3-methylbut-1-en-1-yl)-1H-imidazo[4, 5-d]pyridazin-4-amine (138) 1-(((1R, 4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine; (139) 1- ( ( (1R, 4R) -4-aminocyclohexyl) methyl) -2-butyl-7- ( (E) -3-methylbut-1-en-1-yl) -1H-imidazo[4, 5-d]pyridazin-4-amine; (140) 1- ( ( (1R, 4R) -4-aminocyclohexyl) methyl) -2-butyl-7-isopentyl-1H-imidazo[4, 5-d]pyridazin-4-amine;(141) 1-( ( (1R,4R)-4-aminocyclohexyl)methyl)-2-butyl-7-(1H-pyrrol-3-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (142) 1-( ( (1R,4R)-4-(aminomethyl)cyclohexyl)methyl)-2-butyl-7-(pyrrolidin-1-yl)-1H-imidazo[4,5-d]pyridazin-4-amine; (143) 3-[(4-aminocyclohexyl)methyl]-2-butyl-4-pyrrolidin-1-yl-imidazo[4,5-d]pyridazin-7-amine; (144) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-(2,5-dihydro-1H-pyrrol-3-yl)imidazo[4,5-d]pyridazin-4-amine; (145) 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-7-pyrrolidine-3-yl-imidazo[4,5-d]pyridazin-4-amine; (146) dihydrochloride salt of 3-(6-aminohexyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (147) dihydrochloride salt of 2-butyl-4-isopropoxy-3-[6-(tetrahydropyran-4-ylamino)hexyl]imidazo[4,5-d]pyridazin-7-amine; (148) N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)hexyl]-N-tetrahydropyran-4-yl-acetamide; (149) dihydrochloride salt of 3-(4-aminobutyl)-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine;(150) hydrochloride salt of 2-butyl-4-isopropoxy-3-[4-(tetrahydropyran-4-ylamino)butyl]imidazo[4,5-d]pyridazin-7-amine; (151) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)butyl]-N-tetrahydropyran-4-yl-acetamide; (152) 2-Butyl-3-[4-[(1,1-dioxothiethan-3-yl)amino]butyl]-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (153) N-[4-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)butyl]-N-(1,1-dioxothiethan-3-yl)acetamide; (154) 2-Butyl-3-[6-[(1,1-dioxothiethan-3-yl)amino]hexyl]-4-isopropoxy-imidazo[4,5-d]pyridazin-7-amine; (155) hydrochloride salt of N-[6-(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)hexyl]-N-(1,1-dioxothiethan-3-yl)acetamide; (156) hydrochloride salt of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)methyl]-2-methyl-propan-1,3-diol; (157) hydrochloride salt of 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-yl)methyl]propan-1,3-diol;(158) 1-(4-(aminomethyl)benzyl)-7-isopropoxy-2-propyl-1H-imidazo[4,5-d]pyridazin-4-amine; (159) 1-(4-(aminomethyl)benzyl)-2-(ethoxymethyl)-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (160) 1-(4-(aminomethyl)benzyl)-7-isopropoxy-2-methyl-1H-imidazo[4,5-d]pyridazin-4-amine; (161) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfanyl-imidazo[4,5-d]pyridazin-7-amine; (162) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-2-propylsulfinyl-imidazo[4, 5-d]pyridazin-7-amine; (163) 3-[[4-(aminomethyl)phenyl]methyl]-4-isopropoxy-N2-propyl-imidazo[4, 5-d]pyridazin-2, 7-diamine; (164) 3-[[4-(aminomethyl)phenyl]methyl]-2-(ethylaminomethyl)-4-isopropoxy-imidazo[4, 5-d]pyridazin-7-amine;and (165) 2-butyl-7-isopropoxy-1-(piperidin-4-ylmethyl)-1H-imidazo[4,5-d]pyridazin-4-amine.

6. The Compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, said compound being selected from: (19) 4-(aminomethyl)cyclohexyl(methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine dihydrochloride salt; (20) 4-(aminomethyl)cyclohexyl(methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine 2,2,2-trifluoroacetate; (21) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine; (22) 1-(4-(aminomethyl)benzyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazine-4-amine 2,2,2-trifluoroacetate; (23) 1-(((1S,3R)-3-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-4-amine (and enantiomer); (24) 1-(4-amino-2-butyl-7-isopropoxy-1H-imidazo[4,5-d]pyridazin-1-yl)-2-methylpropan-2-ol;(25) Trans 1-(4-aminocyclohexyl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (26) 1-((5-(aminomethyl)pyridin-2-yl)methyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (28) N-(4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5d]pyridazin-1-yl)methyl)bencyl)acetamida; (33) 2, 2, 2-trifluoroacetate de 1-(3-(aminomethyl)bencyl)-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (35) (4-((4-amino-2-butyl-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-1-yl) methyl) phenyl) methanol; (36) 2-butyl-1-(4-((cyclopropylamino) methyl)bencyl)-7-isopropoxy-1H-imidazo[4, 5-d]pyridazin-4-amine; (39) 2-butyl-7-isopropoxy-1-(4-(((1-methylcyclobutyl)amino)methyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (40) 2-butyl-7-isopropoxy-1-(4-(piperazin-1-ylmethyl)bencyl)-1H-imidazo[4, 5-d]pyridazin-4-amine; (43) 2-butyl-N7-(4-((dimethylamino)methyl)bencyl)-N7, 1-dimethyl-1H-imidazo[4, 5-d]pyridazine-4, 7-diamine;(47) 2-butyl-N7-(4-((2-metoxietil)(metil)amino)metil)bencil)-N7,1-dimetil-1H-imidazo[4,5-d]pyridazina-4,7-diamina; (144) 1-[[4-(aminometil)fenil]metil]-2-butyl-7-(2,5-dihidro-1H-pirrol-3-il)imidazo[4,5-d]pyridazin-4-amina; (156) sal clorhidrato de 2-[(7-amino-2-butyl-4-isopropoxy-imidazo[4,5-d]pyridazin-3-il)metil]-2-metil-propano-1,3-diol; (157) sal clorhidrato de 2-;